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Abstract 
Shiga toxin (Stx) producing E. coli (STEC) infections represent an important 
public health problem given the severity of the disease and sequelae associated 
to it. Since the use of antibiotics enhances the virulence of STEC, new 
therapeutic strategies are urgently required. Thus, the main aim of this project 
is the study of small molecules that are able to block expression of Shiga toxin in 
Escherichia coli O157:H7. 
 
The genes encoding Stx are located on temperate lysogenic phages integrated 
into the bacterial chromosome and expression of the toxin is generally coupled 
to phage induction through the SOS response. We aimed to find new compounds 
capable of blocking expression of Stx type 2 (Stx2) as this subtype of Stx is more 
strongly associated with human disease.  
 
High-throughput screening of a small-molecule library identified a lead 
compound that reduced Stx2 expression in a dose-dependent manner. We show 
that the optimized compound interferes with the SOS response by directly 
affecting the activity and oligomerization of RecA, thus limiting phage activation 
and Stx2 expression. Our work suggests that RecA is highly susceptible to 
inhibition and that targeting this protein is a viable approach to limiting 
production of Stx2 by EHEC. This type of approach has the potential to limit 
production and transfer of other phage induced and transduced determinants. 
  
As a result of the successful identification of a small molecule capable of 
inhibiting Stx2 expression in E. coli O157:H7, an additional high-throughput 
screening (HTS) of small molecules was performed. Two new compounds with 
activity against Stx2 production were successfully identified and characterised in 
biological assays. Finally, we describe the use of a small molecule with 
previously reported anti-quorum sensing activity. Our findings suggest that the 
compound furanone C-30 blocks stx expression in vitro.  
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CHAPTER 1 
 
 
Introduction
 
 
1 Introduction 
 
Escherichia coli is a Gram-negative, facultative anaerobe that is a member of 
the Enterobacteriaceae family.  E. coli strains are often classified based on the 
type of surface antigens present in the cells: the O-antigen found in the outer 
membrane, the H-antigen present in flagella and the capsular K-antigen (J. L. 
Smith and Fratamico 2017). Most E. coli serotypes are harmless symbionts 
naturally found in the gastrointestinal tract of warm-blooded animals. However, 
some strains have acquired virulence genes that make them the causal agents of 
enteric, urinary tract and extraintestinal infections. Thus, E. coli strains can be 
also classified into pathotypes or groups that have similar forms of disease. 
These include Eenterotoxigenic E. coli (ETEC), enteroinvasive E. coli (EIEC), 
enteroaggregative E. coli (EAEC), enterophatogenic E. coli (EPEC), diffusively 
adherent E. coli (DAEC), Shiga toxin producing E. coli (STEC), adherent invasive 
E. coli (AIEC), uropathogenic E. coli (UPEC), sepsis-associated E. coli (SEPEC), 
neonatal meningitis E.coli (NMEC) and avian pathogenic E. coli (APEC). The 
present work focuses on Shiga toxin producing E. coli (STEC).  
 
 
1.1  Shiga toxin producing Escherichia coli (STEC) 
 
The first report of STEC as a human pathogen was in 1983. It was associated with 
a group of people who fell ill after ingestion of undercooked hamburgers at a 
fast-food restaurant in the USA (Riley et al. 1983). The symptoms included 
severe abdominal pain, bloody diarrhoea with little or no fever, manifestations 
today known as haemorrhagic colitis. Later that year, the presence of a toxin-
producing E. coli strain in stools of patients with haemolytic uremic syndrome 
(HUS) revealed the link between the two illnesses (Nataro and Kaper 1998).  
STEC is also commonly referred to as Vero-toxin producing E. coli (VTEC) as it 
was discovered that certain diarrheagenic E. coli strains produced a cytotoxin 
that was able to kill Vero cells (Konowalchuk, Speirs, and Stavric 1977). STEC 
infections are characterised for causing abdominal cramps, bloody diarrhoea 
followed by the life-threatening haemolytic uremic syndrome (HUS). Over 380 
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different STEC serotypes have been identified, but only few cause severe disease 
in humans. E. coli O157:H7 has been found to be the most common serotype 
associated with HUS, but other serotypes have also been linked with severe 
disease, including O26, O111, O103, O121, O45 and O145, also known as the ‘big 
six’.  
 
1.1.1 Virulence factors in E. coli O157:H7  
 
Virulence factors are bacterial components that promote disease by either 
causing damage to the host or evading the immune system (Casadevall and 
Pirofski 1999).  
The main virulence factor responsible for STEC pathogenesis is Shiga toxin (Stx), 
a phage-encoded toxin that blocks protein synthesis in the host cells, leading to 
cell death. A detailed description about Stx and its mechanism of action is 
provided in Section 1.2. Additional genetic elements contribute to STEC 
virulence, include the locus of enterocyte effacement (LEE), a pathogenicity 
island responsible for attaching and effacing activity. The LEE encodes the type 
three secretion system (T3SS) and effector proteins that make host cells more 
susceptible to infection. Two key proteins produced from this T3SS are intimin 
and its receptor Tir (transmembrane intimin receptor). Intimin is the critical 
adhesin that plays a key role in the adherence to the host cells and formation of 
attaching and effacing lesions (A/E).  
E. coli O157:H7 also contains an F-like plasmid of approximately 92-104 kb 
known as pO157. The plasmid encodes several virulence factors, including an 
haemolysin, a catalase-peroxidase, a type II secretion system, a serine protease, 
a metalloprotease, amongst others (Youn, Yoon, and Hovde 2010). Nevertheless, 
the importance of the plasmid for the overall virulence has not been fully 
proved. 
STEC strains also carry systems that confer resistance to extreme acidic 
conditions, a feature that enhances its virulence. Four acid-resistance (AR) 
mechanisms have been identified in E. coli: the oxidative system (AR-1), the 
glutamate decarboxylase system (AR-2), the arginine decarboxylase system (AR-
3) and the lysine decarboxylase system (AR-4) (J. W. Foster 2004). In STEC, the 
AR-2 system provides better protection to low pH environments than the AR-3 
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system, but both systems seem to be equally effective in protecting STEC strains 
against weak acids found in the intestine (Lin et al. 1996). 
 
1.1.2 Transmission sources 
 
Infection occurs when people consume food or water contaminated with STEC 
(Kintz et al. 2017). Person-to-person transmission is a rare but is a possible route 
of transmission and normally occurs in nurseries and geriatric care facilities.  
Ruminants are the main reservoir for STEC, cattle being the most important 
source of infection. Consequently, any products that come in contact with cattle 
or faecal material pose a major risk factor for STEC infection (Persad and 
Lejeune 2014). Interestingly, STEC does not cause disease in infected cattle, 
probably as a result of differences in the Stx receptor availability, the influence 
of the microbiota and the site of colonisation, the terminal rectum. This leads to 
term ‘super-shedders’, a subset of animals that are colonised at the terminal 
rectum and release a high number of infectious units. An E. coli O157 super-
shedder is defined as an animal that excretes >104 CFU per gram of faeces 
(Chase-Topping et al. 2008). Super shedders pose an important risk factor for 
the spreading of STEC in the environment.  
 
Figure 1 STEC transmission cycle.   
1) Ingestion of STEC by cattle, 2) Faecal excretion of STEC leads to contamination of 
environment, including farms and water reservoirs, 3) Contamination of environment and water 
leads to contaminated food, including fruits and vegetables, meat, dairy products and water, 4) 
Transmission animal to person can occur in cases where people are exposed to farms or slaughter 
houses, 5) People get infected by STEC by consuming contaminated food or by person to person 
transmission 
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1.1.3 Pathogenesis of STEC 
 
 As previously mentioned, infection occurs when people consume food or water 
contaminated with STEC. The incubation period varies from 3-10 days. The 
infectious dose is multifactorial as it depends on the STEC strain, the host 
susceptibility, age group, etc. However, the acid-resistance of STEC decreases 
the infectious dose which is thought to be as low as 50 colony forming units 
(Tilden et al. 1996). 
 
Once STEC has passed through the stomach and reached the intestine, 
colonisation starts, initiated by binding of intimin to the cell-surface protein 
nucleolin on the epithelium cells, bringing bacterial cells closer to the intestinal 
epithelium (Sinclair and O’Brien 2002). Once this first contact has occurred, Tir 
is secreted into the host cells via the T3SS, also encoded by the LEE. The T3SS 
forms a needle-like complex that injects Tir and other bacterial effector 
proteins into the host cells. Tir mediates attachment of intimin to the host cell 
membrane, hijacking the host cell cytoskeleton and causing the characteristic 
attaching and effacing lesions (A/E). The additional effector proteins secreted 
into the host cell contribute to make the cell more susceptible to infection. 
These include EspA, B and D, which are involved in the delivery of other 
effectors into the cell; EspG, F, H and Map (mitochondrial associated protein) 
which are thought to interfere with essential signalling pathways within the cell. 
Other non-LEE effectors also contribute to STEC pathogenesis, although their 
function is still unclear.  
Shiga toxin (Stx) production also starts when bacteria reach the intestine, 
normally a few hours after infection. Stxs are responsible for causing the severe 
complications associated to STEC infections and the mechanisms behind this will 
be reviewed with detail in the following sections.  
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1.2  Shiga toxins 
 
Shiga toxins (Stxs) belong to the family of AB toxins. This group of toxins are 
formed by two components or subunits, the active subunit A and the binding 
subunit B. Members of this family include ricin toxin found in the castor oil plant 
Ricinus communis, cholera toxin produced by V. cholerae, the heat labile 
enterotoxin from ETEC, pertussis toxin from Bordetella pertussis and anthrax 
toxin from Bacillus anthracis (Odumosu et al. 2010). The potent and sometimes 
mortal bioactivities of these toxins make them a subject of intense research. 
 
Stxs were originally discovered in Shigella dysenteriae type 1 by the renowned 
bacteriologist Kiyoshi Shiga during a dysentery outbreak in 1897 (Trofa et al. 
1999). They were later referred to as Verocytotoxins given their toxic effects on 
Vero cells. For this reason STEC can also be referred to as Verotoxin producing E. 
coli (VTEC). Further studies showed that the toxins were structurally and 
functionally related. 
  
1.2.1 Structure of Shiga toxins and cellular receptors 
 
Shiga toxins are formed by two non-covalently associated units, the 
enzymatically active subunit A (StxA) and the homopentameric subunit B (StxB). 
StxA exhibits a specific RNA N-glycosidase activity that cleaves an adenine base 
on the 28S ribosomal RNA of eukaryotic ribosomes, inhibiting protein synthesis 
(Johannes and Römer 2010). Two peptide fragments form StxA: A1 (28 kDa) 
responsible for the toxic effect and A2 (4 kDa) responsible for the association 
between StxA and StxB.  
 
StxB is responsible for binding the holotoxin to the neutral glycosphingolipid 
globotriaosylceramide (Gb3) receptor on the cell surface (Figure 2). The B 
subunits are highly specific to the trisaccharide moiety (Galα1-4Galβ1-4Glc 
ceramide) of the Gb3 receptor (Ling et al. 1998). Structural studies on the B 
subunit of Stx1 revealed that there are three trisaccharide-binding sites per B 
monomer, giving a total of 15 Gb3-binding sites per StxB unit. This explains the 
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high affinity of Stx for the host cells (binding constant of 109 M-1) (G. Fuchs et al. 
1986). Although the same number of binding sites have been found in Stx2, there 
is an important difference in the binding affinities between Stx1 and Stx2. Stx1 
has a 10-fold higher affinity for the Gb3 receptor than Stx2 (Head, Karmali, and 
Lingwood 1991), even though Stx2 is more potent than Stx1 with an LD50 400-fold 
lower than Stx1 (V L Tesh et al. 1993). 
 
Figure 2. Structure of Shiga toxins.  
Shiga toxins are formed by two non-covalently associated units, the enzymatically active subunit 
A (StxA) and the homopentameric subunit B (StxB). 
 
The Gb3 receptor is mainly expressed in endothelial, epithelial, mesangial and 
glomerular cells of the kidney, microvascular endothelial cells in brain and 
intestine, and in some subsets of B lymphocytes (Lingwood 1999; Chan and Ng 
2016). This explains the localised damage in both urinary and nervous systems in 
infected humans.  
 
1.2.2 Shiga toxin types and subtypes 
 
As previously mentioned, there are two types of Shiga toxins: type 1 (Stx1) and 
type 2 (Stx2). They are structurally similar but differ in their amino acid 
sequences. The A subunits of Stx1 and Stx2 share 55% similarity, while the B 
subunits are 62% similar. Additionally, both Stx1 and Stx2 are divided in 
subtypes: Stx1, Stx1c and Stx1d, Stx2c, Stx2d, Stx2e, Stx2f and Stx2g (Scheutz et 
al. 2012) 
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There is a clear relationship between toxin subtype and toxicity. Strains that 
produce Stx2a, Stx2c or Stx2d usually lead to development of haemorrhagic 
colitis (HC) and HUS (Melton-Celsa 2014). On the other hand, Stx2b and Stx2e do 
not seem to cause severe symptoms in affected patients (Fuller et al. 2011). 
Several factors cause this difference in toxicities amongst Stx subtypes. In 
general, Stx2 subtypes have been shown to bind tighter to the ribosome than 
Stx1, explaining the higher toxicity seen in this group. Stx2d is 10-fold more 
potent than Stx2c, even though they differ by only two amino acids in the A 
subunit (Bunger et al. 2015). In the case of Stx2e, structural differences in the B 
subunit makes it more prone to bind to the globotetraosylceramide receptor 
(Gb4) instead of Gb3 (Tyrrell et al. 1992). 
 
1.2.3 Intracellular trafficking of Shiga toxin  
 
Once Stx has bound to the Gb3 receptor, the complex toxin/receptor is 
internalised to the host cell by endocytosis (Figure 3). Stx utilises both clathrin-
dependent and clathrin-independent endocytosis to enter the cell (Sandvig et al. 
1989; Lauvrak, Torgersen, and Sandvig 2004; Römer et al. 2007). After entry, the 
Stx/Gb3 complex localises to early and recycling endosomes, to be later 
transferred to the trans-Golgi network (TGN) (Johannes et al. 2008; Bonifacino 
and Rojas 2006).  
 
Stx undergoes retrograde sorting in the early/recycling endosomes in order to 
bypass recycling and degradation pathways and reach the Golgi apparatus. This 
process is mediated by clathrin (a nanodomain organising protein essential for 
the generation of membrane curvatures) and retromer (a heteropentameric 
complex that mediates retrograde transport of cargo molecules from endosomes 
to the TGN) (Saint-Pol et al. 2004; Bujny et al. 2007; Johannes and Römer 2010). 
The mechanism by which clathrin and retromer sort the Stx-containing 
endosomes remains unclear. However, studies suggest that clathrin mediates the 
formation of retrograde tubules on the endosome, followed by retromer-
dependent scission (Popoff et al. 2007; Johannes et al. 2008). This endosome-
sorting process is essential for Stx pathogenesis as it has been proved that cell 
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lines with defective endosome-sorting pathways are immune to Stx intoxication 
(Falguières et al. 2001).  
 
 
Figure 3 Trafficking of Shiga toxin.  
Stxs are internalised by clathrin-dependent and independent pathways. The toxin then 
undergoes retrograde sorting in early endosomes to bypass recycling and degradation pathways. 
Stx are then transferred to the trans-Golgi network (TGN) and endoplasmic reticulum. Finally, 
the cytotoxic subunit A is translocated to the cytosol. (Taken from Johannes and Römer, 2010)   
 
During the retrograde transport, the endoprotease furin divides the StxA 
fragments A1 and A2 by cleaving a bond between the residues Arg251-Met252 
(Garred, van Deurs, and Sandvig 1995). At this point, the A1 fragment remains 
linked to the A2-StxB complex by a disulfide bond between Cys242 (A1) and 
Cys261 (A2). Reduction of this disulfide bond in the endoplasmic reticulum (ER) 
lumen releases the enzymatic A1 fragment (Johannes and Römer 2010).  
In order to exert its bioactivity, the A1 fragment has to be translocated to the 
cytosol via the endoplasmic reticulum associated degradation pathway (ERAD), a 
pathway in the ER responsible for targeting misfolded proteins for ubiquitylation 
and degradation by the proteasome (Mukhopadhyay and Linstedt 2013; M. Yu and 
Haslam 2005; Johannes and Römer 2010). Interestingly, the A1 fragment is able 
to escape ubiquitin-mediated degradation given its lack of lysine residues and its 
ability to refold rapidly (Hazes and Read 1997). 
Once in the cytosol, the A1 fragment exerts its N-glycosidase activity by 
depurinating a conserved adenine residue in the α-sarcin/ricin loop (SRL) of the 
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28S ribosomal RNA, blocking the binding of the elongation factor EF-2, which in 
turn leads to inhibition of translation (Chan and Ng 2016). Although a very small 
percentage of the A1 fragment reaches the cytosol (approximately 4%), severe 
cell damage is caused (Tam and Lingwood 2007).  
 
1.2.4 Shiga toxin mode of action 
 
Stx-mediated intoxication is the result of different effects at the cellular level. 
As previously mentioned, Stxs act on the 28S rRNA of the ribosome, triggering 
the ribotoxic stress response (W. E. Smith et al. 2003). This regulatory network 
leads to the activation of mitogen-activated protein kinase (MAPK) signalling 
pathways that are responsible for controlling cell proliferation and apoptosis. 
More specifically, it has been shown that Stx activates the p38 MAPK pathway, 
the c-Jun N-terminal (JNK) pathway and the extracellular signal-regulated kinase 
(ERK) pathway (Ikeda et al. 2000; Chan and Ng 2016). For a more detailed review 
on the topic see Vernon L. Tesh 2012.  
 
The ribotoxic stress response has also been associated with cytokine production, 
promoting local inflammatory responses. The type of cytokines and their levels 
of expression depend on the type of cell that is being affected. For instance, in 
proximal tubular cells and glomerular epithelial cells, Stx induce production of 
IL-1β, IL-6 and IL-8, whereas an elevation of IL-8 occurs in the intestinal 
epithelial cells (Cherla et al. 2006; G. H. Foster and Tesh 2002). In addition to 
this, it has been shown that the tumour necrosis factor alpha (TNF-α) 
upregulates expression of the Gb3 receptor in endothelial cells, exacerbating the 
vascular damage in the affected tissues (Eisenhauer et al. 2001). 
 
Stxs have also been associated with the activation of the ER stress response and 
the unfolded protein response (UPR), a mechanism that ensures proteins are 
properly folded before leaving the ER (for a detailed description see Schröder 
2008). When unfolded proteins are detected, an attenuation of protein 
translation occurs, together with the activation of genes encoding chaperones 
and proteins of the ERAD pathway. Stxs activate the UPR by three possible 
routes. Firstly, the fragment A1 itself contributes to the activation of the UPR 
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since it has to be misfolded before its translocation to the cytosol. Secondly, the 
actual host protein synthesis inhibition caused by Stx might lead to accumulation 
of unfolded host proteins and finally, alteration of intracellular Ca2+. The 
mechanisms by which the ER stress response induces apoptosis are beyond the 
scope of this work. For a more detailed description please see Lee et al. 2008.  
 
In addition to the cytotoxicity produced in eukaryotic cells, it has also been 
shown that Stx promotes intestinal colonisation of STEC. Robinson and co-
workers demonstrated that epithelial cells exposed to Stx2 had increased 
surface expression of nucleolin, the protein to which intimin binds to promote 
attachment of bacteria to the cell surface (Robinson et al. 2006). Their findings 
also showed that EHEC O157:H7 strain 86-24 adhere better to epithelial cells in 
vitro compared to its stx2 isogenic mutant, and that WT EHEC 86-24 colonised 
mice at a higher rate compared to the stx2 isogenic mutant.  
 
1.2.5 Shiga toxin encoding bacteriophages 
 
Shiga toxins are encoded by lambdoid bacteriophages that are integrated into 
the bacterial chromosome. Bacteriophages are viruses that infect bacteria and 
are the most abundant life form in the planet with an estimated population of 
approximately 1031 (Hendrix, Hatfull, and Smith 2003). Bacteriophages can be 
classified as lytic or temperate, depending on the life cycle they undergo (Figure 
4). Lytic phages are strict bacterial parasites that hijack the cell machineries to 
produce new phage particles that are released through bacterial lysis. These 
type of phages follow what is known as the lytic cycle. On the other hand, 
temperate phages integrate their genome into the bacterial chromosome, 
becoming prophages. Prophages remain in a dormant state, also referred to as 
the lysogenic cycle, in which they are replicated together with the bacterial 
chromosome and passed along to daughter cells. Under certain conditions, 
temperate phages shift to the lytic cycle, the Stx-phages being a clear example 
of this.  
 
Bacteriophages play a key role in the transfer of virulence genes amongst 
bacteria, making an important contribution to bacterial pathogenesis. Several 
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toxins are encoded by phages including diphtheria toxin, cholera toxin, 
botulinium toxin and shiga toxin. Phages also disseminate other virulence traits 
involved in invasion, immune evasion, superantigens, and adhesion factors, 
amongst others (Penadés et al. 2015). 
 
 
 
Figure 4 Bacteriophages can have lysogenic or lytic cycles. 
Phages infect a host bacterium when they interact with receptors on the cell membrane and 
inject their genome. The replication strategy will depend on the type of phage, if it is virulent or 
temperate. Virulent phages, like the phage T4, can only replicate through the lytic cycle. 
Temperate phages like the phage λ, can enter either the lytic or lysogenic cycle. During 
lysogeny, the phage genome is termed ‘prophage’ and it replicates together with the host DNA. 
Under certain stress conditions, prophages can enter into the lytic cycle and produce new virions 
that are released via cell lysis. (Adapted from Salmond and Fineran 2015) 
 
1.2.6 Diversity of Shiga toxin phages 
 
Stx-phages show a high degree of heterogeneity in genome composition and 
morphology. They belong to the family of lambdoid bacteriophages, having all a 
double stranded DNA genome and roughly similar morphology (icosahedral head 
and tail). The genetic organisation of Stx-phages is very similar to the archetype 
phage lambda (λ) but with a genome approximately 50% larger than phage λ. 
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Some studies suggest that the extra DNA may assist the survival of the bacterial 
lysogen in the animal host or help promote colonisation (Barondess and Beckwfth 
1990; Dziva et al. 2004; van Diemen et al. 2005). 
 
Lambdoid bacteriophages have their genome organised in interchangeable 
genetic clusters that facilitates recombination and exchange of genes between 
phages. This results in a high degree of mosaicism amongst Stx-phages. The Stx 
genes in STEC can be either found in cryptic prophages (phage-like sequences 
that cannot produce infective phage particles) or inducible prophages (Herold, 
Karch, and Schmidt 2004). Since multiple cryptic or inducible prophages can 
reside within the genome of a single host cell (Allison et al. 2003; Perna et al. 
2001), recombination events between phage sequences in a single cell can result 
in the generation of new prophages in situ. This phenomenon is enhanced if a 
recombination system like the λ-Red recombinase is being carried by the phage.  
 
The integration site of the Stx-phages in the bacterial chromosome shows also a 
high degree of heterogeneity. In E. coli O157:H7 the most two common sites are 
wrbA and yehV, though the sites sbcB, argW and yecE have also been reported 
(Krüger and Lucchesi 2015; Shaikh and Tarr 2003; Besser et al. 2007). On the 
other hand, the prevailing sites in non-O157 strains are argW, potC, prfC, serU, 
ssrA, wrbA, yciD, yecD, yecE, yjbM, ynfH and Z2577 (Krüger and Lucchesi 2015; 
Shringi et al. 2012; Mellor et al. 2012; De Greve et al. 2002).   
 
Stx-phages are able to infect other E. coli strains, both pathogenic and non-
pathogenic, including strains that are already lysogenized with other Stx-phages. 
This promotes the spread of Stx genes between E. coli and other 
Enterobacteriaceae. The outbreak that took place in Germany in 2011 is a clear 
example of this. The enteroaggregative E. coli (EAEC) strain O104:H4 acquired a 
Stx-phage by horizontal transfer, resulting in a hypervirulent strain that caused 
2987 cases of acute gastroenteritis, 855 cases of HUS and 53 deaths (Hauswaldt 
et al. 2013). This outbreak represented a challenge to the German health system 
and highlighted the serious need for therapeutic strategies to manage STEC 
infections. 
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1.3 Regulation of Shiga toxin expression 
 
Inspite of the mosaicism in Stx-phages, Stx genes are always located at the late 
region of the phage genome, downstream of the anti-terminator Q and upstream 
of the lysis cassette (Pacheco and Sperandio 2012). In lambdoid bacteriophages, 
the cI repressor acts as a genetic switch from the lysogenic state to lytic 
development. The cI protein has a dual functionality by promoting and 
repressing transcription of the phage genes in the lysogenic cycle. Two cI units 
dimerise and cooperatively bind to the operator regions OR and OL to repress 
transcription of the lytic promoters PL and PR, and to stimulate transcription of 
the PRM promoter to express the cI gene in order to maintain the lysogenic 
replication (Stayrook et al. 2008). Stx expression is initiated upon cleavage of 
the cI repressor, process known as prophage induction. This induction happens 
under specific environmental conditions, possibly as a survival mechanism so 
that the phage can move on to better hosts. The bacterial SOS response is the 
most well known mechanism of prophage induction and will be discussed in the 
following section (Little and Mount 1982).  
 
 
1.3.1 The SOS response 
 
The SOS response is a DNA repair system found in most bacterial species 
(Baharoglu and Mazel 2014). This regulatory network induces the expression of a 
set of genes that leads to the arrest of cell division, induction of DNA repair, 
prophages and mutagenesis. There are three DNA repair pathways induced by 
the SOS response: homologous recombination (HR), nucleotide excision repair 
(NER) and translesion synthesis (TLS) (Baharoglu and Mazel 2014). The ultimate 
trigger of all three pathways is the formation of single stranded DNA (ssDNA), 
either by replication errors or external factors. 
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1.3.2 LexA and RecA, the master regulators of the SOS response 
 
The protein LexA acts as a repressor of the SOS response by downregulating its 
own expression and the genes that form the SOS regulon during normal bacterial 
growth. LexA is a 22 kDa protein formed by two domains that are linked by a 
flexible hinge region. LexA dimerises by the carboxy-terminal domain (CTD) and 
interacts with DNA through a helix-turn-helix motif in its amino-terminal domain 
(NTD) (Schnarr et al. 1988; Knegtel et al. 1995). The consensus DNA sequence 
for LexA is the 16-bp-long palindromic motif CTGT-N8-ACAG, also known as the 
LexA box or SOS box (Butala, Žgur-Bertok, and Busby 2009). The self-cleavage 
activity of LexA resides within the CTD, where the residues Ser119 and Lys156 
mediate the cleavage of the bond between Ala84 and Gly85 (Slilaty and Little 
1987; Y. Luo et al. 2001). The CTD in LexA shares a substantial homology with 
the cI repressors found in temperate bacteriophages and this homology is related 
to the ability to interact with RecA-ssDNA-ATP filaments (Stayrook et al. 2008). 
 
On the other hand, RecA acts as an inducer of the SOS response by promoting 
the autocleavage of LexA, which results into its dissociation from the SOS 
promoters. RecA is a 37 kDa multifunctional protein highly conserved in virtually 
all bacteria. Structural and functional homologues of RecA have been found in 
archae and eukaryotic cells (Cox 2007). RecA is involved in several cellular 
processes, including homologous recombination, coprotease activity on LexA, 
the λ repressor and UmuD, and activation of DNA polymerase V during SOS 
mutagenesis (Meghna Patel et al. 2010). Structurally, RecA is formed by a 30-
residue N-terminal domain involved in monomer-monomer interactions, a 240-
residue ATPase core, an 82-residue C-terminal domain and a central domain that 
shares homology with helicases and DNA transport proteins (Prentiss, Prévost, 
and Danilowicz 2015). In normal conditions, there are around 9,000 RecA 
monomers per cell; upon induction of the SOS response, this number rises to 
over 70,000 (Sommer et al. 1998). In order to cleave LexA, RecA forms a 
nucleofilament on the damaged DNA region and the resulting ssDNA-RecA 
filament catalyses the autocleavage of LexA, triggering the SOS response (Figure 
5). 
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Figure 5 RecA mediates the autocleavage of LexA. 
When DNA damage occurs, RecA is activated, forming filaments that mediate autocleavage of 
LexA (the key SOS response repressor), resulting in expression of the SOS regulon. RecA filaments 
also mediate autocleavage of prophage repressors, allowing production of phage particles and 
toxins 
 
 
1.3.3 Filament formation 
 
The mechanism by which ssDNA induces the SOS response has been well 
characterised. Briefly, the recombination proteins RecCBD and RecFOR promote 
the formation of RecA-ssDNA filaments. RecBCD recognises double strand DNA 
breaks (DSB) or double-strand ends (DSE), whereas RecFOR recognises gaps and 
nicks in DNA. Filament formation occurs in two steps: nucleation and extension 
(Figure 6). Nucleation happens more rapidly on ssDNA than on dsDNA. Only five 
RecA monomers are sufficient for nucleation but the presence of single-strand 
DNA binding protein (SSB) significantly slows down this process (Joo et al. 2006). 
The proteins RecO and RecR help to overcome this inhibitory effect by SSB. Once 
nucleation has started, the filament extension proceeds from the 5’-to-3’ 
direction where each RecA monomer covers three nucleotides. ATP binding to 
RecA is essential for filament extension but no ATP hydrolysis. In fact, ATP 
hydrolysis has the opposite effect, it promotes disassembly of the filament 
(Arenson, Tsodikov, and Cox 1999; Bork, Cox, and Inman 2001). It has been 
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reported that the RecA-DNA filament grows at 120-1200 subunits/min whereas 
dissociation occurs at 70 monomers/min in ssDNA or 120 monomers/min in 
dsDNA.  
 
Figure 6 RecA filament formation. 
Nucleation occurs slowly due to the single-stranded DNA binding protein (SSB). Then, the 
filament extends rapidly in the 5’ to 3’ direction and extends to the end to the DNA. ATP binding 
to RecA is essential for filament extension. Modified from Cox 2007. 
 
1.3.4 Regulation of RecA and filament formation 
 
Given the complex nature of RecA, the existence of regulatory mechanisms is 
not surprising. Firstly, there is evidence showing that RecA regulates itself 
through its C-terminal domain. Different studies on this domain show that the 
activity of RecA is enhanced when the domain is absent (Benedict and 
Kowalczykowski 1988; Tateishi et al. 1992). Secondly, a number of accessory 
proteins intervene in the regulation of RecA, including the RecBCD and RecFOR 
systems, RecX, DinI, PsiB and RdgC.  
 
As previously mentioned, the RecBCD and RecFOR proteins are required to start 
and mediate filament formation. The RecBCD proteins create a single-strand 
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extension on the 3’-ending, allowing the binding of RecA to DNA. On the other 
hand, the RecFOR proteins mediate the binding of RecA to SSB-coated DNA.  
 
The RecX protein is another important regulator. It acts as an inhibitor of both 
RecA recombinase and coprotease activities (Stohl et al. 2003). When a RecA 
monomer dissociates during filament extension, the gap is rapidly filled by 
another RecA monomer to continue the extension process. RecX exerts it 
inhibitory activity at his point by capping the assembly ends of the filaments, 
blocking filament formation (Drees et al. 2004).  
 
The DinI protein is expressed early in the SOS response and has been shown to 
play a key role in the stabilisation of nucleofilaments after they are formed 
(Lusetti et al. 2004). The PsiB protein is encoded by conjugative plasmids and is 
believed to inhibit the SOS response during conjugation. The RdgC protein or 
recombination-dependent growth protein is a DNA binding protein that competes 
with RecA for binding sites on the DNA, preventing the cleavage of LexA.  
 
After de-repression of the SOS box, the genes recA and ssb are induced to 
protect and stabilize the fork. The genes uvrA, uvrB, ydjQ, uvrD, recN and ruvAB 
are induced to repair the lesions caused through NER and HR, and the DNA 
polymerases polB, dinB and umuDC assist in translesion DNA synthesis (TLS). Cell 
division is also inhibited during the SOS response by induction of the sulA gene, 
which prevents septation by interacting with the ftsZ gene product. After the 
damage has been resolved, the levels of non-activated RecA and uncleaved LexA 
start rising again. 
 
1.3.5 Induction of the SOS response 
 
As previously mentioned, ssDNA is the main inducer of the SOS response. It can 
be originated as a result of spontaneous DNA breakage during replication, 
commonly after fork stalling, or by external factors. Thus, any DNA damaging 
agent or condition will initiate the SOS response (Baharoglu and Mazel 2014). For 
instance, UV and gamma radiation activate DNA repair by HR and TLS 
(Bolsunovsky et al. 2016; Krishna et al. 2007). Reactive oxygen species (ROS) are 
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also important inducers. For instance, superoxide radicals can lead to the 
release of iron from iron-containing proteins. High concentration of free ferrous 
ions leads to the production of hydroxyl radicals through the Fenton reaction, 
which ultimately cause DNA damage (Henle and Linn 1997; Jena 2012) (Figure 7).  
 
 
Figure 7 Triggers of the SOS response.  
All the different mechanisms responsible for the activation of the SOS response involve DNA 
damage, either directly or indirectly. Taken from (Erill, Campoy, and Barbé 2007) 
 
Certain antibiotics at both lethal and sublethal concentrations can also induce 
the SOS response by multiple mechanisms. For example, β-lactam antibiotics 
have been shown to induce the SOS response by triggering the DpiAB two-
component signal transduction system (C. Miller et al. 2004). DNA-damaging 
agents like mitomycin C or quinolones are powerful SOS inductors (Kimmitt, 
Harwood, and Barer 2000; Costa de Oliveira, Laval, and Boiteux 1987).  
 
High pressure has been shown to promote DSB formation and trigger the SOS 
response through the Mrr nuclease in E. coli (Aertsen and Michiels 2005). The 
interesting fact of this phenomenon is that, thanks to the SOS induced 
mutagenesis; the mrr gene is inactivated to give origin to bacterial cells 
resistant to high-pressure conditions. Changes in the intracellular pH have also 
been associated with the initiation of the SOS response. It has been shown that 
in acidic media, LexA undergoes a series of conformational changes that lead to 
a gradual de-repression of the SOS response (Sousa et al. 2006).  
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1.3.6 Expression of Shiga toxin 
 
The Stx-phages remain dormant when the repressor cI is bound to the right and 
left operator sites, OR and OL respectively, inhibiting the activity of the phage 
promoters PR and PL (Serra-Moreno, Jofre, and Muniesa 2008; Tyler, Mills, and 
Friedman 2004). When the SOS response is triggered, the protein RecA is 
activated. This protein cleaves the cI repressor, leading to expression of the 
anti-terminator Q. Subsequently, the protein Q binds to the promoter PR’ and 
activates transcription of the Stx genes. The fact that Stx is expressed during the 
lytic cycle eliminates the need for an Stx-secretion system, although an 
additional secretion mechanism for Stx2 has been reported (Shimizu, Ohta, and 
Noda 2009).  
 
 
Figure 8 Shiga toxin expression.  
Lambdoid phages remain inactive when the repressor cI is bound to the right and left operator 
sites, OR and OL respectively, inhibiting the activity of the phage promoters PR and PL. When the 
SOS response is triggered, the protein RecA cleaves the cI repressor, leading to expression of the 
anti-terminator Q. Subsequently, the protein Q binds to the promoter PR’ leading to transcription 
of Stx and late phage genes. (Modified from Pacheco and Sperandio, 2012) 
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There are differences in the mechanisms of gene expression between stx1 and 
stx2. While expression of stx2 is promoted by DNA damaging agents (mitomycin 
C or ciprofloxacin), stx1 expression is triggered under low-iron conditions. 
Studies have identified a functional promoter for the stx1 gene that is regulated 
by the environmental iron concentration (Calderwood and Mekalanos 1987; 
Calderwood et al. 1987) .  
 
1.4 Shiga toxins and human disease 
 
1.4.1 Incidence of STEC infections  
 
Given the differences in the surveillance systems in each country, it is difficult 
to have an accurate number of infections produced by STEC around the world 
each year. A recent systematic review made by Majowicz and collaborators 
estimates that STEC causes around 2,800,000 acute illnesses, 3890 cases of HUS, 
270 cases of end-stage renal disease (ESRD) and 230 deaths annually, worldwide 
(Majowicz et al. 2014). Despite the reduced number of cases compared to other 
microorganisms like Salmonella or Campylobacter, STEC has a bigger economic 
impact given the large number of hospitalisations and the costly treatment. 
  
Most outbreaks produced by STEC are caused by the serotype O157:H7. Only in 
the USA, 350 E. coli O157 outbreaks were reported from 1982 to 2002 causing 
1493 hospitalisations, 354 cases of HUS and 40 deaths (Rangel et al. 2005). In a 
more global context, Canada, the United States, Japan and Scotland have 
reported the highest annual reported incidences of E. coli O157:H7 infections 
during the last 20 years, Scotland being the country with the highest per capita 
incidence (3-5.73 cases per 100,000 individuals) (Chase-Topping et al. 2008) 
(Figure 9).  
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Figure 9 Incidence of E. coli O157:H7 around the globe.  
Map of the worldwide relative rate of E. coli O157:H7 infections per 100,000 individuals in 2005. 
Purple shading represents detection of E. coli O157:H7 in a country where no incidence rate is 
available. White represents countries where no data are available, although infections may have 
occurred. Taken from Chase-Topping et al. 2008 
 
In the particular case of Scotland, the high incidence rate has been attributed to 
the Stx phage type and super-shedding. The phage 21/28 accounted for 50% of 
the cattle isolates and 72% of isolates obtained from human infections (Chase-
Topping et al. 2008). The association between this particular phage type and 
super-shedding is thought to be due an altered regulation of the type III 
secretion system that allows for a better colonisation. 
 
1.4.2 Detection of STEC 
 
Given the severity of STEC infections, it is of great importance to have effective 
detection methods for an appropriate and quick management of the patients. 
Currently, the methods available include chromogenic agars, enzyme 
immunoassays (EIA) and molecular techniques. Excellent reviews in the area can 
be found elsewhere (Parsons et al. 2016), but a brief description follows.  
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1.4.2.1  Culture methods 
 
Isolation of STEC by culture methods is advisable to identify and characterise the 
strain. However, sometimes it is difficult to isolate STEC given the low number 
of bacterial cells present in the sample or interference with other bacteria 
species. Nevertheless, it is still a valuable method used for the diagnosis of STEC 
infections.  One of the characteristics of E. coli O157:H7 is its inability to 
ferment sorbitol. This peculiarity allowed the use of sorbitol-MacConkey (SMAC) 
agar to identify the pathogen (Pai et al. 1984). SMAC plates were inoculated 
with the faecal specimen and examined after 18-24 h, looking for the presence 
of colourless colonies. However, it was later revealed that SMAC was not able to 
detect non-O157 STEC strains as well as sorbitol-fermenting O157 isolates 
lysogenized with Stx phages (Ammon, Petersen, and Karch 1999). More sensitive 
and specific alternatives to SMAC have been developed and their details are 
explained in Table 1 (Parsons et al. 2016). 
 
 
Table 1 Culture methods for the detection of Stx 
 
 
 
 
Name of media Description Sensitivity/Specificity References 
CHROMagar™ 
O157 
Detects O157 STEC strains through 
chromogenic substrates 
 
96.3%/100% (Church et al. 2007) 
CHROMagar™ 
STEC 
Detects O157 STEC and non-O157 
strains through chromogenic 
substrates 
 
84.6-85.7%/87-95.8% (Wylie et al. 2013) 
CHROMagar™ 
O104 STEC 
Detects O104:H4 STEC strains 
through chromogenic substrates 
 
71.4%/99.1% (Gouali et al. 2013) 
Rainbow®Agar 
O157 
Detects O157 and some non-O157 
STEC strains through β-
glucoronidase and β-galactosidase 
activities. 
Not determined (Zelyas et al. 2016) 
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1.4.2.2  Vero cell cytotoxicity assays 
Vero cells - African green monkey kidney cells - have a high number of Gb3 and 
Gb4 receptors on their cell surface, making them extremely sensitive to the 
effects of Stx. Historically, this assay played an important role in the diagnosis 
of STEC infections but lacks of practicality nowadays. Basically, the cells are 
incubated with a filter-sterilised sample e.g. faecal culture or extract, and 
examined for cytophatic effects after 48-72 h. Although verocytotoxicity is still 
considered a gold standard to confirm Stx production, especially in cases where 
isolation of the organism is difficult, it requires access to tissue culture 
facilities, trained personnel and long waiting times to give a diagnosis.  
 
1.4.2.3 Enzyme immunoassays 
Probably one of the most widely used approaches for the diagnosis of STEC is the 
immunodetection of Stx. This is achieved through the use of antibody-based Stx 
detection assays. Since these assays are available as ready to use kits, they are 
commonly used in routine laboratories. The first ELISA developed for Stx 
detection was developed in 1987 by Kongmuang and collaborators (Kongmuang, 
Honda, and Miwatani 1987). The development of more specific and sensitive 
polyclonal and monoclonal antibodies has led to the commercialisation of ELISA-
based assays for the detection of Stx, including the Premier EHEC, Ridascreen 
Verotoxin, ProSpecT STEC Microplate assay and VTEC Screen Seiken RPLA. These 
assays normally require enrichment of the sample to be able to detect the toxin 
but are distinguished for their sensitivity, specificity and robustness.  
 
1.4.2.4  Molecular techniques for the detection of STEC 
STEC-specific PCR is the most sensitive assay, for both O157 and non-O157 
strains. DNA extracts from single colonies, faeces or food extracts can bed used 
as templates for PCR. The complexity of the samples matrix may sometimes 
contain inhibitors of Taq polymerase and decrease the sensitivity. This problem 
can be avoided if template DNA is extracted from broth cultures. 
Recently, Martinez-Castillo and Muniesa highlighted the importance of free Stx-
converting bacteriophages in the environment and how they can influence the 
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detection of STEC in samples, especially with molecular techniques like PCR 
(Martínez-Castillo and Muniesa 2014).  
 
1.4.2.5  Serological diagnosis of STEC 
When patients in the late course of the disease seek medical attention, it 
becomes more difficult to detect STEC by both molecular and immunogenic 
methods because of the low numbers of STEC found in faeces. In these cases, 
the humoral immune response triggered by STEC can be exploited as a diagnostic 
tool. Bitzan and collaborators showed a high incidence of serum antibodies to E. 
coli O157 lipopolysaccharide (LPS) in patients with HUS and highlighted the 
potential of using serological methods for STEC diagnosis (Bitzan et al. 1991). 
Another study also reported the utility of using antibodies for the detection of 
LPS O157 when faecal bacteria or Stx cannot be detected (Chart et al. 1991). To 
date, there are not commercially available serological detection assays for STEC 
detection but is something that could be exploited in the future. 
 
1.4.3 Haemolytic Uremic Syndrome 
 
Haemolytic uremic syndrome (HUS) is a disease characterised by haemolytic 
anaemia, low platelet count and renal impairment (Noris and Remuzzi 2005). It 
is estimated that 15% of STEC infections progress to HUS, children and the 
elderly being the most susceptible population groups (Tarr, Gordon, and 
Chandler 2005). The majority of cases of HUS are consequences of STEC 
infections and around 5-10% of cases is classified as atypical HUS.   
 
Symptoms of HUS develop around 7 days after the first symptoms, when the 
diarrhoea is improving. These include acute paleness accompanied by renal 
failure signs, including oedema, nausea, vomit, oliguria and high blood pressure. 
Neurological, cardiac and respiratory complications may also appear and are 
normally associated with a worse outcome (Karpman et al. 2017). 
  
Since STEC does not cause bacteraemia, Stx has to gain access to the circulation 
to reach its target organs. There are different possible mechanisms responsible 
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for Stx translocation into the circulation. Malyukova and collaborators showed 
that Stx could be taken up by Gb3-free intestinal cells through macropynocytosis 
and transcytosis (Malyukova et al. 2008). Another study carried out by Hurley 
and co-workers suggests that the interaction between STEC and intestinal 
epithelia results in neutrophil recruitment to the intestinal lumen and this 
transmigration enhances Stx movement across intestinal epithelial cells (Hurley, 
Thorpe, and Acheson 2001). A more recent study in the highly virulent E. coli 
O104:H4 strain made by Kunsmann and colleagues shows that Stx could be 
delivered to the host cells via outer membrane vesicles (OMVs) (Kunsmann et al. 
2015). 
 
When Stx gains access to the circulation, it binds to different blood cells, 
including neutrophils, platelets, monocytes and erythrocytes (Karpman et al. 
2017). Stxs are then released from the blood cells in the form of microvesicles in 
order evade the host immune system and successfully deliver the toxin to target 
tissues (Figure 10) (Ståhl et al. 2015).  
 
 
 
Figure 10 Transfer of Shiga toxin from the circulation to the kidney.  
Once Stxs have reached the bloodstream, they bind to the Gb3 receptor on platelets. The toxin 
is internalised to be later released in microvesicles. These microvesicles circulate and reach the 
target organ where they are taken up by endothelial cells. Finally, Stx is released from the 
vesicles inside the cells. Taken from Karpman et al, 2017 
 
Haemolysis and thrombocytopenia are classic indicators of HUS. Stx-induced 
haemolysis is caused by mechanical breakdown in microthrombi occluded 
capillaries, oxidative damage and complement activation (Ruggenenti, Noris, 
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and Remuzzi 2001; Túri et al. 1994; Yazdanbakhsh 2005). Thrombocytopenia is 
the result of platelet activation by Stx, O157 LPS and cytokines.  
 
Currently, treatment of STEC-induced HUS is merely supportive. Administration 
of isotonic fluids before the onset of HUS seems to have a nephroprotective 
effect, reducing the need for dialysis. Since STEC-induced HUS causes 
complement activation via the alternative pathway, inhibition of this pathway 
using antibodies has been attempted. Eculizumab, a monoclonal anti-C5 
antibody has been used as part of the treatment. However, no clear beneficial 
effect was observed.  
 
The use of antibiotics to treat STEC infections remains controversial and will be 
discussed with more details in the next section.  
 
1.4.4 Antibiotics and STEC infections  
 
The use of antibiotics to treat STEC infection remains a controversial topic as 
some studies show that administration of antibiotics enhances the risk of 
developing HUS whereas other studies claim that antibiotics are neither 
effective nor harmful. Panos and collaborators did a systematic review about the 
use of antibiotics for the treatment of STEC infections and its influence in the 
development of HUS (Panos, Betsi, and Falagas 2006). Their work identified a 
large amount of contradiction in the literature that makes it difficult to claim if 
the use of antibiotics is safe or beneficial. Nevertheless, the available data 
suggests that the class of antibiotic and stage at which they are administered 
have an impact on the outcome of the treatment. For example, it has been 
found that the use of doxycycline, phosphomycin, azithromycin and gentamycin 
decreases Stx production in vitro in E. coli O157:H7, whereas the use of 
trimethoprim-sulfamethoxazole, ciprofloxacin and ampicillin showed the 
opposite effect (McGannon, Fuller, and Weiss 2010). Bielaszewska and 
collaborators carried out a similar study looking at the effect of different 
antibiotics on Stx2 expression in E. coli O104:H4. Their results showed that 
ciprofloxacin significantly increases Stx2 expression in vitro, fosfomycin, 
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gentamicin and kanamycin have no significant effect, and chloramphenicol, 
meropenem, azithromycin, rifamixin and tigecycline decrease expression of the 
toxin (Bielaszewska et al. 2012). However, further in vivo studies are required to 
prove the potential usefulness of these antibiotics in the clinical setting. 
 
Rifampicin is another antibiotic that has been shown to prevent induction of Stx 
prophages. Rahal and co-workers found that administration of a MIC of 
rifampicin prior to bacterial eradication with a minimum bactericidal 
concentration (MBC) of gentamicin reduces Stx production in E. coli O157:H7 by 
inhibiting transcription of the stx genes, both in vitro and in vivo (Matar and 
Rahal 2003; Rahal et al. 2011). A subsequent study revealed that the same 
combination of antibiotics did not activate the SOS response in the pathotype E. 
coli O104:H4, giving as a result a decreased production of Stx2 (Fadlallah et al. 
2015). The main drawback of this combinatorial therapy is the rapid 
development of resistance to rifampicin by E. coli, limiting its usefulness.  
 
 
1.5 Anti-virulence approach to treat bacterial infections 
1.5.1 Concept, advantages and potential limitations 
 
During the last few years there has been a growing interest in developing drugs 
that target bacterial virulence instead of bacterial growth or viability. The large 
number of putative virulent targets offers an extraordinary source of potential 
new therapies. This is reflected in the increasing number of publications in this 
area over the last decade (Figure 11). 
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Figure 11 Emergence of anti-virulence research.  
During the last decade there has been a steady progress in the anti-virulence field. Taken from 
Dickey, Cheung, and Otto 2017 
 
Anti-virulence (AV) drugs offer new potential advantages in comparison to 
traditional antibiotics. For instance, blocking a particular virulence factor is 
expected to have little or no effect on the survival and propagation of the 
targeted bacteria, imposing less selective pressure for the development of 
resistance mechanisms like conventional antibiotics do. In addition, as most 
virulence factors are restricted to a single or closely related species, horizontal 
transfer of resistance traits is expected to be unlikely.  
 
From a clinical perspective, AV drugs could be used synergistically with 
conventional antibiotics in circumstances where their use is contraindicated or 
when the pathogen is already resistant. Additionally, as antivirulence therapies 
tend to target processes that are species-specific, they are expected to have 
little or no effect on the host microbiome. 
 
This approach has, however, some disadvantages or challenges that still need to 
be addressed. For instance, development of AV drugs is expected to be a more 
expensive and longer process as large clinical trials might be required to prove 
clinical efficacy compared to antibiotics alone, especially in cases where there is 
still an effective treatment. In addition, the narrow spectrum of AV drugs might 
lead to the use of combination therapies involving the use of different AV drugs 
or a combination of antibiotic and AV drugs to increase bacterial coverage. 
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Furthermore, since AV drugs rely on the host immune system to clear the 
disarmed bacteria from the host, immunocompromised patients might still 
require the use of traditional antimicrobial agents (Clatworthy, Pierson, and 
Hung 2007).  
 
AV drugs are highly desirable for pathogens that are already resistant to the 
current antibiotic arsenal, like the ESKAPE pathogens (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Actinobacter, Pseudomonas 
aeruginosa and Enterobacter) (Pendleton, Gorman, and Gilmore 2013; Boucher 
et al. 2009). Toxin-producing bacteria like C. difficile, C. botulimum, B. 
anthracis, V. cholerae and STEC could also be tackled with the AV approach 
given the current lack of effective treatment strategies. 
 
1.5.2 Anti-virulence strategies against STEC 
 
Efforts to find inhibitors that block the binding of Stx to Gb3 have been 
attempted, but no success has been achieved yet (Kitov et al. 2000; Trachtman 
et al. 2003; Watanabe et al. 2004). In the past few years, there has been a 
growing interest in trying to find strategies to block Shiga toxin activity and its 
production by STEC strains, with the aim of preventing the complications 
associated to it. A brief description of the different approaches made to date 
follows.  
 
A recent study made by Li and collaborators describes the discovery of small 
peptides with Stx2 neutralising activity both in vitro and in vivo (T. Li et al. 
2016). The peptides TF-1 and WA-8 were found to interact with the StxB subunit, 
interfering at the receptor-binding step. When administered to mice and rats, 
TF-1 was able to protect the animals from lethal doses of Stx2 administered 
intraperitoneally and intravenously respectively, making it a promising anti-Stx 
agent. Dong and collaborators explored the anti-Stx2 activity of baicalin, a 
natural occurring flavonoid isolated from Scutellaria baicalensis Georgi (J. Luo 
et al. 2016). Their studies show that baicalin binds to Stx2 and promotes 
formation of toxin oligomers that lack of cytotoxicity. When used in a HUS 
mouse model, baicalin provided ~70% protection against Stx2 relative to the non-
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treated group; baicalin also ameliorated renal and hematologic damage. 
Although baicalin was not toxic in mice even when high doses were employed, 
safety in humans still needs to be evaluated. 
 
As previously mentioned, Stx gets into the hosts cells using the retrograde 
trafficking pathway (Spooner et al. 2006). Stechmann and collaborators 
discovered two small molecules, Retro-1 and -2 that selectively block the 
transport of ricin and Stx (Stechmann et al. 2010). Further studies done by 
Secher and co-workers demonstrated the protective effects of Retro-2 against 
Stx (Secher et al. 2015). Administration of 100 mg/kg of Retro-2 to STEC 
infected mice significantly reduced clinical symptoms and increased survival 
rates, in comparison to the non-treated group. Another independent study made 
by Somshuvra and Linstedt showed that manganese (Mn2+) blocks the endosome-
to-Golgi transport of Stx, protecting eukaryotic cells from the Stx toxic effects 
(Mukhopadhyay and Linstedt 2012). In vivo evaluation of Mn2+ in mice exposed to 
Stx1 revealed that mice treated with Mn2+ did not show any clinical 
manifestations associated with Stx and survived the entire study, compared to 
the non-treated group. The low cost and lack of toxicity in humans makes Mn2+ a 
potential anti-virulence adjuvant for STEC infections.  
 
Some other elements have shown to be active against Stx. A recent study made 
by Surendran-Nair and collaborators showed that selenium (Se) down-regulates 
the expression of stx1 and stx2 in STEC without affecting bacterial growth 
(Surendran-nair et al. 2016). In addition, Se was also able to reduce expression 
of the Gb3 receptor in human lymphoma cells, enhancing the anti-Stx activity. 
However, efficacy in vivo as well as the potential toxic effects associated with 
Se still need to be assessed. In the same area, Crane and collaborators 
discovered that zinc (Zn2+) downregulates Stx production in STEC without 
affecting bacterial viability (Crane, Byrd, and Boedeker 2011). Further studies 
demonstrated that Zn2+ blocks the bacterial SOS response by supressing RecA 
expression induced by DNA damaging agents such as ciprofloxacin, hydrogen 
peroxide or mitomycin C (Crane et al. 2014). 
 
Using biochemical methods and NMR-based comparative metabolomics, 
Bommarius and co-workers discovered indole-based molecules produced by E. 
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coli that are able to regulate the phisiology and virulence of other pathogenic E. 
coli strains (Bommarius et al. 2013). Amongst the indole derivatives identified, 
indole-3-carboxaldehyde (ICA) was able to reduce motility, biofilm formation 
and Stx production in EHEC. ICA was able to reduce by 10-fold the cytotoxic 
effects of Stx2 produced by EHEC on mammalian cells. Although indole has been 
widely studied as signalling molecule between bacteria and could be exploited 
for the development of antivirulence compounds, the mechanism of action still 
remains obscure (J. H. Lee, Wood, and Lee 2015; Melander, Minvielle, and 
Melander 2014; J. Kim and Park 2015).  
 
Lee and collaborators studied the effect of coumarin and several derivatives on 
the regulation of bacterial virulence in EHEC (J. H. Lee et al. 2014). One 
compound, esculetin, repressed the expression of the stx2 gene without 
affecting bacterial growth and attenuated the virulence in vivo when tested in 
Caenorhabditis elegans. More studies are required to elucidate the mechanism 
of action. 
 
Nowicki and co-workers discovered that certain naturally occuring isothiocyantes 
(ITCs) block Stx expression in EHEC due to the induction of the bacterial 
stringent response, a regulatory pathway triggered under nutrient deprivation 
conditions (Nowicki et al. 2014; Boutte and Crosson 2013; Nowicki et al. 2016). 
Their findings suggest that ITCs block phage DNA replication by upregulation of 
(p)ppGpp, a key alarmone involved in the stringent response. ITCs prevented the 
induction of Stx prophages by agents like hydrogen peroxide or mitomycin C, 
making them a viable alternative to be used as anti-virulence adjuvants that can 
be used together with conventional antibiotics. 
 
1.6 The drug discovery process 
 
The driving force to start a drug discovery project is an unmet need for 
treatment of a disease or clinical condition (Lombardino and Lowe III 2004). This 
brings together people from different disciplines in order to come up with ideas, 
hypotheses and a work plan to achieve specific objectives. The drug discovery 
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process can be divided in three main stages: discovery and development, pre-
clinical stage and clinical stage (Figure 12). 
 
 
Figure 12 The drug discovery process at a glance.  
A drug discovery project starts when a medical problem is identified. Experts from different 
fields get together to come up with a hypothesis, ideas on how to tackle the problem and 
specific objectives. Then, testing of chemical libraries in an appropriate biological test begins in 
order to identify bioactive molecules. Structure-activity relationship (SAR) studies on the hit 
compounds are usually performed to improve the bioactivity or physicochemical properties. The 
bioactivity of the new analogues is further validated both in vitro and in vivo, together with 
their toxicity profile. Once a drug candidate has been identified, processes like scale-up of the 
synthesis, chronic safety in animals and formulation start. Next, with consent of the Food and 
Drug Administration (FDA) in the US or a comparable institution elsewhere, the clinical phase 
takes. Testing in humans starts with toleration studies in healthy individuals (Phase I), followed 
by efficacy and dose assessment in individuals who suffer from the disease (Phase II) and finally a 
larger study in several thousands of patients to confirm efficacy and safety (Phase III). This 
provides the required data to get an approval from the FDA and release the drug into the 
market. Modified from Lombradino 2004. 
 
 
 
51 
  
1.6.1 Discovery and development 
1.6.1.1  Target identification and validation 
 
This stage usually starts with the identification and validation of a ‘druggable’ 
target i.e. a biological entity involved in the development of the disease whose 
activity can be modulated to prevent or revert the disease. Different sources of 
information including scientific publications, gene expression and proteomics 
data, transgenic phenotyping, etc. can be used to have a more in-depth 
understanding of the problem. One of the approaches used in target 
identification involves comparing the genomes of healthy individuals with those 
of people with the disease. Differences in the genomes can help to formulate 
hypotheses on which proteins are involved in the development of the disease. A 
similar approach involves changing one gene at a time (knock-out) in cells or 
simpler organisms and see if the phenotype has similarities with the disease 
state. This provides clues about the relationship between the mutated gene and 
the disease. In microbial drug discovery, genes or pathways that are essential for 
bacterial growth or virulence are good starting points.  
 
Once a target has been identified, the next step is the validation using in vitro 
and in vivo tools. The process of validation basically demonstrates that the 
target is essential for the development of the disease. Cell-based or animal 
models of the disease are frequently employed, but best results are achieved 
when a combination of approaches is used.  
 
A common deviation from the classic target identification and validation 
approach occurs when there is already a compound with demonstrated activity, 
or when known drugs show unexpected pharmacological effects, but with an 
undefined mechanism of action. In these cases, the project focuses on the 
identification of the target(s) and mode of action. Failure to identify the target 
does not necessarily disqualify a compound as a drug candidate, but might 
interfere with the potential improvement of the pharmacological properties.  
It is also worth mentioning that important discoveries have been made by 
accident throughout history, phenomena known as serendipity. Many of the 
52 
  
commercially available drugs today were discovered in this way, including 
penicillin, imipramine or sildenafil, which reminds us that luck truly plays a role 
in drug discovery (Ban 2006) 
 
1.6.1.2   Hit discovery 
 
Following target identification and validation, the hit discovery process starts. A 
‘hit’ can be defined as ‘a compound which has the desired activity in a 
compound screen and whose activity is confirmed upon retesting’ (J. P. Hughes 
et al. 2011). High-throughput screening (HTS) is one of the most popular 
approaches used to discover bioactive compounds and can be defined as the 
automated testing of large numbers of small molecules in order to identify 
inhibitors (antagonists) or activators (agonists) of a particular biological target or 
process (Broach and Thorner 1996). There are different screening strategies 
available. The selection is usually based on the available knowledge of the 
target or biological process (Table 2). 
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Table 2 Different types of screening strategies used in drug discovery 
 
1.6.1.3   The importance of the biological assay used in HTS 
 
The type of assay used for the screening of compounds has a great impact on the 
outcome of the project. There are two types of assays used in HTS campaigns: 
phenotype-based and target-based assays. The choice of the assay depends on 
the biology of the problem studied, infrastructure, resources, experience of the 
scientists involved, etc. (Figure 13). 
 
Screening strategy 
 
Description 
High throughput 
Automated analysis of large numbers of compounds in a relevant biological 
assay, generally in 384-well plate format. No prior knowledge of the chemical 
scaffold likely to have activity is required. 
 
Focused screen 
The screening uses compounds that have been previously identified as 
bioactive against a specific class of targets (e.g. kinases) and that have a 
similar chemical scaffold. May limit the discovery of novel bioactive 
structures. 
 
Fragment screen 
Usually, crystals of the protein of interest are soaked with small molecule 
fragments (<300 Da) and the fragment-protein binding interactions are 
analysed using biophysical techniques like NMR or X-ray crystallography. This 
allows for the design of larger molecules with improved affinity for the 
target. 
 
Physiological screen 
This approach uses physiological models of the disease (e.g. a tissue-based 
model) to screen compounds. It is considered to be low-throughput given the 
complexity of the assay, but its phenotypic nature provides a broader pool of 
targets and signalling pathways. 
 
Structure-based 
drug design 
It is normally used as an adjunct to other screening strategies. This approach 
uses the crystal structure of the target and molecular modelling techniques to 
design compounds with improved activity and/or selectivity. 
 
Virtual screen Large virtual libraries of compounds are evaluated using in silico models 
based on the X-ray structure of the target in order to find bioactive 
molecules. It can help to identify a particular chemical scaffold that can be 
used in a focused screen, reducing the number of compounds to be tested.  
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Figure 13 Differences between the phenotype and target-based approaches. 
With the phenotype-based approach, the biological assay is developed first in order to start the 
screening of compounds. Then, studies to understand the mode of action start. On the other 
hand, the target-based approach starts with a defined target. Based on the properties of the 
target, an assay is developed, followed by the screening of compounds to identify the hits. 
Taken from Terstappen et al. 2007 
 
Phenotypic-based assays consist in testing libraries of compounds in a 
physiologically relevant platform to find molecules that produce a specific 
phenotype or response. This approach has gained more popularity in recent 
years as it permits to study multiple targets or pathways that are otherwise 
overlooked in the target-based approach (Haasen et al. 2017).  
 
Historically, phenotypic assays were the pioneers of the discovery of new drugs 
when defined substances were tested in complex living systems or isolated 
organs, looking for changes in the phenotype (Terstappen et al. 2007). Two 
possible downsides of the phenotypic-based approach are the lower throughput 
compared to the target-based method and the complex task of target 
deconvolution. 
 
With the advances in biochemistry and molecular biology, the target-based 
approach emerged with the hope of making the discovery process more ‘rational 
and efficient’. This approach involves overexpression and purification of the 
target protein in order to develop an assay able to measure the effect of 
compounds on the target’s activity, followed by testing in a biological model. 
Even though the pharmaceutical sector perceived a decline in productivity after 
the introduction of the target-based approach (Sams-Dodd 2005), it is still widely 
used in drug discovery programmes. One of the main disadvantages of this 
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approach is that it underestimates the complexity of the target’s activity in 
physiological conditions. It also increases the risk of finding compounds with 
poor physicochemical properties that prevent their progression to biological 
testing (e.g. solubility issues, poor cell permeability, biotransformation, etc.).  
 
1.6.1.4   Hit confirmation 
Once the active compounds or ‘hits’ have been identified, it is important to 
confirm that the activity observed in the primary assay is correct. This starts by 
the generation of dose-response curves, preferably with freshly synthesised or 
repurchased samples of the compounds. This enables to compare the potencies 
of the compounds and to confirm that the activity is not due to a degradation 
impurity from the compound stock (Keserű and Makara 2006).  
 
The use of counter-screens to eliminate false positives or compounds with 
undesirable mechanisms is also a common practice at this stage (Thorne, Auld, 
and Inglese 2010). For example, a hit compound can be tested against a 
different member of the target family using the same assay conditions. If the 
compound shows activity in both assays, it is likely to be non-specific or a false 
positive. These molecules are known as pan-assay interference compounds 
(PAINS). PAINS tend to react in a non-specific manner with different biological 
targets, giving false signals in assays (Baell J. B. and Holloway G. A. 2010). This 
class of compounds give false redaouts in different ways, including 
autofluorescence or colour, chelation of metals essential for the assay or 
chemical modification of the protein of interest. 
Some of the best-known PAINS include toxoflavin, a redox cycler that activates 
or inactivates proteins, polyhydroxylated natural products like curcumin, 
epigallocatechin gallate and resveratrol, phenol sulphonamides, 
isothiazolonones, amongst others (Priyadarsini K. I. 2013).  
Awareness of these molecules and precautionary practices could help to prevent 
spending time and resources in the optimisation of compounds that are very 
unlikely to become drugs.  
These practices include the identification of the most common structural classes 
found in PAINS, the use of software tools that can filter PAINS from screening 
libraries, assess the hits using secondary assays and verify the purity and identity 
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of the hits to discard that he activity is a result of breakdown product of the 
compound identified in the screen (Baell J. B. and Walters M. A. 2014).  
 
   
1.6.1.5   The hit to lead process 
The next step after hit identification involves the performance of structure-
activity relationship (SAR) studies on the lead compound(s). A lead compound 
can be defined as ‘a chemical structure or series of structures that show activity 
and selectivity in a pharmacological or biochemical relevant assay’ (Lombardino 
and Lowe III 2004). 
 
The medicinal chemists play an important role at this stage, as systematic 
chemical modifications need to be performed on the lead compound. The aim of 
this is to improve or manipulate the pharmacological properties of the 
compound, such as potency or undesired effects. It also allows for the 
modification of the pharmacokinetic properties, including the distribution and 
elimination profiles, biotransformation and chemical stability under 
physiological conditions. 
 
There are two ways of doing SAR on a lead compound (Guha 2013). The first one 
involves the crystallisation of the target protein and the compound in order to 
identify the binding interactions. However, this might not be always possible if 
the target is a difficult protein to crystallise or if the target is yet to be 
determined. In these situations, a certain number of compounds with structural 
variations are synthesised and the effect that such modification have on the 
biological activity is studied. 
 
 
1.6.1.6   Preclinical stage 
Once a lead compound has been selected as a potential drug candidate, the next 
step is the toxicity testing. This usually starts with in vitro tests using cell 
culture assays and/or in vivo testing, commonly using transgenic mice to assess 
any possible carcinogenic or teratogenic properties (Strovel et al. 2004). The 
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assays consist of the administration of large doses to induce a toxic effect for a 
short period of time. The animals studied are euthanized and their organs 
examined to see any possible alterations. Long-term toxicological test are also 
performed using lower doses of the drug to see if the drug shows any chronic 
toxicity. The toxicity of a given drug can be measured by its LD50 value i.e. the 
dose required to kill 50% of the population. 
 
It is also important to study the biotransformation of the compounds in the 
human body. This includes the study of the drug metabolites formed and see 
what biological activity they might have. This is an important safety issue, as 
some metabolites might be toxic or have undesired side effects. Ideally, drug 
metabolites should be inactive and quickly eliminated from the body (Shu, 
Johnson, and Yang 2008). 
 
1.6.1.7   Clinical stage 
 
The next stage in the drug discovery process consists in the design of clinical 
trials to test the drug in humans. In order to reach this stage, more in-depth 
studies on the pharmacology of the drug are required, to see whether it has off-
target activity or simply to gain more insights on the drug’s mechanism of 
action. In addition, formulation studies need to take place in order to develop a 
dosage form of the drug that is both stable and suitable for the condition to be 
treated. These studies include the characterisation of the drug’s chemical and 
physical properties in order to choose suitable ingredients for the preparation. It 
also involves pharmacokinetic studies in order to ensure a successful delivery of 
the drug.  
 
The formulation studies do not have to be finalised in order to start the clinical 
studies, as simple preparations can be used at early stages. Long-term stability 
studies will still need to be carried out. The clinical trials are divided in phase I, 
II, III and IV. A complete review of each stage is out of the scope of this work but 
the reader is referred to excellent literature material (J. P. Hughes et al. 2011; 
Hefti 2008).  
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1.7 Aims of the project 
The general aim of this project was to develop small-molecule inhibitors of Shiga 
toxin expression in E. coli O157:H7.  
This interdisciplinary project involved the high- throughput screen of chemical 
libraries, synthesis and biological evaluation in vitro and in vivo of new chemical 
entities able to suppress Shiga toxin expression and affect bacterial virulence. 
This novel approach is attractive as, unlike traditional bactericidal antibiotics, 
there is far less selective pressure for the development of resistance. 
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2 Materials and methods 
 
2.1 Chemicals and molecular reagents 
 
Chemicals used in the present work were purchased from Sigma-Aldrich, Fisher 
Scientific and Invitrogen, unless otherwise stated. 
 
2.2 Growth media 
 
All bacterial growth media was prepared using deionised water, and sterilised in 
autoclave. 
Table 3 Growth media 
Media Components per litre 
LB broth Tryptone  
Yeast extract 
NaCl  
10 g 
5 g 
10 g 
LB agar Tryptone 
Yeast extract 
NaCl 
Agar 
10 g 
5 g 
10 g 
15 g 
M9 salts Na2HPO4 7H2O 
KH2PO4 
NaCl 
NH4Cl 
64 g 
15 g 
2.5 g 
5 g 
M9 media M9 salts 
MgSO4 1 M 
Glucose 20% w/v 
CaCl2 1 M 
200 mL 
2 mL 
20 mL 
100 µL 
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2.3 Cell culture 
 
2.3.1  Shiga toxin cytotoxicity assay 
 
Vero cells were grown in Minimum Essential Medium Eagle, HEPES modification 
(Sigma Aldrich) supplemented with 10% heat-inactivated fetal bovine serum 
(Gibco), 1% penicillin-streptomycin (Gibco) and 1% L-glutamine (Gibco) and 
incubated at 37°C in a humidified 5% CO2 incubator. On the previous day before 
the experiment, Vero cells were seeded at 1x104 cells/well in 96-well plates and 
incubated overnight.  
 
In order to evaluate Shiga toxin production, overnight cultures of C. rodentium 
(λstx2dact) were diluted 1/100 in fresh LB medium supplemented with 100 µg/mL 
chloramphenicol and grown until an OD600 of 0.3. Then, the culture was split in 
samples containing 2 mL of culture and the compound was added at different 
concentrations, taking care of maintaining the final DMSO concentration below 
1%. Shiga toxin production was triggered by the addition of 1 µg/mL of MMC to 
the samples containing the compound and to the positive control. Cultures were 
filter sterilised using 0.2 µm syringe filters and serially diluted, starting at 1:5. 
The growth media of the Vero cells plates was replaced by 100 µL of diluted 
lysate, and the cells were incubated for further 48 h at 37°C in a humidified 5% 
CO2 incubator. Cytotoxicity was assessed using the methylthiazolydiphenyl-
tetrazolium bromide (MTT) assay. MTT (Sigma Aldrich) was dissolved in 
phosphate-buffered saline (PBS) to 1 mg/mL and filter sterilised. The growth 
media in the Vero cells plates was substituted with 100 µL of the MTT solution 
and incubated for 4 h. After this time, the liquid was removed from the wells 
and the precipitate - purple formazan - was dissolved by addition of 100 µL 
DMSO. Plates were read at 540 nm to quantify cell viability. 
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2.4  Storage and handling of bacterial strains 
  
Bacterial stocks were prepared by adding 0.5 mL of bacterial culture to 1 mL 
glycerol (40%) and peptone (2%) and stored at -80°C. To obtain a bacterial 
working plate, bacteria from the frozen stock were streaked onto fresh LB plates 
(supplemented with antibiotics if required), grown overnight at the required 
temperature and stored at 4°C for approximately 2-3 weeks.  
 
2.4.1  Bacterial strains 
All bacterial strains used in this work are listed and described in table 4.  
 
Table 4 Bacterial strains used in this study 
Strain Description and genotype Source 
Escherichia coli   
TUV93-0 Stx-negative derivative of O157:H6 
EDL933 
Campellone et al, 2002 
ZAP0273 Stx-negative derivative of O157:H7 
Sakai 
Prof. David Gally, University 
of Edinburgh 
JP10819 MG1665 strain lysogenig for ϕP27, 
stx2::Tet 
Quiles-Puchalt et al, 2014 
K-12 MG1665 Non-lysogenic laboratory strain Blattner et al, 1997 
BL21 (DE3) Protein expression strain New England Biolabs 
   
Staphylococcus aureus 
JP5011 RN4220 strain lysogenic for ϕSLT, 
pvl::tet 
Ferrer et al, 2011 
RN4220 Non lysogenic laboratory strain Nair et al, 2011 
   
Citrobacter rodentium  
Citrobacter 
rodentium λstx2dact 
lux 
lux-positive C. rodentium with stx2 
prophage 
Mallick et al 2012 
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2.5  Plasmids 
 
All plasmids used in this work are listed and described in table 5. 
Table 5 Plasmids used in this study 
Plasmid Vector type Antibiotic resistance Source 
pstx2::GFP Reporter Chloramphenicol Prof. D. Gally 
prpsM::GFP Reporter Chloramphenicol Roe et al, 2003 
pKD46 Helper Ampicillin Datsenko et al, 2000 
pKD4 Template Kanamycin Datsenko et al, 2000 
pKD3 Template Chloamphenicol Datsenko et al, 2000 
pTXB1 Expression Ampicillin New England Biolabs  
pCP20 Helper Ampicillin Datesenko et al, 
2000 
 
2.6  Bacterial growth conditions 
Unless otherwise specified, overnight cultures consisted on a single colony taken 
from an agar plate suspended in 5 mL of LB (supplemented with antibiotics if 
required), and grown overnight in a shaking incubator at 37 °C, 200 rpm. 
Subcultures were obtained by 1/100 dilution of the overnight culture in fresh LB 
and grown to the desired OD600.  
Table 6 Antibiotics used for the growth of GMO with antibiotic resistance markers 
Antibiotic Final concentration (µg/mL) 
Ampicillin 100 
Chloramphenicol 35 
Erythromycin 500 
Kanamycin 50 
Tetracycline 6 
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2.7  Molecular techniques  
2.7.1  Oligonucleotide primers 
Primers used in the present study were designed using MacVector and 
synthesised by Life Technologies. A 100 µM working stock was used in PCR. All 
primers are listed in table 7 
Table 7 Primers used in this study 
Name Sequence 5’ to 3’ 
Lambda red luxS 5’ 
E. coli Sakai 
GAGGTGGCTAAATGCCGTTGTTAGATAGCTTCACAGTCGGTGTAGGCTGG
AGCTGCTTC 
Lambda red luxS 3’ 
E. coli Sakai 
CTGACTAAATGTGCAGTTCCTGCAACTTCTCTTTCGCATATGAATATCCTC
CTTAG 
Lambda red luxS 5’ check GAGGTGGCTAAATGCCGTTGTTAGA 
Lambda red luxS 3’ check CTGACTAAATGTGCAGTTCCTGCAA 
Lambda red sdiA 3’  
E. coli Sakai 
AGGGGCGTTGCGGTTTACTATGCAGGATACGGATTTTTGTGTAGGCTGGA
GCTGCTTC 
Lambda red sdiA 5’ 
E. coli Sakai 
GACAGAAAAGAGATCAAATTAAGCCAGTAGCGGCCGCGTCATATGAATAT
CCTCCTTAG 
Lambda red sdiA 5’ check 
Sakai 
ACTCTCAGGGGCGTTGCGGTTTACT 
Lambda red sdiA 3’ check 
Sakai 
TCTGGCACGCAGGACAGAAAAGAGA 
Lambda red luxS 5’ 
E. coli MG1665 φ27 
GTGGCTAAATGCCGTTGTTAGATAGCTTCACAGTGTAGGCTGGAGCTGCT
TC 
Lambda red luxS 3’ 
E. coli MG1665 φ27 
TGTGAAGATAGTTTACTGACTAGATGTGCAGTTCCTGCAACATATGAATAT
CCTCCTTAG 
Lambda red luxS 5’ check 
Sakai 
AAATGCCGTTGTTAGATA 
Lambda red luxS 3’ check 
Sakai 
TACTGACTAGATGTGCAGTT 
Lambda red sdiA 5’  
E. coli MG1665 φ27 
GTTGCGGTTTACTATGCAGGATAAGGATTTTTTCAGCTGGGTGTAGGCTG
GAGCTGCTTC 
Lambda red sdiA 3’  
E. coli MG1665 φ27 
GACAGAAAAGAGATCAAATTAAGCCAGTAGCGGCCGCGTAACATATGAAT
ATCCTCCTTAG 
Lambda red sdiA 5’ check 
MG1665 
CAGGGGCGTTGCGGTTTACT 
 
Lambda red sdiA 3’ check 
MG1665 
TGGCACGCAGGACAGAAAAGAGA 
 
Cloning RecA 5’ GGAATTCCATATGATGGCTATCGACGAAAACAAACAGAAA 
Cloning RecA 3’ CCGTGATGCAGGAAGAGCCAAAATCTTCGTTAGTTTCTGC 
pTXB1 check 5’ CGACTCACTATAGGGGAATTGTGAGCGGATAACAATT 
pTXB1 check 3’ CTCGGGTAGGGCAACTAGTGCATCTCCCGT 
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Stx2dact B subunit 5’  ATGAAGAAGATATTTGTAGCGGCTTTATTTGCTT 
Stx2dact B subunit 3’ TTAATTAAACTGCACTTCAGCAAATCCTGAACCT 
Stx2dact A subunit 5’ ATGAAGTGTATATTATTTAAATGGGTACTGTGCCT 
Stx2dact A subunit 3’ TTATTCTCCGGATGTATTTAAAGAGTGGGC 
  
2.7.2  Preparation of genomic DNA 
Genomic DNA was extracted from 1 mL overnight culture of the desired strain 
using the ChargeSwitch gDNA mini bacteria kit (Invitrogen) following the 
manufacturer’s instructions. The DNA was dissolved in 200 µL of nuclease free 
water and stored at -20°C  
 
2.7.3  Polymerase chain reaction (PCR) 
All reactions were performed in nuclease free PCR tubes. When the template 
used was plasmid or genomic DNA, samples were diluted to a 1/100 stock and 
used in the reaction. For colony PCR, a colony was picked from a fresh working 
plate using a micropipette tip and resuspended in 50 µL sterile H2O. The mix was 
boiled at 95°C for 10 minutes and 1 µL used as template for the reaction. 
Table 8 Components of a PCR reaction 
GoTaq Green Master Mix 12.5 µL 
10 µM 5’ primer 0.5 µL 
10 µM 3’ primer 0.5 µL 
Template DNA 1 µL 
Nuclease free H2O 10.5 µL 
 
Table 9 Standard PCR protocol (30 cycles) 
Step Temperature (°C) Time (s) 
Initial denaturation 95 300 
Denaturation 95 45 
Annealing 55 45 
Extension 72 60 per kb 
Final extension 72 600 
Hold 4 Hold 
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2.7.4 Extraction of plasmid DNA 
An overnight culture (5 mL) of the desired strain was centrifuged at 3750 rpm for 
10 minutes. The plasmid was purified using the QIAprep® Spin Miniprep kit 
protocol (Qiagen). The purified plasmid was eluted in 25-40 µL of nuclease free 
water (Ambion) and the concentration was determined using a NanoDrop™ 
(Thermo Fisher) at 200 nm, followed by storage at -20°C. 
 
2.7.5 Agarose gel electrophoresis 
To separate DNA using agarose gel electrophoresis, 1% w/v agarose gels were 
prepared by heating 1 g of ultrapure agarose in 100 mL of 1X Tris-acetate-EDTA 
(TAE) buffer and cooled down at room temperature. SYBR™ Safe DNA gel stain 
(Thermo Fisher) was added at a 1:10,000 dilution before the solution was poured 
into a gel tray and allowed to set. Samples were loaded using the BlueJuice™ 
loading buffer (Thermo Fisher), using 1 Kb Reference DNA ladder as standard 
marker of size. Gels were run at 100 V for 40 minutes and visualised using an 
AlphaImager transilluminator (Alpha Innotech) 
 
2.7.6 Restriction enzyme digests 
All restriction enzyme digests were performed according to the manufacturer’s 
procedures (New England Biolabs). Each digestion consisted of 20 µL containing 
1µg/µL DNA (1 µL), 1x digestion buffer (1 µL), 10 units/µL restriction enzyme (1 
µL) and nuclease-free water (7 µL). Reactions were incubated at 37 °C for 2 h, 
and the digestion products were resolved by agarose gel electrophoresis.  
 
2.7.7 DNA gel purification 
PCR products or linearised DNA from restriction enzyme digestion were resolved 
by agarose gel electrophoresis. DNA was visualised using an AlphaImager 
transilluminator (Alpha Innotech) and the band of interest was excised from the 
gel a purified using the QIAquick Gel Extraction Kit (Qiagen) following the 
manufacturer’s instructions. The purified DNA was then eluted with 25-50 µL of 
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nuclease free water and the concentration determined using a NanoDrop™ 
(Thermo Fisher) at 200 nm, followed by storage at -20°C 
 
2.7.8 DNA ligation 
Ligation reactions were performed following manufacturer’s instructions (New 
Englad Biolabs). Briefly, reactions were carried out in a final volume of 10 µL 
containing 100 ng/µL of linearized plasmid (1 µL), 100 ng/µL of insert DNA (3 
µL), T4 ligase (1 µL), 10x T4 DNA ligase buffer (1 µL) and nuclease-free water (4 
µL). Reactions were incubated at room temperature overnight or at 16°C.  
 
2.7.9 Preparation of electrocompetent E. coli  
An overnight culture of the desired strain is diluted (1/100) in 25 mL of fresh LB. 
The subculture is grown at 37 °C and 200 rpm until an OD600 of 0.6. Culture was 
centrifuged at 3000 x g for 10 minutes at 4°C. The supernatant was discarded 
and the cell pellet resuspended in 20 mL of ice-cold 10% (v/v) glycerol (or cold 
sterile water) before a further centrifugation for 10 min. The pellet is 
resuspended again in 1 ml of ice-cold 10% glycerol and centrifuged for 2 
minutes, and this step was repeated a further 4 times. Finally, the pellet was 
resuspended in 100 µL of ice-cold 10% glycerol and used for transformation. 
 
2.7.10 Electroporation transformation 
For each transformation, 40 µL of electrocompetent cells were mixed either 2 µL 
of purified plasmid or 2-5 µL of the ligation reaction and immediately 
electroporated at 2.5 kV and a capacitance of 25 µF using an Eporator 
electroporator® (Eppendorf). 1 mL of pre-warmed SOC media was added to the 
transformation mixture and transferred to a 1.5 mL eppendorf tube. Cells were 
recovered with incubation at either 30 or 37°C with shaking for 2 h. The cells 
were plated onto LB agar plates supplemented with the required antibiotic, and 
incubated overnight at the appropriate temperature.  
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Table 10 SOC media recipe (1 L) 
Tryptone 20 g 
Yeast extract 5 g 
NaCl 5 M 2 mL 
KCl  1 M 2.5 mL 
MgCl2 1 M 10 mL 
MgSO4 1 M 10 mL 
Glucose 1 M 20 mL 
dH2O Q.S. 1 L 
 
2.7.11 Heat-shock transformation  
For each transformation, 50 µL of chemically competent BL21 Star (DE3) were 
mixed with 4 µL of purified plasmid and incubated on ice for 30 min. The cells 
were then heat shocked for 45 seconds at 42°C, followed by a 2 min incubation 
in ice. Then, 1 mL of pre-warmed SOC media was added and the cells recovered 
with incubation at 37°C, 200 rpm for 2 h. Finally, cells were plated onto LB agar 
plates supplemented with the appropriate antibiotic and incubated overnight.  
  
2.7.12 Gene inactivation using the lambda red recombineering 
system 
Gene ‘knockouts’ were performed using lambda red recombineering. Briefly, the 
technique involves the amplification of an antibiotic resistance cassette that 
contains 5’ and 3’ overhangs that flank the gene of interest. The PCR product is 
transformed into bacterial cells and the gene of interest if replaced with the 
resistance cassette, which allows for identification of such mutants. The lambda 
red recombineering system requires three components to work: gam (encodes a 
protein that prevents the digestion of linear DNA introduced into the cells), exo 
(encodes a 5’ to 3’ exonuclease that degrades linear dsDNA) and beta (encodes a 
ssDNA annealing protein that protects the ssDNA created by Exo and promotes its 
annealing to a complementary ssDNA). These elements are encoded on the 
arabinose-inducible pKD46 plasmid. In this way, when the resistance cassette 
PCR product is transformed into the cells that have pKD46, the Gam protein 
prevents degradation, Exo converts the 5’ ends into 3’ ssDNA overhangs and Beta 
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uses these overhangs to pair them with their complementary target (Datsenko 
and Wanner 2000) 
 
Experimentally, the procedure involved the transformation of the AmpR pKD46 
plasmid into the target strain. The plasmid is temperature sensitive so cells had 
to be grown at 30°C. To design the antibiotic resistance with flanking regions of 
the knockout gene, the kanamycin or chloramphenicol genes are amplified from 
the pKD4 or pKD3 plasmids respectively. Primers should have internal overlap 
with the resistance marker and external overlap with the target gene (50 bp 
upstream and downstream). The PCR products from 10 reactions were run on 
0.5% agarose gel, DNA excised, purified and pooled.  
 
Cells transformed with the pKD46 plasmid were grown in 25 mL of LB media 
supplemented with ampicillin and 0.1 M arabinose at 30°C. Once the culture 
reached an OD600 of 0.6, the cells were made electrocompetent following the 
‘preparation of electrocompetent E. coli’ protocol. Cells were transformed with 
approximately 3-4 µL of the PCR product, plated onto agar plates supplemented 
with the corresponding antibiotic, and grown at 42°C. Colonies were re-streaked 
on LB agar plates + antibiotic and incubated at 42°C for 2-3. This was done to 
allow curing of the mutant of the pKD46 plasmid. Successful gene knockouts 
were identified by colony PCR, using primers that only flank the target gene. 
 
2.7.13 Removal of antibiotic resistance cassettes by FLP 
recombination  
 
In order to remove the antibiotic resistance cassette as a consequence of the 
lambda red gene inactivation process, competent cells of the mutant of interest 
were prepared following the ‘preparation of electrocompetent E. coli’ protocol. 
Cells were transformed with the plasmid pCP20, which has a temperature 
sensitive origin of replication resistant to chloramphenicol and ampicillin. Cells 
were recovered at 30°C, 200 rpm, for 3 h and plated onto ampicillin plates.  
 
Few transformants were picked and inoculated into 5 mL of LB (no antibiotic) 
and incubated at 42°C overnight to induce FLP recombinase expression and 
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select for the loss of pCP20. After the incubation period, transformants were 
plated onto two ampicillin plates, one was incubated at 30°C and the other one 
at 42°C. Colonies that only grew on the 42°C plate were picked and resuspended 
in 10 µL of LB and 3 µL were plated onto a set of three plates: chloramphenicol, 
37°C; Ampicillin 30°C; no selection, 37°C. Colonies that only grew on the no 
selective plate had lost both the pCP20 plasmid and the CmR cassette. This was 
confirmed through PCR. 
 
2.7.14 Reporter assays 
Shiga toxin expression assays were performed using the pstx2::GFP reporter 
fusion plasmid (pNY16). The plasmid was transformed by electroporation into 
ZAP0273 and transformants cultured overnight in LB medium containing 35 
µg/mL chloramphenicol. Overnight cultures were diluted into fresh LB (1/100) 
and grown to and OD600 of 0.3 at 37°C and 200 rpm. Compounds and mitomycin C 
(MMC, 1 µg/mL) were added at this point, and fluorescence and optical density 
of cultures measured hourly. GFP fluorescence of 200 µL aliquots was measured 
in a 96-well blank microtiter plate using a FLUOstar Optima plate reader (BMG, 
Germany).  
 
2.7.15 Phage transduction assays 
 
Overnight cultures of E. coli JP10819 and S. aureus JP5011 (Quiles-Puchalt, et 
al., 2014) were diluted 1/100 in LB (E. coli) or TSB (S. aureus) media and grown 
at 37°C, 200 rpm until an OD600 of 0.25 was reached. Compounds and 1 µg/ml 
MMC were added at this point and cultures were incubated at 32°C, 80 rpm 
shaking for 4 h, followed by room temperature without shaking for 16 h. 
  
On the next day, cultures were filter sterilised using 0.2 µM syringe filters, and 
serially diluted in phage buffer (100 mM NaCl, 0.5 M tris pH 7.8, 1 mM MgSO4, 4 
mM CaCl2). In parallel, cultures of the recipient strains MG1655 (E. coli) or 
RN4220 (S. aureus) were grown to an OD600 of 1.4, after which CaCl2 was added 
to a final concentration of 10 mM. 100 µl of phage lysate was added to 1 ml 
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aliquots of the recipient strain and samples were incubated without shaking at 
37 °C for 30 minutes. Then, 3 ml of pre-warmed (45°C) top agar was added, and 
samples were poured onto LB or TSB agar plates containing 6 µg/ml tetracycline 
and 1.7 mM sodium citrate. A negative control lacking addition of phage lysate 
was also included to confirm the absence of phage contamination. Colonies were 
subsequently counted to define the number of transduction events per sample.  
 
2.8  Biochemical techniques 
2.8.1  RecA Protein overexpression 
For expression of RecA, E. coli BL21(lDE3) cells were heat-shock transformed 
with the pTXB1-recA expression vector. Cells were cultured in M9CA medium 
supplemented with 100 µg/ml ampicillin and grown at 37°C, 200 rpm to an OD600 
of 0.8. When the desired OD600 was reached, IPTG was added to a final 
concentration of 500 µM and the culture flasks were transferred to a shaker 
incubator set at 18°C, 200 rpm and incubated for 16-18h. The next day, cells 
were harvested by centrifugation and resuspended in sucrose lysis buffer (3.5 mL 
per gram of cell pellet). Cells were sonicated at 75 W, 40% output for 5 min with 
pulses of 5 seconds on and 10 seconds off, using a Soniprep 150 sonicator (MSE). 
The soluble fraction was centrifuged at 13000 rpm for 15 min at 4°C. Chitin 
beads (New England Biolabs) were loaded in a 1.5x12 cm column and washed 
with chitin binding buffer (10 column volumes) prior to the loading of the soluble 
fraction. Generally, 10 mL of chitin beads can be used for one-liter culture 
purification, so the bed volume and column size should be adjusted accordingly. 
Once the column was equilibrated with the chitin-binding buffer, the soluble 
fraction was loaded onto the column at a flow rate between 0.5-1 mL/min. 
When the entire soluble fraction was loaded, the column was washed with 10 
bed volumes of chitin-binding buffer. Two bed volumes of chitin cleavage buffer 
were quickly flushed to homogenously distribute the DTT through the column. 
The column was then sealed and incubated at 4°C overnight to allow intein 
autoproteolysis. The next day, the released RecA was eluted with 3-5 bed 
volumes of elution buffer in fractions of approximately 1 mL.  The protein 
concentration in each fraction was determined using the Bradford Assay and the 
most concentrated fractions were pooled and dialyzed overnight against 2 L of 
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dialysis buffer. On the next day, the protein was concentrated to approximately 
1 mg/mL using 25 mL concentrators 30 MWCO (Vivaspin). 
 
In order to regenerate the chitin resin, the column was washed with 3 bed 
volumes of 0.3 M NaOH (stripping solution) and allowed to soak for 30 min and 
then washed with 7 bed volumes of stripping solution. The column was then 
rinsed with 20 bed volumes of distilled water and 5 bed volumes of chitin-
binding buffer for storage. 
Table 11 RecA purification buffers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Buffer Components  
Lysis buffer Sucrose 
Tris HCl pH 7.5 
Brij-35 
EDTA 
25% (w/v) 
80 mM 
0.5% (v/v) 
5 mM 
 
Chitin binding buffer Tris HCl pH 7.5 
NaCl 
EDTA 
CHAPS 
20 mM 
1.5 mM 
1 mM 
0.5 % (w/v) 
 
Chitin cleaving buffer Tris HCl pH 8 
Glycerol 
EDTA 
Triton X-100 
DTT 
20 mM 
10% (v/v) 
0.1 mM 
0.1% (v/v) 
50 mM 
 
Elution buffer  Tris HCl pH 8 
Glycerol 
EDTA 
Triton X-100 
 
20 mM 
10% (v/v) 
0.1 mM 
0.1 % (v/v) 
 
Dialysis buffer Tris HCl pH 7.5 
Glycerol  
DTT 
20 mM 
10% (v/v)  
1 mM 
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2.8.2 SDS-PAGE 
Protein samples for analysis by SDS-PAGE were mixed with 4x NuPAGE® LDS 
loading buffer and boiled for 10 min at 70°C prior to the loading onto NuPAGE® 
4-12% Bis-Tris pre-cast gels (Invitrogen). A total of 10-15 µL of sample were 
loaded and SeeBlue plus2 pre-stained protein standard (Invitrogen) was used as a 
molecular weight marker. The gels were run using NuPAGE MES SDS Running 
buffer for 45-50 min at 150 V. The gels were stained with Coomassie blue for 
protein visualization or taking for immublotting. Coomassie blue stain is formed 
by dissolving Coomassie blue R-250 (0.1% w/v) in water-methanol-glacial acetic 
acid (5:4:1).  
 
2.8.3 General Western blot procedure 
Proteins for immunobloting were transferred from SDS-PAGE to PVDF membrane 
(Millipore) at 30 V for 90 minutes using the Mini Blot module (Thermo Fisher). 
The membrane was then blocked with 4% skimmed milk (Marvel) suspended in 
PBST for 1 h at room temperature in an orbital shaker. This was followed by an 
overnight incubation with the primary antibody dissolved in PBST in an orbital 
shaker at 4°C. On the next day, the membrane was washed with PBST three 
times, followed by incubation with the secondary horseradish-peroxidase 
conjugated antibody for 1 h at room temperature. At the end of this incubation, 
the membrane was washed with PBST a further three times. Finally, the 
membrane was developed with SuperSignal West Pico Chemiluminescent ECL 
substrate (Thermo Scientific) according to the manufacturer’s specifications. 
Table 12 Antibodies used in this study 
Primary antibody Dilution Secondary antibody 
Mouse anti-StxB (Abcam) 1:1000 Goat anti-mouse 
Rabbit anti-GroEL (Enzo) 1:10,000 Goat anti-rabbit 
Rabbit anti-RecA (Abcam) 1:6000 Goat anti-rabbit 
 
 
2.8.4 RecA ATPase assays 
RecA ATPase activity was assessed using an Innova Biosciences ATPase assay kit 
(#601-0120) following the manufacturer’s protocol. Briefly, the assays were 
74 
  
performed in 96-well plates; each reaction consisted in 50 µL containing 0.25 µM 
RecA, 5 µM ssDNA, 25 µL of SB mix (0.5 M Tris pH 7.5, 0.1 M MgCl2, 10 mM ATP, 
H2O) and nuclease free water q.s. 50 µL. The small molecule inhibitors were 
added to the wells before addition of ssDNA. Care was taken to keep the DMSO 
at a final concentration of 1% to avoid interference with the assay. The plate 
was incubated at 37°C for 30 minutes and reactions were stopped by addition of 
12.5 µL of PiColorLock™, followed by addition of 5 µL of stabilizer. Absorbance 
was measured at a wavelength 590-660 nm. 
 
2.8.5 Sample preparation for metabolomics analysis 
Preparation of samples for metabolomics was adapted from Creek et al. 2011. 
Briefly, bacterial cultures were grown in 10 mL of M9 minimal medium to an 
OD600 of 0.9. 2.5 mL of the bacterial culture were mixed with 2.5 mL of fresh M9 
medium, followed by addition of the compound of interest at the desired 
concentration. The solution was incubated for 1 h at room temperature. 1 mL of 
the incubated solution was mixed with 100 µL of 10-bromodecade oil and the 
mixture was centrifuged at 13000 rpm, 4°C for 2 min. 12.5 µL of supernatant 
were transferred into a sterile micro-centrifuge tube and mixed with 500 µL of a 
1:3:1 chloroform:methanol:water extracting solution, generating the 
supernatant sample. The rest of the supernatant was removed and the cell 
pellet was resuspended in 200 µL of the extracting solution to create the cell 
sample. All the samples were performed in triplicate and stored at -80°C until 
MS analysis. Dr. Karl Burgess and Dr. Stefan Weidt from the University of 
Glasgow Polyomics Division carried out the metabolomics analysis. Samples were 
analysed through hydrophilic interaction liquid chromatography (HILIC) on 
Dionex UltiMate 3000 RSLC system (Thermo Fisher Scientific, Hemel Hempstead, 
UK) using a ZIC-pHILIC column (Merck Sequant). Samples were eluted with a 
linear gradient using A) 20 mM ammonioum carbonate in water and B) 
acetonitrile over 26 min at a flow rate of 0.3 mL/min as shown in table 13. 
 
 
 
 
 
75 
  
Table 13 Elutions of samples in HILIC 
Time/min %A %B 
0 20 80 
15 80 20 
15 95 5 
17 95 5 
17 20 80 
24 20 80 
 
The injection volume was 10 µL and samples were maintained at 4°C prior to 
injection. The MS analysis was performed using a Thermo Orbitrap Exactive 
(Thermo Fisher Scientific), operated in polarity switching mode with a resolution 
of 50’000. Samples of cell-free medium and appropriate compound 
concentration were used as controls. 
 
      
2.9 Biophysical techniques 
 
2.9.1 Microscale thermophoresis 
RecA protein was covalently labelled with NT-647 Red dye (Nanotemper 
technologies). The dye carries a reactive NHS-ester group that modifies primary 
amines present in amino acids like lysine. Excess dye was removed using a 
gravity flow column. The compound AHU3 was dissolved in a PBS-DMSO (4%) 
solution and diluted from 200 µM to 12 pM. RecA was dissolved in PBS at 100 µM. 
RecA was incubated with the different concentrations of AHU3 for 5 minutes at 
room temperature, followed by loading into MST NT.115 glass capillaries and the 
MST analysis was performed using a Monolith NT (NanoTemper Technologies) 
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2.10   High throughput screening 
2.10.1 Primary screen 
A high-throughput screening campaign to find inhibitors of Stx expression was 
carried out at the Drug Discovery Unit (DDU), University of Dundee. A total of 
29,504 were screened using the stx2::GFP reporter assay as described below. 
 
Compounds from the Gates and DDU targeting sets, the Epigenetics set and 
Easyset libraries were dispensed into barcoded clear-bottomed black 384-well 
plates (Greiner#781091) using an Echo 550 acoustic dispenser (Labcyte) to reach 
a final concentration of 30 µM (125 nL). Separately, an overnight culture of E. 
coli stx2::GFP was diluted (1:50) into freshly prepared M9 minimal media 
supplemented with chloramphenicol (35 µg/mL). The culture was grown at 37°C, 
200 rpm until an OD600 of 0.2-0.25 was reached. The culture was split in two 
flasks. Flask 1 was treated with MMC (1 µg/mL) and flask 2 was not. Using a 
Multidrop™ Combi reagent dispenser (Thermo Scientific), 30 µL of the bacterial 
culture in flask 1 were dispensed into columns 1-23 of all assay plates. Culture 
from flask 2 was dispensed into column 24 using a VIAFLO II electronic pipette 
(Integra Biosciences). The plates were sealed with parafilm, placed into a moist 
box and incubated at 37°C, 150 rpm for 6 h. Care was taken to avoid stacking 
more that 4 plates high. Using a Pherastar plate reader (BMG Labtech), the 
plates were read for GFP 485/520 nm set at 10 flashes per well and settling time 
0.2 s. The raw data was processed using ActivityBase software version 8.0.2.15 
(IDBS) 
For all the data analysis, the relative fluorescence units (RFU) measured were 
normalized to a percentage effect of the positive control using the following 
formula:  
 % Effect = Raw data −Median (MMC+)Median MMC − −Median (MMC−) 
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2.10.2 Counter-screen of hit compounds using E. coli 
rpsM::GFP 
An overnight culture of E. coli rpsM::GFP was diluted (1:50) into freshly 
prepared M9 minimal media supplemented with chloramphenicol (35 µg/mL). 
The culture was split in two flasks. Flask 1 was treated with ampicillin (100 
µg/mL) and flask 2 was not. Using a Multidrop™ Combi reagent dispenser 
(Thermo Scientific), 30 µL of the bacterial culture in flask 2 were dispensed into 
columns 1-11 and 13-24 of all assay plates. Culture from flask 1 was dispensed 
into columns 12 and 24 using a VIAFLO II electronic pipette (Integra Biosciences). 
The plates were sealed with parafilm, placed into a moist box and incubated at 
37°C, 150 rpm for 6 h. Care was taken to avoid stacking more that 4 plates high. 
Using a Pherastar plate reader (BMG Labtech), the plates were read for GFP 
485/520 nm set at 10 flashes per well and settling time 0.2 s. The raw data was 
processed using ActivityBase software version 8.0.2.15 (IDBS) 
 
 
2.10.3 Dose response calculation 
The dose response evaluation of the compounds was calculated using MathIQ 
model 203 in ActivityBase XE. The potency of the hit compounds was assessed 
using the stx2::GFP assay, two-fold serial dilutions of the compounds. For all 
data analysis, the RFU of each well was normalised to as percentage effect (% 
Effect) of the positive control. ActivityBase XE (IDBS) was used for all data 
processing. Potency was determined using a 4 –parameter logistic fit (minimum, 
maximum, hill slope and IC50), being defined in reference to the negative 
logarithm of the molar value at the point of inflection of a sigmoidal dose-
response curve (pIC50). All the plates assessed were subject to quality control 
analysis, ensuring that the SB ratio ≥ 2, CV %<10% and Z’ ≥ 0.4. 
 
2.11   Cytotoxicity of AHU series 
Cytotoxicity evaluation of the AHU1-3 compounds was carried out at the 
European Screening Port (Hamburg, Germany). Human embryonic kidney 293 
(HEK 293) cells were grown on surface modified T175 cell culture flasks (Greiner 
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Bio-One) in DMEM (Life Technologies) with 10% FCS, streptomycin (100 µg/mL) 
and 100 U/mL penicillin G. Cells were incubated at 37°C in the presence of 5% 
CO2 and were harvested at 80-90% confluency. The compounds (200 nL of 10 mM 
DMSO stock) were spotted onto polystyrene 384-well cell culture microtitre 
plates (Greiner Bio-one) using the Echo 550® Liquid Handler (Labcyte). Each 
assay plate also contained 16 wells for the positive control (cells treated with 3 
mM cisplatin) and 16 wells for the negative control (cells treated with 0.1% 
DMSO). To harvest the cells, 1.5 mL of trypsin/EDTA was added per flask and 
incubated at 37°C in a 5% CO2 incubator for 2 min. Detached cells were 
resuspended in pre warmed media to a density of 0.2x106 cells/mL. A total of 20 
µL were added to each well of the 384-well plate, giving a final compound 
concentration of 100 µM and 0.1% v/v DMSO. The plates were incubated 24 h at 
37°C in a 5% CO2 incubator, followed by addition of 20 µL of Cell Titer-Glo 
reagent (Promega) to each well and the plate was placed upon a linear shaker 
for 1 minute at room temperature and further incubated at room temperature 
without shaking for 10 min. Luminescence was read using the EnVision® 
Multilable Reader (PerkinElmer) with 0.5 sec read time per well. The compounds 
were tested on three different days in duplicate.  
 
2.12  Animal experiment 
 
2.12.1 Mice maintenance 
Female inbred BALB/c mice, aged 6-8 weeks were purchased from Harlan 
Laboratories, UK. Mice were housed in groups of 4 and 5 in a room with 
controlled temperature 22°C, with a 12 h light/darkness cycle. Animals had 
access to BK001E Beekay rat and mouse diet (Special Diet Services) and water at 
all times. 
 
2.12.2 Infection of mice with C. rodentium λstx2dact 
LUX marked C. rodentium λstx2dact was cultured overnight in LB at 37°C and 
subcultured in pre-warmed DMEM and grown to an OD600 of 0.8. Bacteria were 
harvested by centrifugation and resuspended in sterile PBS to get a 100x 
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concentrate of the original culture. The infection dose was determined by serial 
dilution of the inoculum and plating onto LB agar plates and was determined to 
be 3.1 x1010 CFU/mL.  
 
2.12.3 Preparation of peanut butter/hazelnut cocoa pellets 
and dosing 
Pellets were prepared mixing equal amounts of peanut butter and hazelnut 
cocoa spread. Approximately 100 mg ± 2.5 mg of the mixture were dispensed in 
1.5 mL eppendorf tubes. The compound furanone C-30 was added from a 10 mM 
ethanol stock in order to get doses of 4 µg per gram of weight. Placebo pellets 
contained an equal amount of vehicle only. The pellets were thoroughly mixed 
by hand with a spatula, spun down in a bench centrifuge, and stored at -20°C 
until use. Doses were voluntarily administered by oral route twice a day at 9:00 
and 18:00 hrs using sterile micropipette tips.  
 
2.12.4 Live imaging of infected mice using the IVIS® Spectrum 
system 
The extent and location of colonisation in mice was monitored using the IVIS® 
Spectrum imaging system. Animals were anesthetized by inhalation of 2% 
isofluorane and bioluminescence produced by the LUX marked C. rodentium 
λstx2dact strain was measured as photons per second (p/s) using an exposure time 
of one minute, with large or medium binning.  
 
2.12.5 Faecal shedding bacterial counts 
Bacterial colonization was determined by faecal shedding. Faecal samples were 
collected from individual mice and resuspended in sterile PBS to get a faecal 
concentration of 100 mg/mL. The samples were incubated at 4°C for 30 min, 
then vortexed to disrupt the pellets and release the bacteria. After a very short 
centrifugation, the supernatant was serially diluted using sterile PBS and 10 µL 
of each dilution were spotted in triplicate onto LB agar plates containing 
erythromycin and chloramphenicol. The number of colony forming units was 
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calculated from the dilution that contained between 5-30 colonies. The 
following equation was used for the calculation of colony forming units (CFUs) 
 CFU/mL = (#colonies)(dilution factor)volume plated (mL)  
 
2.12.6 Tissue collection and histology 
To assess the intestinal and kidney damage caused by C. rodentium λstx2dact in 
infected mice, at necropsy, distal colon (≈0.5 cm) and one kidney were 
removed, opened longitudinally and placed in 10% formal saline for histological 
assessment. Five-micrometer tissue sections were cut and stained with H&E 
stain at the Veterinary Diagnostics department, University of Glasgow. Slides 
were scanned at the Academic Unit of Medical Genetics and Clinical Pathology, 
Queen Elizabeth University Hospital and visualized Leica Biosystems visualization 
software. 
 
2.13  Organic synthesis  
 
2.13.1 General 
  
All chemicals and solvents were used as received. Tetrahydrofuran, toluene and 
acetonitrile were purified through a Pure Solv 400-5MD solvent purification 
system (Innovative Technology, Inc). Solvents were evaporated under reduced 
pressure at 40°C. All reactions described were performed under argon 
atmosphere unless otherwise stated and monitored by thin layer chromatography 
(TLC) with precoated TLC plates (Merck Silica Gel 60 F254). Plates were 
visualized by UV light (254 nm), iodine vapours or stained with anisaldehyde. 
Compounds were purified using flash column chromatography using silica gel 
(Fluro Chem Silica LC 60A) as the stationary phase. 1H NMR and 13C NMR spectra 
were recorded at 400 MHz and 100 MHz or at 500 MHz and 125 MHz using either a 
Bruker DPX Avance400 instrument or a Bruker Avancell500 instrument, 
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respectively. IR spectra were obtained using a Shimadzu FTIR-8400 
spectrometer.  
 
2.13.1.1 Synthesis of AHU compounds 
 
 
4-(4-nitrophenyl)morpholine (1a). 1-fluoro-4-nitrobenzene (0.50 g, 3.5 mmol) 
and K2CO3 (0.53 g, 3.8 mmol) were stirred in DMSO (0.75 mL) for 0.5 h at room 
temperature. Then, morpholine (0.30 mL, 3.5 mmol) was added slowly to the 
reaction mixture and this was left stirring overnight. Subsequently, the contents 
were poured into ice-water and the precipitate was filtered and dried to afford 
1a (0.6 g, 92%) as a yellow powder.  
1-methyl-4-(4-nitrophenyl)piperazine (1b). Following the procedure for 
compound 1a, 1-fluoro-4-nitrobenzene (0.50 g, 3.5 mmol), K2CO3 (0.53 g, 3.8 
mmol), DMSO (0.75 mL) and 1-methylpiperazine (0.40 mL, 3.5 mmol) afforded 
1b (0.72 g, 92%) as a yellow powder. The NMR data obtained is in accordance 
with the literature. 
1H NMR (CDCl3, 400 MHz): 8.14 (2H, d, J=9.5 Hz), 6.85 (2H, d, J=9.5 Hz), 3.46 
(4H, m), 2.58 (4H, m), 2.38 (3H, s).  
1-buthyl-4-(4-nitrophenyl)piperazine (1c). Following the procedure for 
compound 1a 1-fluoro-4-nitrobenzene (0.50 g, 3.5 mmol), K2CO3 (0.53 g, 3.8 
mmol), DMSO (0.75 mL) and 1-butylpiperazine (0.50 mL, 3.5 mmol) afforded 1c 
(0.72 g, 78%) as a yellow powder.  
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1H NMR (CDCl3, 400 MHz): 8.15 (2H, d, J=9.5 Hz), 6.85 (2H, d, J=9.5 Hz), 3.47 
(4H, m), 2.61 (4H, m), 2.43 (2H, m), 1.54 (2H, m), 1.35 (2H, sextet, 7.2 Hz), 
0.97 (3H, t, 7.3 Hz).  
4-morpholinoaniline (1b). To a mixture of 4-(4-nitrophenyl)morpholine (0.50 g, 
2.4 mmol) in anhydrous methanol (7 mL) under atmosphere of argon was added 
Pd/C (50 mg, 10%) followed by replacement of the argon with a hydrogen 
atmosphere. The reaction mixture was stirred at room temperature until 
completion (2 h). The crude mixture was filtered over celite and the methanol 
was removed in vacuo to afford 1b (0.41 g, 96%) as a beige powder.  
1H NMR (CDCl3, 400 MHz): 6.83 (2H, d, J=8.8 Hz), 6.70 (2H, d, J=8.8 Hz), 3.88 
(4H, m), 3.05 (4H, m).  
4-(4-methylpiperazin-1-yl)aniline (2b). Following the procedure for compound 
2a, 1-methyl-4-(4-nitrophenyl)piperazine (0.70 g, 3.1 mmol), anhydrous 
methanol (15 mL) and Pd/C (70 mg, 10%) afforded 2b (0.47 g, 78%) as a brown 
powder. The NMR data obtained is in accordance with the literature 
(Galstukhova N. B et al 1972).  
1H NMR (CDCl3, 400 MHz): 6.85 (2H, d, J=8.9 Hz), 6.69 (2H, d, J=8.9 Hz), 3.10 
(4H, m), 2.61 (4H, m), 2.38 (3H, s).  
4-(4-butylpiperazin-1-yl)aniline (3b). Following the procedure for compound 
2a, 1-butyl-4-(4-nitrophenyl)piperazine (0.70 g, 2.7 mmol), anhydrous methanol 
(15 mL) and Pd/C (70 mg, 10%) afforded 3b (0.63 g, 90%) as a brown powder.  
1H NMR (CDCl3, 400 MHz): 6.84 (2H, d, J=8.9 Hz), 6.67 (2H, d, J=8.9 Hz), 3.09 
(4H, m), 2.63 (4H, m), 2.41 (2H, m) 1.53 (2H, m) 1.37 (2H, sextet, J=7.2 Hz) 
0.95 (3H, t, J= 7.3 Hz).  
1-(4-morpholinophenyl)-1H-pyrrole-2,5-dione (1c). A solution of 4- 
morphoaniline (0.20 g, 1.1 mmol) in DCM (5 mL) was treated by the slow 
addition of maleic anhydride (0.10 g, 1.1 mmol). The reaction was stirred at 
room temperature for 1 h. Then, the DCM was removed in vacuo to afford the 
maleanilic acid, which was dissolved in acetic anhydride (5 mL) and sodium 
acetate (22 mg, 10%). The mixture was heated for 2 h under reflux. Then the 
reaction was cooled down, quenched with water and neutralised with a K2CO3 
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saturated solution. The solution was then transferred to a separation funnel and 
extracted with DCM. The combined organic layers were dried with Na2SO4 and 
concentrated in vacuo. The product was purified through column 
chromatography (petroleum ether/AcOEt, 5/5) giving 0.20 g (72%) of 1c as an 
orange powder.  
1H NMR (CDCl3, 400 MHz): 7.13 (2H, d, J=9.1 Hz), 6.89 (2H, d, 9.1 Hz), 6.75 (2H, 
s), 3.79 (4H, m), 3.11 (4H, m).  
13C NMR (CDCl3, 100 MHz): 169.9, 150.9, 134.1, 127.1, 122.8, 115.7, 66.8, 48.9.  
IR ʋmax (film)/cm-1
 
30071, 2358, 1707, 1517. MS (EI) calcd for C14H14N2O3 [M]+ 
258.10 m/z, found 258.2 m/z. 
1-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrrole-2,5-dione (2c). Following the 
procedure for compound 1c, 4-(4-methylpiperazin-1-yl)aniline (0.2 g, 1.04 
mmol), maleic anhydride (0.1 g, 1.12 mmol), DCM (5 mL), acetic anhydride (5 
mL) and sodium acetate (22 mg, 10%) yielded 0.13 g (56.2%) as an orange solid. 
1H NMR (CDCl3, 400 MHz): 7.22 (2H, d, J=9.1 Hz), 7.01 (2H, d, J=9.1 Hz), 6.86 
(2H, s), 3.28 (4H, m), 2.61 (4H, m), 2.39 (4H, m).  
13C NMR (CDCl3, 100 MHz): 169.9, 150.9, 134.1, 127.1, 122.3, 116.6, 55.8, 48.7, 
46.1.  
IR vmax (film)/cm-1
 
3089, 2947, 2804, 2359, 1700, 1517. MS (EI) calcd for 
C15H17N3O2 [M]+ 271.13 m/z, found 271.2 m/z. 
1-(4-(4-butylpiperazin-1-yl)phenyl)-1H-pyrrole-2,5-dione (3c). Following the 
procedure for compound 1c, 4-(4-butylpiperazin-1-yl)aniline (0.2 g, 0.85 mmol), 
maleic anhydride (0.08, 0.85 mmol), DCM (5 mL), acetic anhydride (5 mL) and 
sodium acetate (22 mg, 10%) yielded 0.19 g (70%) as an orange solid. 
1H NMR (CDCl3, 400 MHz): 7.22 (2H, d, J=9.1 Hz), 7.01 (2H, d, J=9.1 Hz), 6.86 
(2H, s), 3.28 (4H, m), 2.61 (4H, m), 2.39 (4H, m).  
13C NMR (CDCl3, 100 MHz): 169.9, 150.9, 134.1, 127.1, 122.2, 116, 58.4, 53.1, 
48.7, 29, 20.7, 14.  
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IR ʋmax (film)/cm
-1 3086, 2925, 2359, 1700, 1517. MS (EI) [M]+ calcd for 
C18H23N3O2 313.18, found 313.3 m/z.  
2-(4-morpholinophenyl)isoindoline-1,3-dione. Following the procedure for 
compound 1c, 4-morpholinoaniline (0.090 g, 0.5 mmol), maleic anhydride (0.07 
g, 0.5 mmol), DCM (3 mL), acetic anhydride (3 ml) and sodium acetate (0.01 g, 
10%) yielded 0.14 g (96.5%) as a yellow solid.  
1H NMR (CDCl3, 400 MHz): 7.96 (2H, dd, J= 5.5, 3 Hz), 7.80 (2H, dd, J= 5.4, 3 
Hz), 7.34 (2H, m), 7.03 (2H, m), 3.90 (4H, m), 3.24 (4H, m).  
13C NMR (CDCl3, 100 MHz): 167.6, 150.9, 134.2, 131.9, 127.4, 123.6, 123.2, 
115.78, 66.83, 49. IR ʋmax (film)/cm
-1 2952, 2864, 2364, 1707, 1517.  
 
tert-butyl piperazine-1-carboxylate (ii)  
 
 
A solution of di-tert-butyl-dicarbonate (1.26 g, 5.77 mmol) in i-PrOH (7.5 mL) 
was added dropwise to a stirring solution of piperazine (1 g, 11 mmol) in i-PrOH 
(7.5 mL) and NaOH (0.6 mL of a 2.5 M solution). The reaction mixture was 
stirred at room temperature for 2 h. The solvent was evaporated in rotavapor. 
The solid was redissolved in H2O (7 mL) and the 1,4-diprotected piperazine was 
filtered off. The pH of the aqueous layer was increased to 10 using saturated 
NaHCO3 solution and extracted with CH2Cl2 (3x40 mL). The combined organic 
layers were dried with Na2SO4 and concentrated in vacuo to give a white solid 
(0.9 g, 83%). The NMR data is in accordance with the literature (M. T. Wu et al. 
1990).  
1H NMR (CDCl3, 400 MHz) δ (ppm): 3.24 (4H, m), 2.66 (4H, m), 1.31 (9H, br s).  
 
tert-butyl-4-(4-nitrophenyl)piperazine-1-carboxylate (iii)  
HN
N
O
O
ii
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To a mixture of tert-butyl piperazine-1-carboxylate (0.2 g, 1 mmol), K2CO3 
(0.17 g, 1.2 mmol), in DMSO (1 mL) was added 4-fluoronitrobenzene (0.17 g, 1.2 
mmol) dissolved in DMSO (0.5 mL). The reaction mixture was stirred at room 
temperature overnight. The crude mixture was washed with a NaHCO3 saturated 
solution (3x20 mL) and brine (3x20 mL) and extracted with CH2Cl2 (3x30 mL). 
The combined organic layers were dried with Na2SO4 and concentrated in vacuo. 
The product was obtained as a yellow powder (0.26 g, 81%). The NMR data is in 
accordance with the literature (Patel and Telvekar 2014).  
1H NMR (CDCl3, 400 MHz) δ (ppm): 8.05 (2H, d, J=9.4 Hz), 6.76 (2H, d, J = 9.4 
Hz), 3.54 (4H, m), 3.35 (4H, m), 2.53 (9H, br s)  
 
tert-butyl-4-(4-aminophenyl)piperazine-1-carboxylate (iv)  
 
To a mixture of tert-butyl-4-(4-nitrophenyl)piperazine-1-carboxylate (0.1 g, 0.3 
mmol) in anhydrous methanol (5 mL) under atmosphere of argon was added Pd/C 
(0.01 g, 10% w/w) followed by replacement of argon with a hydrogen 
atmosphere. The reaction mixture was stirred at room temperature until 
completion (3 h). The crude mixture was filtered over celite and the methanol 
N
N
NO2
O O
iii
NH2
N
N
O O
iv
86 
  
was concentrated in vacuo to afford iv (0.084 g, 92%) as a brown powder. The 
NMR data is in accordance with the literature (VanderWel et al. 2005).  
1H NMR (CDCl3, 400 MHz) δ (ppm): 6.81 (2H, d, J= 8.8 Hz), 6.65 (2H, d, J = 8.8 
Hz), 3.55 (4H, m), 2.98 (4H, m), 1.49 (9H, s).  
tert-butyl 4-(-4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)phenyl)piperazine-1-
carboxylate (v)  
 
To a solution of tert-butyl-4-(4-aminophenyl)piperazine-1-carboxylate (0.2 g, 
0.72 mmol) in DCM (5 mL) was dropwise added a solution of maleic anhydride 
(0.15 g, 1.53 mmol) in DCM (2 mL). The reaction was stirred at room 
temperature for 1 h. Then, the CH2Cl2 was evaporated in vacuo to afford the 
maleanilic acid, which was redissolved in acetic anhydride (5 mL) and sodium 
acetate (0.04 g, 0.49 mmol). The mixture was heated for 2 h under reflux. Then 
the reaction was cooled down, quenched with water (7 mL) and neutralised with 
K2CO3 (10 mL) saturated solution. The solution was then extracted with CH2Cl2 (3 
x 20 mL). The combined organic layers were dried with Na2SO4 and concentrated 
in vacuo. The product was purified through column chromatography (petroleum 
ether/AcOEt, 5/5) giving v (0.16 g, 63%) as a red powder.  
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.13(2H, d, J=9.1 Hz), 6.91 (2H, d, J=9.1 Hz), 
6.76 (2H, s), 3.51 (4H, m), 3.10 (4H, m), 1.42 (9H, s).  
13C NMR (CDCl3, 125 MHz) δ (ppm): 170.1, 154.7, 148.5, 135.9, 130.7, 121.8, 
118.5, 80.4, 50.1, 43.2, 28.3  
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1-(4-nitrophenyl)piperazine (xvii)  
 
To a mixture of piperazine (0.4 g, 4.6 mmol), K2CO3 (0.73 g, 5.42 mmol), TBAI 
(0.013 g, (0.035 mmol) in DMSO (1 mL) was added 4-fluoronitrobenzene (0.50 g, 
3.5 mmol) dissolved in DMSO (0.5 mL). The reaction mixture was stirred at room 
temperature overnight. The crude mixture was washed with a NaHCO3 saturated 
solution and brine and extracted with CH2Cl2. The combined organic layers were 
dried with Na2SO4 and concentrated in vacuo. The product was obtained as a 
yellow powder (0.77 g, 81%). The NMR data is in accordance with the literature 
(Hepperle, Eckert, and Gala 1999).  
1H NMR (CDCl3, 400 MHz) δ: 8.16 (2H, d, J = 9.5 Hz), 6.86 (2H, d, J = 9.5 Hz), 
3.41 (4H, m), 3.06 (4H, m).  
1-(4-nitrophenyl)-4-(prop-2-yn-1-yl)piperazine (xviii)  
 
A solution of 1-(4-nitrophenyl)piperazine (0.20 g, 0.96 mmol) and K2CO3 (0.40 g, 
2.9 mmol) in MeCN (5 mL) was treated by the slow addition of propargyl bromide 
(0.10 mL, 1.3 mmol) dissolved in MeCN (1 mL). The mixture was heated 
overnight at 90°C. Then the reaction was cooled down, washed with a NaHCO3 
saturated solution and AcOEt. The combined organic layers were dried with 
Na2SO4 and concentrated in vacuo. The product was purified through column 
chromatography (petroleum ether/AcOEt, 5/5) giving xviii (0.05 g, 21%) as a 
yellow powder. The NMR data obtained is in accordance with the literature 
(Risseeuw et al. 2013). 
1H NMR (CDCl3, 400 MHz) δ: 6.84 (2H, d, J= 8.6 Hz), 6.62 (2H, d, J=8.7 Hz), 3.35 
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(2H, d, J=2.4 Hz), 3.08 (4H, m), 2.71 (4H, m), 2.28 (1H, t, J=2.4 Hz)  
 
4-(4-(prop-2-yn-1-yl)piperazin-1-yl)aniline (xix) 
 
A solution of 1-(4-nitrophenyl)-4-(prop-2-yn-1-yl)piperazine (0.14 g, 0.57 mmol), 
SnCl2 (0.64 g, 2.9 mmol) in EtOH (5 mL) was heated overnight at 70°C. The 
reaction was cooled down and the pH of the crude mixture was increased to 7-8 
using a NaHCO3 saturated solution. The compound was extracted with AcOEt. 
The combined organic layers were dried with Na2SO4 and concentrated in vacuo. 
The product was purified through column chromatography 
(AcOEt/MeOH:Ammonia 90/10) giving xix (0.10 g, 87%) as a brown solid. The 
NMR data obtained is in accordance with the literature (Risseeuw et al. 2013).  
1H NMR (CDCl3, 400 MHz) δ: 6.84 (2H, d, J = 8.6 Hz), 6.62 (2H, d, J = 8.7 Hz), 3.4 
(2H, br s), 3.35 (2H, d, J = 2.4 Hz), 3.08 (4H, m), 2.71 (4H, m), 2.28 (1H, t, J 
=2.4 Hz)  
1-(4-(4-(prop-2-yn-1-yl)piperazin-1-yl)phenyl)-1H-pyrrole-2,5-dione (xx)  
 
To a solution of 4-(4-(prop-2-yn-1-yl)piperazin-1-yl)aniline (0.1 g, 0.5 mmol) in 
DCM (5 mL) was dropwise added a solution of maleic anhydride (0.05 g, 0.5 
mmol) in CH2Cl2 (2 mL). The reaction was stirred at room temperature for 1 h. 
Then, the CH2Cl2 was evaporated in vacuo to afford the maleanilic acid, which 
was redissolved in acetic anhydride (5 mL) and sodium acetate (0.01 g, 0.12 
mmoles). The mixture was heated for 2 h under reflux. Then the reaction was 
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cooled down, quenched with water (5 mL) and neutralised with K2CO3 (10 mL) 
saturated solution. The solution was then transferred to a separation funnel and 
extracted with CH2Cl2. The combined organic layers were dried with Na2SO4 and 
concentrated in vacuo. The product was purified through column 
chromatography (petroleum ether/AcOEt, 5/5) giving xx (0.07 g, 52%) as a red 
solid.  
1H NMR (CDCl3, 400 MHz) δ: 7.48 (2H d J=10.1 Hz), 7.21 (2H, d, J= 9.1 Hz), 7.10 
(2H, d, J=9.1 Hz), 3.40 (2H, d, J=2.5 Hz), 3.30 (4H, m), 2.76 (4H, m), 2.31 (1H, 
t, J=2.5 Hz)  
13C NMR (CDCl3, 125 MHz) δ: 169.5, 148.1, 135.1, 131.3, 120.5, 116.4, 75.9, 
72.8, 51.1, 50.1, 42.1.  
3-azidopropan-1-amine (xi)  
 
To a solution of 3-chloropropylamine hydrochloride (1.2 g) dissolved in water, 
sodium azide was added. The reaction mixture was heated to 80°C overnight. 
Adding saturated K2CO3 aqueous solution increased the pH of the solution and 
the compound was extracted with Et2O (3x50 mL). The combined organic layers 
were dried with Na2SO4, filtered and concentrated in rotavapor. A light yellow 
volatile liquid was obtained. The NMR data obtained is in accordance with the 
literature (Landi et al. 2010).  
1H NMR (CDCl3, 400 MHz) δ: 3.35 (2H, t, J=6.8 Hz), 2.90 (2H, J= 6.8 Hz), 1.83 
(2H, quintet, J=6.8 Hz), 1.35 (2H, br s).  
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1-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanoyl)pyrrolidine-2,5- dione (xiii)  
 
To a solution of (D)-biotin (0.97 g, 4 mmoles) in DMF (4 mL) was added N-
hydroxysuccinimide (0.68 g, 6 mmoles) and the reaction was stirred at room 
temperature overnight. Ice-water was added to the reaction flask and the 
precipitate was filtered, washed with water (3 x 5 mL) and dried in rotavapor. A 
white solid (0.78 g, 60%) was obtained. The NMR data obtained is in accordance 
with the literature (F. Yu et al. 2013). 
1H NMR (CDCl3, 400 MHz) δ: 5.22 (1H, s), 4.94 (1H, s), 4.53 (1H, m), 4.33 (1H, 
m), 3.15 (1H, m), 2.88-2.96 (1H, m), 2.85 (4H, s), 2.75 (1H, d, J= 12.8 Hz), 2.57-
2.71 (2H, m), 1.6-1.91 (4H, m). 1.51-1.59 (2H, m).  
N-(3-azidopropyl)-5-((3aS,4S,6aR)-oxohexahydro-1H-thieno[3,4-d]imidazole-
4- yl)pentanamide (xiv)  
 
To a solution of 22 (0.1 g, 0.30 mmoles) in anhydrous methanol (4 mL) was 
added 3-azidopropan- 1-amine (0.075 g, 0.75 mmoles). The reaction was stirred 
overnight at room temperature. The crude was purified by column 
chromatography using CH2Cl2:MeOH:NH4OH (9:1:0.1) giving xiv as a white solid 
(0.047 g, 48%). The NMR data obtained is in accordance with the literature (F. 
Yu et al. 2013).  
1H NMR (CD3OD, 400 MHz) δ: 4.65 (1H, dd, J=7.1 Hz), 4.48 (1H, dd, J= 7.5 Hz), 
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3.53 (2H, t, J=6.8 Hz), 3.41 (2H, t, J=6.8 Hz), 3.37 (2H, m), 3.10 (1H, dd, J=5.3, 
12.8 Hz), 2.39 (2H, t, J=7.2 Hz), 1.98-1.77 (6H, m), 1.65-1.59 (2H, m).  
13C NMR (CD3OD, 125 MHz) δ: 176.1, 166.2, 63.4, 61.7, 57.1, 50.3, 41.1, 37.8, 
36.9, 29.8, 29.6, 26.9. 
 
N-(4-iodophenyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazole-4- yl)pentanamide (xxiii)  
 
To a solution of (D)-biotin (0.05g, 0.2 mmoles) in anhydrous CH2Cl2 (3 mL) was 
added EDCl (0.047g, 0.25 mmoles), DMAP (0.037 g, 0.3 mmoles) and the reaction 
mixture was heated to reflux for 30 min. Then, 4-iodoaniline was added and the 
reaction mixture was stirred overnight under reflux. The crude was purified by 
column chromatography using CH2Cl2:MeOH:NH4OH (9:1:0.1) giving xxiii as a 
white powder (0.026g, 30%).  
1H NMR (CD3OD, 400 MHz) δ: 7.45 (2H, dd, J=8.67 Hz), 6.86 (2H, dd. J=8.67 Hz), 
2.98-2.85 (1H, m), 2.79 (2H, s), 2.70 (1H, d, J= 12.8 Hz), 2.8-2.4 (2H, m), 1.8-
1.6 (4H, m). 1.57-1.50 (2H, m).  
13C NMR (CD3OD, 125 MHz) δ (ppm): 175.2, 160.2, 136.1, 135.6, 124.8, 96.2, 
66.4, 62.7, 54.2, 36.9, 32.6, 31.8, 23.8, 23.0  
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CHAPTER 3 
 
Identification and characterisation of novel 
compounds blocking Shiga toxin expression in 
Escherichia coli O157:H7 
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3 Identification and characterisation of novel 
compounds blocking Shiga toxin expression in 
Escherichia coli O157:H7 
 
3.1 Introduction 
Production of Shiga toxin by EHEC is essential for the development of HUS in 
infected patients. The use of conventional antibiotics results in increased Stx 
release and thus greater risk of HUS manifestation. New therapeutic strategies 
that aim to prevent or decrease the production of Stx may be an effective was 
to prevent EHEC-mediated disease.  
 
Recently, in order to identify potential inhibitors of Shiga toxin expression in E. 
coli O157:H7, a high-throughput screen (HTS) of 17,500 compounds using a 
stx2::GFP reporter assay was performed. A total of 76 hit compounds were 
identified in the primary screen, which were then narrowed to 6 compounds 
following dose-response validation assays. This was followed by the generation 
of a focused set of derivatives based on the best performing compound in order 
to get structure-activity (SAR) information and improve their activity. This 
optimisation resulted in the compound AHU3, a 2,5-pyrroledione synthesised in 
four steps (Figure 14). SAR studies determined that the 2,5-pyrroledione moiety 
was responsible for activity, whilst the two remaining rings could tolerate 
manipulations.  
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Figure 14 Synthesis of compounds with inhibitory activity against Shiga toxin expression 
 
 
Once the compound was proven active against Stx expression, the next step was 
therefore the elucidation of the molecular mechanism responsible for activity. 
The work presented in this chapter describes the approaches used to find the 
molecular target of AHU3.  Our data suggests that the compound interferes with 
the SOS response and autocleavage of the λ phage repressor cI by directly 
affecting the activity and oligomerization of RecA, thus limiting prophage 
induction and stx2 expression. The findings suggests that RecA is highly 
susceptible to inhibition and that targeting this protein is a viable approach to 
limiting production of Stx2 by STEC.  
 
 
3.2 Biological assay used in the screening 
  
As previously described, Shiga toxin is expressed at very low levels under non-
inducing conditions and its expression is up-regulated in the presence of DNA-
damaging agents that activate the bacterial SOS response. Under laboratory 
conditions this is usually achieved by addition of MMC, a potent DNA crosslinker. 
In order to identify potential small-molecule inhibitors of stx2, the pstx2::GFP 
promoter fusion plasmid containing the stx2 promoter fused to the GFP gene was 
transformed into Stx-negative E. coli Sakai ZAP0273 strain. The compounds were 
tested in bacterial cultures in mid-logarithmic growth, and the SOS response was 
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induced by addition of 1 µg/mL, a concentration low enough to allow the growth 
during the first couple of hours but that eventually leads to bacteriophage 
induced lysis after 3-4 h. Fluorescence and bacterial growth were monitored at 
intervals of 1 h, for a 6-8 h after addition of the compounds and MMC (Figure 
15). 
 
 
Figure 15 pstx2::GFP reporter assay.  
The lysogenic Stx-negative Sakai E. coli strain transformed with pstx2::GFP reporter fusion are 
treated with a DNA damaging agent (mitomycin C). Induction of the SOS response leads to 
activation of the stx2 promoter, which can be measured as means of fluorescence. Any small-
molecule with that has an antagonistic effect on the expression of Stx will therefore cause a 
decrease in fluorescence. 
 
3.3 Identification of a hit compound with inhibitory 
activity on stx2 expression 
 
Using the stx2::GFP reporter assay previously described, a high throughput 
screening of small molecules was carried out at the Laboratory for Chemical 
Biology, Umeå. The ChemBridge library comprised 17,500 chemically diverse 
compounds that have previously proven valuable for the identification of novel 
therapeutics. Compounds were initially tested at a concentration of 50 µM for 
the ability to suppress MMC-induced expression of stx2::GFP in ZAP0273. Two 
additional reporter fusions were used in the screen, sulA::GFP and rpsM::GFP. 
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SulA is a LexA regulated protein essential for the arrest of cell division during 
SOS response, and the rpsM promoter activity (30S ribosomal subunit) was 
chosen as a housekeeping gene control as it is not related to Stx expression. In 
total 76 hits, comprising 48 compounds that reduced fluorescence in the 
stx2::GFP screen only and 28 compounds that reduced fluorescence in the 
stx2::GFP and sulA::GFP screen, were selected (Figure 16). 
 
Figure 16 Flow chart summarizing the HTS of the ChemBridge library.  
A library of 17,500 compounds was screened using stx2::GFP, rpsM::GFP and sulA::GFP reporter 
fusions. Seventy-six compounds that showed significant activity on stx2::GFP and suIA::GFP were 
identified from this initial screen, and further dose-response assays narrowed this to six hits that 
reduced stx2::GFP expression in a dose-dependent manner. The single most potent compound 
was taken forward for mechanistic studies. 
 
For the hit validation step, the compounds were studied in dose-response 
experiments. Concentrations of compounds ranging from 0.2 to 200 µM were 
prepared using 2-fold serial dilutions. The dose-response experiments were 
performed in the stx2::GFP and rpsM::GFP reporter assay to evaluate inhibitor 
potency and specificity, respectively. From the initial screen of 76 primary hits, 
6 compounds showed a reproducible dose-dependent reduction of MMC-induced 
stx2::GFP expression. The most effective of these was the Hit2Lead compound 
ID 5324836, a phenyl pyrroledione henceforth called AHU1. The compound 
showed a reproducible dose-dependent reduction of MMC-induced stx2::GFP 
expression (Figure 17). 
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Figure 17 Effect of AHU1 on stx2::GFP expression.  
ZAP0273 transformed with pstx2::GFP was cultured in the presence of 25- 100 µM AHU1, and 
induced with 1 µg/ml MMC. Expression of stx2::GFP was measured by fluorescence. (A) Inhibition 
of MMC-induced stx2::GFP expression by AHU1 over time. (B) AHU1 significantly decreases 
stx2::GFP expression in a dose dependent manner. (C) Chemical structure of AHU1, a phenyl 
pyrroledione. Experiments were performed in triplicate, and data plotted as the mean with 
standard deviation from the mean displayed by error bars 
 
 
Bacterial growth was also monitored during the assay. An interesting observation 
was that the compound was also able to block the MMC-induced phage mediated 
lysis, at concentrations 50 and 100 µM (Figure 18). More importantly, the 
compound did not affect bacterial growth rate in the absence of MMC, a 
desirable feature in anti-virulence drugs.  
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Figure 18 The compound AHU1 does inhibits MMC-induced lysis and does not interfere with 
bacterial growth rate. 
(A) Inhibition of MMC-induced lysis by AHU1. (B) Effect of AHU1 on bacterial growth in the 
absence of MMC. Experiments were performed in triplicate, and data plotted as the mean with 
standard deviation from the mean displayed by error bars. 
 
In order to obtain an IC50 for the AHU compounds, a range of different 
concentrations were tested in the stx2::GFP assay. The IC50 values obtained were 
AHU1= 17 µM, AHU2=30 µM and AHU3=19 µM (Figure 19). 
 
Figure 19 Phenotypic half maximum inhibitory concentration for the AHU compounds. 
Different concentrations of the compounds were analysed in the stx2::GFP assay. The IC50 values 
obtained were AHU1= 17 µM, AHU2=30 µM and AHU3=19 µM 
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Three structural analogues of AHU1 were synthesized in order to get structure-
activity relationship (SAR) information on AHU1 (Figure 20-C). Evaluation of the 
three analogues against AHU1 revealed that the maleimide moiety was essential 
for activity, and a more potent inhibitor was obtained: AHU3. The compound 
AHU3 produced a greater increase in inhibitions at 25 µM when compared to 
AHU1 (Figure 20-A). Thus, it was selected for use in all further experiments.  
 
 
Figure 20 Comparison of activity between the analogues AHU1-4.  
(A) Inhibition of MMC-induced bacterial lysis after addition of AHU1-4 and MMC. AHU3 showed to 
be more potent compared to the other compounds. (B) Inhibition of stx2::GFP expression by 25 
and 50 µM AHU1-4 at 6 h after addition of AHU1-4 and MMC. (C) Chemical structures of the AHU 
compounds. Data were calculated from triplicate experiments and displayed as the mean 
inhibition with error bars showing the standard deviation from the mean. Asterisks indicate a 
significant difference (**p < 0.001) from the original AHU1 concentration inhibition, determined 
by Student’s unpaired t-test  
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3.4 The compound AHU3 affects phage lytic development 
 
When the compound AHU3 was tested on the stx2::GFP reporter assay, it was 
observed that the compound also blocked phage mediated lysis, in comparison to 
the untreated control. This observation prompted exploration in more detail of 
the effect of the compound on prophage induction in EHEC. To this end, phage 
transduction assays were performed using the strain E. coli JP10819 that carries 
only the lysogenic Stx2 prophage φP27, which contains a tetracycline resistance 
cassette inserted into the stx2 gene (Quiles-Puchalt et al. 2014). The Stx2 
prophage was induced by the addition of mitomycin C (MMC) in the presence and 
absence of 50 µM AHU3, and the phages produced were isolated by filtration. 
The non-lysogenic E. coli strain K-12 MG1665 was used as a recipient strain, 
which was treated with serial dilutions of the cell lysate and grown on agar 
plates containing tetracycline.  
 
As shown in figure 21, bacterial cultures that were not induced with MMC 
produced low levels of Stx phage (104 PFU/mL), whereas the presence of MMC 
increased the levels by four logs to 108.  The presence of 50 µM of AHU3 
significantly decreased the amount of Stx phage produced with a titre of 105 
PFU/mL. This demonstrated that the compound inhibits the production of 
functional Stx phages.  
 
 
Figure 21 The compound AHU3 affects MMC-induced phage lytic development.  
Induction of JP10819 with 2 µg/ml MMC resulted in significantly increased Stx phage production. 
Addition of 50 µM AHU3 produced a significant decrease in phage production by both non-induced 
and MMC-induced JP10819. The interaction between MMC and AHU3 was determined to be 
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significant (p < 0.001), implying that the reduction in phage production by MMC-induced cells 
observed is not the result of the inhibitory effect of AHU3 on bacterial growth. The data shown 
are the average of triplicate individual experiments with standard deviation from the mean 
displayed as error bars. Statistical significance was determined by GLM analysis 
 
 
The next step was studying if the compound also had effect on phage-mediated 
lysis in Gram-positive bacteria. To assess this, the strain of Staphylococcus 
aureus JP5011, which carries the φSLT phage containing a tetracycline 
resistance cassette inserted into the plv gene, was used. Induction of S. aureus 
JP5011 with MMC produced approximately 106 PFU/mL. Addition 50 µM of AHU3 
decreased the titre more than a log as shown in Figure 22.  
 
Figure 22 AHU3 also affects phage lytic development in S. aureus.  
Induction of JP5011 with 2 µg/ml MMC resulted in significantly increased SLT phage production. 
Addition of 50 µM AHU3 produced a significant decrease in phage production by MMC-induced 
JP5011. Asterisks indicate a significant difference (*p < 0.05, **p < 0.001) in phage production 
between the groups indicated by capped lines. The data shown are the average of triplicate 
individual experiments with standard deviation from the mean displayed as error bars. Statistical 
significance was determined by GLM analysis 
 
While the inhibitory effect of AHU3 on S. aureus is less potent than the observed 
in E. coli, the transduction assay demonstrated that the compound does not 
exclusively target expression of the Stx2 phage only, but has a broader 
mechanism of action, likely involving aspects of phage biology. 
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3.5 Effect of AHU3 on Stx2 production by EHEC 
 
To assess if AHU3 could impact on Stx2 production in EHEC we directly assayed 
toxin production in ZAP1620, a wild-type strain that is lysogenized with both 
Stx2a- and Stx2c-encoding phages and was isolated from a human patient. 
ZAP1620 was cultured to mid-exponential phase and MMC added to induce toxin 
expression. Culture supernatants were isolated and the levels of toxin assessed 
using an ELISA-based assay (RIDASCREEN R verotoxin, R-Biopharm). Data were 
calculated as a percentage of expression compared with the positive control 
(100%), consisting of inactivated Stx. Analysis of the supernatant of ZAP1620 
showed strong MMC-dependent production of Stx2, at 85% (±7%) activity 
compared with the positive control. Addition of 50 µM AHU3 reduced Stx2 
expression to 47% activity (±3%) compared with the positive control, 
demonstrating that AHU3 markedly inhibits Stx2 production in wild-type isolates 
(Figure 23).  
 
Figure 23 The compound AHU3 blocks expression in E. coli ZAP1620, a wild-type strain that 
is lysogenized with both Stx2a- and Stx2c-encoding phages.  
Addition of 50 µM of AHU3 significantly decreased the MMC-induced production of the toxin in 
comparison to the untreated control.  
 
3.6 Finding the target of AHU3 
 
Transduction assays showed that AHU3 blocks phage production in both Gram-
negative and positive organisms, including phages unrelated to Stx. As discussed 
in section 1.3, the SOS response plays a key role on prophage induction, so it 
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appeared likely that AHU3 could be acting on an essential component of this 
pathway. Prophage genes are under the control of repressors that help prevent 
the phage from enetering the lytic cycle and causing bacterial lysis. When the 
SOS response is initiated, protein filaments of RecA induce the autocleavage of 
the phage repressors as well as autocleavage of LexA, the key repressor of the 
SOS genes.  
 
Since AHU3 showed activity in both Gram-negative and positive organisms, the 
compound would need to target a protein highly conserved across bacteria. We 
therefore hypothesised that RecA could be a potential target, either by 
preventing it binding to ssDNA, preventing the formation of activated filaments 
or interacting with the phage repressor cI. Inhibition of the expression or 
function of other SOS components was considered unlikely, as while this would 
affect the SOS response, the prophage would be unaffected.  
 
3.7 The compound AHU3 does not affect RecA expression 
Studies have shown that production of Stx in recA mutant strains of E. coli 
O157:H7 is considerably decreased than that of the wild-type strains, and 
complementation with a recA vector restores the toxin production (S. Fuchs et 
al. 1999). This is due to the key role that RecA plays in prophage induction 
(Matsushiro et al. 1999). We therefore decided to assess whether the compound 
was exerting its inhibitory activity by down-regulation of RecA expression. 
Expression of RecA was studied in response to AHU3 and MMC, AHU3 and MMC. 
Immunoblotting for RecA did not show a decrease of expression when AHU3 was 
added to E. coli O157:H7 cultures (Figure 24).  
 
Figure 24 Effect of AHU3 on RecA expression.  
Bacterial cultures of E. coli O157:H7 were incubated in the presence and absence of AHU3 in 
order to study its effect on RecA expression. Samples were processed after 3 h incubation with 
the compound and the cell lysates were processed for a Western Blot analysis of RecA. The 
compound did not affect RecA expression. GroEL was used as a housekeeping protein control 
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Since the compound did not have an effect on RecA expression, the next step 
was to assess if AHU3 was interfering with the activity of RecA, as explained in 
the following sections.  
 
3.8 Microscale thermophoresis 
 
The use of methods for the study of interactions between proteins and other 
biomolecules like DNA, RNA or small molecules is of great importance for the 
understanding of cellular processes and for the development of new drugs. There 
is a wide range of techniques already available for this purpose but there are 
still some caveats that limit their use. Microscale thermophoresis is a relatively 
new biophysical technique used in the study of biomolecular interactions based 
on the thermophoresis of molecules in solution. Thermophoresis can be defined 
as the direct movement of molecules through a temperature gradient (Rainard, 
Pandarakalam, and McElroy 2018). Amongst the advantages that this technique 
offers are the easy sample preparation, low quantity of sample required and the 
broad range of dissociation constants that can be measured (pM to mM).  
 
A typical MST experiment consists of one fluorescent binding partner and one 
non-fluorescent, also known as titrant. Usually, fluorescence is provided by a 
fusion protein like GFP or by using a fluorescent label covalently attached to the 
molecule of interest. The concentration of the fluorescent molecule is normally 
kept low (around 50 pM-100 nM) and the non-florescent partner is prepared at 
different concentrations (titration). It is important to keep the buffer and other 
elements like DMSO constant throughout samples. During the experiment, an 
infrared laser induces a microscopic temperature gradient and the directed 
movement of molecules is detected and quantified (Figure 25). The 
thermophoresis signal is plotted against the ligand concentration, obtaining a 
dose-response curve from which the binding constant can be calculated 
(Jerabek-Willemsen et al. 2014) . 
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Figure 25 Microscale thermophoresis.  
(A) The Monolith NT.115 from NanoTemper Technologies. (B) The samples are loaded in 
capillaries with a total volume of 4 µL. The fluorescence of the samples is excited and detected 
through the same objective. The IR laser heats a defined sample volume and the thermophoresis 
of fluorescent molecules through the temperature gradient is detected. (C) Initially, the 
molecules in the samples are homogenously distributed and a basal fluorescence is detected. 
After activation of the IR laser, a rapid change in fluorophores properties due the fast 
temperature change is observed. Then, a movement of the fluorescently labeled molecules out 
of the heated sample volume is detected. When the IR laser is deactivated, the molecules 
diffuse back to their initial state. (D) The thermophoretic movement of a fluorescent molecule 
(black, ‘unbound’) changes when it binds to a non-fluorescent ligand (red, ‘bound’). The change 
in thermophoresis is expressed as the change in the normalised fluorescence (ΔFnorm), which is 
defined as Fhot/Fcold (F-values are the average fluorescence values between defined areas marked 
in the figure). The gradual change in thermophoresis is caused by the titration of the non-
fluorescent ligand. Such gradual change is plotted as ΔFnorm, generating a binding curve that can 
be fitted to obtain binding constants. (Taken from Jerabek-Willemsen et al. 2014) 
 
 
In order to investigate the possible interaction between RecA and AHU3, the 
RecA protein was fluorescently labeled with NT-647 Red dye (NanoTemper 
technologies). The dye carries a reactive NHS-ester group that modifies primary 
amines present in amino acids like lysine. Since AHU4 did not show activity on 
the stx2::GFP assay, it was used as a negative control during the experiment. 
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The concentrations of both AHU3 and AHU4 were varied between 200 µM – 12 
nM. As shown in Figure 26, AHU3 showed to be interacting with RecA whereas 
AHU4 did not show to have affinity towards RecA.  
 
Figure 26 Exploring the interaction of RecA with the AHU3 and AHU4 compounds using MST. 
The concentration of the fluorescent labeled RecA was kept constant throughout the 
experiment, while the concentrations of the non-labeled components (AHU3 in yellow asterisks 
and AHU4 in green squares) were between 200 µM - 12 nM. Concentrations are plotted in nM. The 
results indicate that RecA is interacting with AHU3, whereas no interaction is observed in the 
presence of AHU4.  
 
3.9 The compound AHU3 inhibits the ATPase activity of 
RecA 
As previously mentioned, ssDNA is the main inducer of the SOS response. Most of 
the different functions of RecA involve the formation of helical homopolymeric 
filaments of ATP-bound RecA monomers around the ssDNA. This RecA-DNA 
complex has the ability to hydrolyze ATP. As a consequence, monitoring the 
ATPase activity of this RecA-DNA complex can be exploited as a diagnostic assay 
to monitor RecA’s activity. This approach has been used to identify small 
molecule inhibitors of RecA by in vitro screening (Peterson et al. 2012; Wigle et 
al. 2009).  
We decided to apply this concept to investigate if the compound AHU3 was 
interfering with RecA’s activity. We attempted to use the phosphomolybdate-
blue ATPase assay described by Sexton and collaborators, but we were unable to 
reproduce the assay (Sexton et al. 2010). We then decided to use the Innova 
Biosciences ATPase kit. Following the manufacturer’s instructions, the optimal 
concentrations for the reaction were found to be 0.25 µM RecA and 5 µM ssDNA. 
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The DMSO concentration was kept below 2% to avoid any possible interference 
with the assay. The ability of AHU3 to inhibit RecA mediated ATP hydrolysis was 
investigated at concentrations between 0.1 to 100 µM. A dose-response curve 
was plotted using the data obtained, giving to AHU3 an IC50 of 7.72 µM (Figure 
27). While the inhibition of the ATPase does not give insights into the mechanism 
of action of AHU3, it provides evidence that the compound is acting as an 
inhibitor of RecA and validates the results obtained through MST (Section 3.8). 
The inactive AHU4 compound was used as a negative control and the reported 
RecA inhibitor curcumin as a positive control. 
 
Figure 27 AHU3 inhibits RecA-mediated ATP hydrolysis. 
(A) Dose-response inhibition of RecA’s ATPase activity by RecA. Data are plotted as a percentage 
of the average absorbance of the assay well containing 0 µM AHU3. The curved showed an IC50 of 
7.72 µM for AHU3. (B) Dose-response curve for the known RecA inhibitor curcumin, exhibiting an 
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IC50 of 6.69 µM. (C) Dose-response curve for AHU4, showing no inhibition of RecA’s ATPase 
activity. 
 
3.10  AHU3 affects RecA oligomerisation 
 
A crucial process for a successful induction of the SOS response is the formation 
of the RecA filaments. Thus, we decided to explore if the compound was 
interfering with the formation of RecA filaments. Analytical ultracentrifugation 
(AUC) is a biophysical technique that allows the quantitative analysis of 
macromolecules in solution. Previous studies have used AUC sedimentation 
equilibrium experiments (SE) to analyze the oligomerization of E. coli RecA, 
revealing monomers in reversible equilibrium with trimers, hexamers and 
dodecamers.  To assess whether AHU3 affects the oligomerization dynamics of 
the protein, we performed SE for RecA in the presence and absence of AHU3 in 
collaboration with Prof. Olwyn Byron and Dr Zoe Marjenberg. We also controlled 
for any influence of DMSO, included as a solvent for AHU3, on protein behavior. 
The SE data were analyzed with SEDPHAT using the species analysis model with a 
single species, in order to gain a model-independent measure of the whole-cell 
weight average molecular mass. The average molecular mass of RecA oligomers 
in the absence of AHU3 and DMSO was 556 kDa at 10,000 rpm and 404 kDa at 
14,000 rpm (Figure 28).  
 
 
Figure 28 AHU3 decreases RecA oligomerization.  
Whole cell weight average molecular mass of RecA at AUC rotor speeds of 6, 10, and 14 k rpm. 
Ten micrometer RecA was studied alone, in the presence of 0.5% DMSO, and in the presence of 
0.5% DMSO and 100 µM AHU3. 
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In the presence of AHU3, the average molecular mass of RecA oligomers was 
greatly reduced at all rotor speeds tested. The greatest changes were observed 
at 6,000 rpm, with a 70% decrease in the average molecular mass compared with 
untreated RecA. At 10,000 and 14,000 rpm, the decreases were still marked, at 
56 and 52%, respectively. As a control we also compared the average molecular 
mass of RecA with that of the same protein in the presence of DMSO and found 
only very minor effects on RecA oligomerization. These data demonstrate that 
AHU3 is affecting the formation of larger oligomeric RecA species, resulting in an 
increase in lower molecular mass oligomers. 
  
3.11 Synthesis of a biotynilated derivative of AHU3 for 
affinity chromatography 
 
Affinity chromatography is one of the most widely used methods for target 
identification. Typically, this approach starts with structure-activity relationship 
(SAR) studies on the molecule of interest. This allows for the identification of 
the functional groups responsible for activity and the nonessential sites that can 
be used as points of attachment to an affinity tag (e.g. biotin) or solid matrix 
(e.g. Affi-Gel agarose beads) (Lomenick, Olsen, and Huang 2011). In cases where 
biotin is used as an affinity tag, a biotinylated version of the compound is 
synthesized. The compound will have the ability to bind to streptavidin beads, 
due to the strong non-covalent interaction that biotin has with streptavidin (Kd= 
1x10-14 M)(Taldone et al. 2013). The beads are incubated with lysates of the 
strain or cells of interest in order to ‘pull-down’ the target.  After a certain 
period of time, washes to remove non-specific interactions are performed and 
the protein(s) bound to the beads are eluted using either an excess of the 
compound or denaturing conditions. Finally, the proteins are analysed by SDS-
PAGE and the protein bands are identified by mass spectrometry.  
 
There are several examples of the application of this approach for target 
identification. A good example is the identification of the target proteins for the 
salicylidene acylhidrazides, a family of novel anti-virulence compounds that 
inhibit the type three secretion system in Gram-negative bacteria (Dai Wang et 
al. 2011). Using this approach, Wang and collaborators identified the bacterial 
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proteins that are targeted by this class of compounds using a biotinylated 
derivative of the hit compound ME0052.  
 
Given the potential that this approach offers and the SAR information of AHU3 
already available, it was decided to synthesise a biotinylated derivative of AHU3 
in an attempt to identify the molecular target. Since AHU3 has a secondary 
amino group on the piperazine ring that is labile to chemical modifications and it 
was not required for bioactivity, it was decided to try to couple the secondary 
amino group with biotin using peptide-coupling chemistry. Firstly, compound vi 
was synthesised following the synthetic route showed in Figure 29. 
 
 
Figure 29 Synthesis of vi. 
 
Compound vi was subjected to different coupling conditions in order to link it to 
(+)-biotin vii. Unfortunately, the desired product viii was not obtained (scheme 
2). Different reagents and conditions were attempted (table 14) however the 
product viii was never isolated. Intermediates of vii formed with the coupling 
reagents were isolated in some cases and decomposition of the starting 
materials was observed when high temperatures were used. 
 
 
Figure 30 Coupling between (+)-biotin and compound vi was attempted using peptide 
coupling reagents.  
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Table 14 Different conditions used for the coupling between AHU1 and biotin 
Reagents Temperature Reaction time Product(s) 
HBTU, DIPEA, CH2Cl2 rt 12 h Active ester of vi + 
vii 
HBTU, DIPEA, CH2Cl2:DMF 40°C 12 h Active ester of vi + 
vii 
HBTU, DIPEA, DMF 140°C 12 h Decomposition 
SOCl2, CH2Cl2 rt 12 h Decomposition 
DCC, DMAP, CH2Cl2 40°C 12 h Starting materials 
EDCl, DMAP, DMF 80°C 12 h Starting materials 
EDCl, DMAP, DMF Mw, 110°C 1 h Decomposition 
 
Given the unsuccessful results trying the amide coupling, the copper-catalysed 
azide-alkyne cycloaddition was considered as an alternative, a 1,3-dipolar 
cycloaddition between an azide and a terminal or internal alkyne to produce 
1,2,3-triazoles (Berg and Straub 2013).  The azide component was obtained by 
reacting 3-chloropropylamine hydrochloride (ix) with sodium azide (x) to give 
the corresponding azidopropylamine (xi). Low yields were obtained in this 
reaction owing to the volatility of the product (Figure 31).  
 
 
Figure 31 Synthesis of azidopropylamine. 
 
To add the azide functionality to (D)-biotin, it was converted in to the N-
hydroxysuccinimide ester (NHS) by reacting it with N-hydroxysuccinimide using 
EDCl in DMF. Then, compounds xi and xiii were reacted in methanol at room 
temperature to give xiv in moderate yields (Figure 32).  
 
H2N N N N
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Figure 32 Biotin was converted into its N-hydroxysuccinimide ester (NHS) in order to obtain 
its N-(3-azidopropyl) derivative xiv. 
 
The coupling partner bearing the alkyne functionality was then synthesised 
producing xx. To do so, piperazine (xvi) was arylated by reacting it with 4-
fluoronitrobenzene (xv) in presence of tetrabutylammonium iodide (TBAI), giving 
the nitroaryl piperazine compound xvii, which was then N-alkylated using 
propargyl bromide under basic conditions, forming the nitro alkyne xviii. 
Reduction of the nitro group using tin(II) chloride gave the aniline xix, which 
was subsequently refluxed with maleic anhydride in acetic anhydride to give the 
alkyne-functionalised maleimide xx (Figure 33).  
 
Figure 33 Synthesis of 1-(4-(4-(prop-2-yn-1-yl)piperazin-1-yl)phenyl)-1H-pyrrole-2,5-dione 
 
The click reaction was tried using the conditions reported by Yu and 
collaborators (F. Yu et al. 2013). They described a base-free click reaction to 
synthesise a biotinylated derivative of echinocystic acid, using copper sulphate 
and sodium ascorbate in a mixture of THF:H2O. Unfortunately, the use of these 
conditions did not produce the desired product xxi (Figure 34). Purification of 
the reaction mixture only showed decomposition products.  
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Figure 34 Copper-catalysed azide-alkyne cycloaddition. 
 
Given the difficulties experienced with the click reaction, it was decided to try a 
different approach. Since the compound xx was already synthesised, the 
possibility of using the Sonogashira coupling was considered. To this aim, (D)-
biotin (vii) was reacted with 4-iodoaniline (xxii) to obtain the aryl halide xxiii 
(Figure 35). The coupling was performed using EDCl, DMAP in CH2Cl2 under 
reflux. The product xxiii was obtained although in low yields. 
 
 
Figure 35 Sonogashira coupling. 
 
Guilagaber and co-workers developed a methodology to perform Sonogashira 
couplings using mild conditions (Ghilagaber, Hunter, and Marquez 2007). The 
reaction was carried out using tetrakis(triphenylphosphine)palladium(0) and 
copper iodide as catalysts. Unfortunately, the desired product (xxiv) was not 
obtained (Figure 36).  
 
 
Figure 36 Sonogashira coupling using tetrakis(triphenylphosphine)palladium(0) 
HN
NH
S
O
N
H
O
N N
N
N
N
N
O
O
HN NH
S
O HN
O
N
N
N
N
O
O
N
N
+
H
H
H
H
AscNa, CuSO4
THF:H2O
xx
xiv
xxi
+
HN NH
S
O
O
OH
H
H
vii
H2N
I
EDCl, DMAP
DCM
reflux
30%
HN NH
S
O
O
H
N
H
H
xxiii Ixxii
N
N
N
O
O
+
xx
Pd(PPh3)4,, CuI
DMF
rt N
N
N
O
O
NHHN
S
O
O
NH
H
H
I
HN NH
S
O
O
H
N
H
H
xxiii xxiv
114 
  
 
After purification through column chromatography, 1H NMR analysis showed the 
recovery of the starting material xxiii and a by-product of xx. The by-product 
showed the loss of the alkynyl hydrogen but signals of aromatic protons were 
observed instead, suggesting that either the intermediate complex alkyne-Pd 
(showed as (8) in Figure 37) or the homocoupling product of xx were formed. 
Longer reaction times (up to 72 h) and higher temperatures were tried (up to 80 
°C), but no product formation was observed. 
 
Figure 37 The catalytic cycle for the Sonogashira reaction.  
The reaction consists of a fast oxidative addition of R1-X1 (R1=aryl, hetaryl, vinyl; X= I, Br, Cl, 
OTf) to the catalyst Pd0L2 formed by reduction of different palladium(II) complexes. The next 
step involves a transmetalation with the copper acetylide formed during the copper catalytic 
cycle to generate a R1Pd(-C CR2)L2 species, which gives the coupled alkyne after cis/trans 
isomerisation and reductive elimination with regeneration of the catalyst (Chinchilla and Najera 
2007). 
 
Hansen and collaborators reported the synthesis of a biotynilated derivative of 
phorboxazole A via Sonogashira coupling using PdCl2(PPh3)2, CuI and Et3N in THF, 
reporting moderate yields (Hansen, Engler, and Forsyth 2003). The aryl iodide 
xxiii and the alkyne xx were subjected to these conditions. The desired product 
xxiv was not obtained and loss of the alkyne in xx was again observed in the 1H 
NMR spectra. The reaction was also attempted using microwave radiation but yet 
again no product was isolated.  
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Given the unsuccessful results using the Sonogashira coupling, it was decided to 
stop trying it. In the copper-catalysed azide-alkyne cycloaddition, the main issue 
was the stability of the maleimide moiety. Thus, it was decided to build up the 
molecule in a way that the click reaction could be done at early stages, before 
the maleimide group was added. Hence, biotin azide (xiv) was reacted with the 
nitro alkynyl compound xxv and the desired product xxvi was obtained with 
moderate yield (Figure 38).  
 
 
Figure 38 Copper-catalysed azide-alkyne cycloaddition using AscNa and CuSO4. 
 
Reduction of the nitro compound of xxvi yielded the corresponding aniline 
xxvii, which was then refluxed with maleic anhydride in acetic anhydride to 
obtain the final product xxviii (scheme 12). Unfortunately, after purification, 
the 1H NMR spectra showed decomposition products of xviii, probably due to the 
high temperatures employed (130°C). Lower temperatures were tried, but no 
difference was observed (Figure 39).  
 
Figure 39 The biotinylated derivative of AHU3 was not obtained. 
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Given the amount of time spent trying to synthesise the biotinylated version of 
AHU3 it was decided that it was unsuitable to continue working on it.  
 
 
3.12 Toxicological profiling of the AHU compounds 
 
As part of any drug discovery programme, it is crucial to evaluate the 
toxicological profile of any potential lead compound, particularly if in vivo 
testing is being considered.  
The AHU1-3 compounds were tested for toxicity in HEK 293 at the European 
Screening Port (Hamburg, Germany). Unfortunately, all three compounds showed 
to be highly toxic at a concentration of 100 µM. Dose-response studies on the 
compounds revealed pIC50 values of approximately 5 µM (table 15). Ideally, a 
lead compound in order to progress on a drug discovery campaign should have no 
toxicity at 10 µM. Thus, given the IC50 values obtained for the AHU compounds, it 
was concluded that they were not suitable for progression into in vivo testing.  
  
Table 15 Toxicological evaluation of the AHU compounds. 
Compound Hill slope pIC50 
AHU1 5.19 ± 0.47 5.10 ± 0.01 
AHU2 4.30 ± 0.25 5.30 ± 0.01 
AHU3 5.30 ± 0.30 5.09 ± 0.01 
  
The toxicological profile of a lead compound can be modified by structural 
modifications, but care should be taken to prevent the loss of the desired 
activity. In the case of AHU3, a more thorough SAR study is required to find 
analogues that show a better toxicological profile. 
 
3.13 Expression and purification of RecA 
 
In order to produce RecA in large quantities, the recA gene from E. coli was 
cloned into the pTXB1 vector, which contains a self-cleavable intein tag from 
the Mycobacterium xenopi gyrA gene, and a chitin-binding domain (CBD) 
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(Singleton et al. 2002). RecA was inserted between the NdeI and SapI sites of 
pTXB1, which resulted in the fusion of the intein tag to the C-terminus of RecA, 
without addition of any extra amino acids. The advantage of using the pTXB1 
vector is the ability to purify a native recombinant protein in a single 
chromatographic step without the use of proteases for its release. Instead, the 
intein undergoes self-cleavage at its N-terminus upon addition of thiols such as 
cysteine, DTT or β-mercaptoethanol, releasing the protein from the chitin-bound 
intein tag (Figure 40). 
 
Figure 40 Intein-mediated purification of RecA.  
The mini-intein Mxe gyrA and a chitin-biding domain (CBD) are fused to the C-terminal of RecA. 
The CBD allows its binding to the chitin resin. The fusion protein undergoes a N-S acyl 
rearrangement forming a thioester that is cleaved by DTT. RecA is eluted fro the column while 
the intein-CBD fusion remains bound to the resin. Modified from Singleton et al. 2002 
 
To ovexpress RecA, the plasmid pTXB1-RecA was transformed into E. coli 
BL21(DE3) and the expression was induced by addition of 0.5 mM IPTG. The 
purification was performed using a chitin resin. SDS-PAGE analysis of the 
purification fractions showed successful production of RecA (Figure 41). RecA 
was obtained in good yields (8 mg/mL) without the need of further purification. 
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Figure 41 SDS-PAGE of purification fractions for RecA.  
The protein bands were visualized by staining with 0.1% Coomassie brilliant blue R-250. 1, 
protein marker, 2 Crude extract from cells induced with IPTG at 16°C for 16 h; note expression 
of RecA (38 kDA) fused to the Intein-CBD fragment (27 kDA). 3, Flow through from chitin column 
after loading of the cell lysate. 4, Wash with column buffer, 5, DTT flush to distribute it evenly 
in the column. 6, Elution of RecA after induced cleavage at 4°C for 16 h. 7, RecA control from a 
commercial supplier. 
 
 
In order to gain more insights into the mechanism of action of AHU3 on RecA, we 
decided to try to co-crystallize RecA and the compound. Since the crystal 
structure of RecA has been already described (PDB ID: 2REB, Story et al, 1992), 
we decided to try known crystallization conditions using the hanging drop 
method.  
 
The hanging drop method for crystallization of macromolecules is a popular 
approach in structural biology (McPherson and Gavira 2014). The technique 
consists of suspending the protein of interest in the buffer. A drop of this 
mixture is then placed in a chamber that contains a reservoir filled only with the 
buffer. Typically the concentration of the buffer in the droplet is lower than the 
reservoir. Given this concentration difference, water vapour leaves the drop and 
ends up in the reservoir in order to achieve equilibrium. This concentration of 
the droplet promotes the formation of protein crystals in the droplet.  
 
Shinohara and co-workers reported the DNA-free crystal structure of RecA using 
the hanging drop method using 24% PEG400, 10% glycerol, 10 mM MgCl2 and 0.1 
M MES pH 6.5 (Shinohara et al. 2015). Different concentrations of the 
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precipitating agent PEF400 were explored. Crystal trays were incubated at room 
temperature and monitored daily. No crystals were obtained in a two-month 
period. Given time constraints, we were unable to continue exploring more 
conditions.  
 
3.14 Evaluation of a reported inhibitor of RecA 
 
Recently, Alam and collaborators reported the activity of copper 
phthalocyanine-3,4’,4’’,4’’’-tetrasulfonic acid (3,4-Cu-PcTs) and iron(III) 
phthalocyanine-4,4’,4’’,4’’’-tetrasulfonic acid (Fe-PcTs) as RecA inhibitors (Alam 
et al. 2016). Their findings were based on the fact that metatungstate (W12O406-) 
salts were able to inhibit the ATPase, DNA-binding and DNA strand-exchange 
activities of MvRadA, a RecA homolog in Methanococcus volatae (Y. Li, He, and 
Luo 2009). Since metatungstate did not have the same effect on RecA, molecules 
with similar anionic nature were studied. Phthalocyanine tetrasulfonate-based 
molecules were found to inhibit RecA, potentially as a result of their interaction 
with the cationic DNA-binding site of RecA (Mecozzi, West, and Dougherty 1996). 
These compounds were able to block the ciprofloxacin-induced activation of the 
SOS response, potentiated the effect of bactericidal antibiotics and reduced the 
acquisition of ciprofloxacin resistance in a murine animal model (Alam et al. 
2016) 
 
We decided to study the ability of these compounds to supress Stx2 expression. 
Fe-PcTs was shown to be the best performing compound at 100 µM. Its potential 
to block stx2 expression was assessed using the pstx2::GFP reporter fusion 
plasmid. Unfortunately, the coloured nature of the compound (intense blue) 
proved to be an issue in the reporter assay as it acted as a fluorescence-
quenching agent.  
 
Thus, we next assessed the effect that Fe-PcTs had on phage lytic development 
in the E. coli strain that carries only the lysogenic Stx2 prophage ϕP27. Prophage 
induction was initiated by addition of mitomycin C (2 µg/mL) in the presence 
and absence of Fe-PcTs (100 µM) and AHU3 (50 µM) as a control. The non-
lysogenic E. coli K-12 MG16665 was used as the acceptor strain. In the absence 
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of MMC, basal levels of Stx2 phage (104 PFU/mL) were observed, whereas the 
addition of MMC produced a two orders of magnitude increase (106 PFU/mL) 
(Figure 42-A). The presence of FePcTs did not impair the phage lytic 
development as the phage titre was similar to the MMC induced control (106 
PFU/mL). In contrast, the presence of AHU3 caused a significant decrease on the 
production of plaque forming units, close to the basal levels (104 PFU/mL).  
This was also studied in the S. aureus strain carrying the prophage ϕSLT. The 
same results were obtained as shown in Figure 42-B. The presence of FePcTs did 
not reduce the phage titre.  
 
 
Figure 42 Effect of FePcTs on phage production.  
A) FePcTs did not reduce the phage titer in S. aureus when cultures when grown in the presence 
of 100 µM FePcTs B) FePcTs did not reduce the phage titer in E. coli. Data shown is the average 
of triplicates with standard deviation indicated as error bars 
 
Table 16 Efficiency of the development of lambdoid bacteriophages in E. coli and S. aureus 
after mitomycin C induction and treatment with FePcTs 
Strain 
Phage titer (PFU/mL) obtained (mean) 
MMC- FePcTs, MMC- MMC+ FePcTs, MMC+ AHU3, MMC+ 
E. coli  (ϕP27) 1.06x104 2x104 2.14x106 2.32x106 3x104 
S. aureus (ϕSLT) 1.66x104 3x104 1.88x106 1.72x106 1x104 
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We further investigated if FePcTs was able to regulate Stx2 expression by 
western blot analysis. As STEC is a category three microorganism under UK 
regulations, it is not possible to handle Stx+ strains in our laboratory. Thus, 
Citrobacter rodentium lysogenized with the Stx phage ϕ1720a-02 was used for 
relative quantification of the toxin (Mallick et al. 2012).  
 
C. rodentium (λstx2dact) was grown to early exponential phase (OD600 = 0.25) 
followed by addition of either FePcTs (100 µM) or AHU3 (50 µM) and MMC. After 
1 h incubation, cells were pelleted and the intracellular content of Stx2 was 
analysed by western blot (Figure 43). The presence of FePcTs did not supress 
stx2 expression in comparison to AHU3.  
 
Figure 43 Effect of FePcTs on Stx2 expression in C. rodentium λstx2dact.  
Cell lysate of C. rodentium non-induced and induced with MMC was blotted for Sxt2B. The 
presence of FePcTs in the MMC induced culture did not suppressed stx2 expression in contrast to 
AHU3 that clearly reduced the amount of stx2 produced (50-60% expression). Pixel density was 
measured using the software ImageJ. The data shown are the average of three individual 
experiments with standard deviation from the mean displayed as error bars 
 
The lack of activity of FePcTs made us wonder if the anionic nature (Figure 44) 
and size of the molecule was impeding the uptake by bacterial cells. To assess 
this, we decided to perform an uptake assay in order to quantify both the 
intracellular and extracellular distribution of the compound using mass 
spectrometry. The uptake of FePcTs was assessed in E. coli TUV 93-0 by 
incubating bacteria (OD600=0.9) with the compound (25 µM) in M9 minimum 
media for 1 h at room temperature. After this time, cells were pelleted through 
bromodecane oil to effectively isolate the bacterial cells from the surrounding 
supernatant. A solvent mixture made of CHCl3:H2O:MeOH (1:1:3) was added to 
the aqueous layer and this was considered as the supernatant fraction. Then, 
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bromodecane oil was removed from the cell pellet and cells were resuspended in 
the same solvent mixture previously described. This was considered as the cell 
fraction. The same procedure was performed with the AHU3 compound to be 
used as a control. 
Samples were analysed at the Glasgow Polyomics facilities using hydrophilic 
interaction liquid chromatography (HILIC) and the metabolites analysed by 
electrospray ionisation mass spectrometry.  
 
Figure 44 Chemical structure of FePcTs. 
 
Table 17 Average peak intensities of compounds across different groups 
Peak 
intensities 
AHU3 FePcTs 
Blank Cells Supernatant Blank Cells Supernatant 
Mean 656909581 14623091 49320131 - - - 
SD - 1983029.94 6672882.23 - - - 
 
As shown in Table 17, only AHU3 was detected both inside and outside the cell, 
whereas FePcTs was not. Although the molecular size of FePcTS is within the 
scan range of the mass spectrometer, it could not be detected as the molecule 
might be multiply charged from the iron atom. This was unfortunate as it was 
not possible to demonstrate whether the lack of activity towards stx2 expression 
is due to the poor uptake of the molecule. 
 
It is worth mentioning that other RecA inhibitors previously described share the 
same anionic and aromatic nature. That is the case of suramin, reported by 
Singleton and collaborators (Wigle and Singleton 2007). Suramin inhibited the 
ATPase activity and the RecA-mediated DNA strand exhange reaction with an IC50 
of 2 µM. Its uptake in E. coli TUV 93-0 was also explored using the same 
methodology previously described. In this case suramin could not be detected as 
its molecular size is out of the scan range of the mass spectrometer. 
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3.15 Discussion 
 
The work presented in this chapter shows the identification of the lead 
compound AHU3 with an inhibitory effect on stx2 expression. The use of the 
stx2::GFP reporter assay in the HTS campaign ensured that any hits identified 
were active against intact bacteria. The selection criteria for the active 
compounds included a significant reduction in stx2 expression, and a minimal 
effect on growth rate or off-target genes. Dose-response studies on the best 
performing compounds revealed that AHU3 showed inhibition of the stx2 gene 
and phage production at a concentration that had minimal impact on bacterial 
growth.  
 
Four lines of evidence led to the conclusion that AHU3 blocks Shiga toxin 
expression by acting as inhibitor of the SOS response and prophage induction, 
more specifically as an inhibitor of the RecA protein.  First, when cultures of E. 
coli O157:H7 were incubated in the presence of AHU3, the compound blocked 
the MMC-induced lysis and phage lytic development compared to the non-
treated control. Second, the compound was able to block phage production in 
both Gram-negative and positive organisms. Third, AHU3 had the ability to 
inhibit RecA-meditated ATP hydrolysis in vitro in a dose-dependent manner. 
Fourth, analytical ultracentrifugation revealed that AHU3 interferes with the 
oligomerisation dynamics of RecA, potentially explaining its inhibitory effect on 
stx2 expression.  
 
3.15.1 Electrophilic nature of AHU3 and its implications in the 
mode of action 
 
One of the main features of AHU3 is its electrophilic nature. Maleimide moieties 
are susceptible to additions to their double bond either by Diels-Alder reactions 
or Michael additions. The maleimide moiety is rare in nature, but some natural 
products bearing this functionality have been reported. Pencolide is a maleimide 
with bacteriostatic and fungicidal activity produced by Penicillium strains 
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(Lucas, Castro, and Takahashi 2007). A compound isolated from Streptomycin 
showdoensis, showdomycin, was shown to target oxidorreductases and 
transferases involved in major cellular functions associated with virulence, 
growth and persistence in both Gram-negative and Gram-positive organisms 
(Böttcher and Sieber 2010).  
 
Maleimides react readily with the highly nucleophilic thiol groups of cysteine 
residues in proteins at physiological pH (Bednar 1990). It is therefore highly 
likely that AHU3 reacts with RecA through this addition mechanism, covalently 
binding to one or more of the three cysteine residues present in E. coli RecA 
(Figure 45). This mechanism of inhibition has been reported for other small 
maleimide-based molecules, including a phenyl-substituted maleimide GNX-686, 
with anti-angiogenic properties for ocular pathologies and cancer (Nowak-
Sliwinska et al. 2012), and a series of maleimide-based compounds with 
inhibitory activity on the monoamine oxidase B as a potential new therapy for 
Parkinson’s disease (Manley-King et al. 2009).  
 
Conservation analysis of cysteine across different bacterial species shows that it 
is not always present in RecA. For instance, as shown in figure 45, 
Staphylococcus aureus RecA does not have any cysteine residues. This 
observation suggests that the inhibitory activity of AHU3 on RecA’s activity could 
be result of a different type of molecular interaction. Given the electrophilic 
nature of AHU3, covalent binding to other nucleophilic amino acids such as 
lysine, threonine and serine, could be possible. One approach to determine the 
binding of AHU3 to cysteine or other residues would be to genetically modify 
these residues and assess the impact that such modifications have on activity. 
Additionally, a protease digest and mass spectrometry of AHU3-bound RecA 
would also help to investigate which residues interact with RecA. 
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E. coli O157:H7 
MAIDENKQKALAAALGQIEKQFGKGSIMRLGEDRSMDVETISTGSLSLDIALGAGGLPMGRIVEIYGPESSGKTTLTLQVIAAAQREGKTCAFIDAEH
ALDPIYARKLGVDIDNLLCSQPDTGEQALEICDALARSGAVDVIVVDSVAALTPKAEIEGEIGDSHMGLAARMMSQAMRKLAGNLKQSNTLLIFINQI
RMKIGVMFGNPETTTGGNALKFYASVRLDIRRIGAVKEGENVVGSETRVKVVKNKIAAPFKQAEFQILYGEGINFYGELVDLGVKEKLIEKAGAWY
SYKGEKIGQGKANATAWLKDNPETAKEIEKKVRELLLSNPNSTPDFSVDDSEGVAETNEDF 
 
S. aureus MRSA252 
MDNDRQKALDTVIKNMEKSFGKGAVMKLGDNIGRRVSTTSTGSVTLDNALGVGGYPKGRIIEIYGPESSGKTTVALHAIAEVQSNGGVAAFIDAEH
ALDPEYAQALGVDIDNLYLSQPDHGEQGLEIAEAFVRSGAVDIVVVDSVAALTPKAEIEGEMGDTHVGLQARLMSQALRKLSGAISKSNTTAIFINQI
REKVGVMFGNPETTPGGRALKFYSSVRLEVRRAEQLKQGQEIVGNRTKIKVVKNKVAPPFRVAEVDIMYGQGISKEGELIDLGVENDIVDKSGAWY
SYNGERMGQGKENVKMYLKENPQIKEEIDRKLREKLGISDGDVEETEDAPKSLFDEE 
 
S. enterica 
MAIDENKQKALAAALGQIEKQFGKGSIMRLGEDRSMDVETISTGSLSLDIALGAGGLPMGRIVEIYGPESSGKTTLTLQVIAAAQREGKTCAFIDAEH
ALDPVYARKLGVDIDNLLCSQPDTGEQALEICDALARSGAVDVIVVDSVAALTPKAEIEGEIGDSHMGLAARMMSQAMRKLAGNLKQSNTLLIFINQ
IRMKIGVMFGNPETTTGGNALKFYASVRLDIRRIGAVKEGDNVVGSETRVKVVKNKIAAPFKQAEFQILYGEGINFYGELVDLGVKEKLIEKAGAWY
SYNGEKIGQGKANATTWLKENPATAKEIEKRVRELLLSNQNATPDFAVDDSEGVAETNEDF 
 
B. subtilis 
MSDRQAALDMALKQIEKQFGKGSIMKLGEKTDTRISTVPSGSLALDTALGIGGYPRGRIIEVYGPESSGKTTVALHAIAEVQQQGGQAAFIDAEHAL
DPVYAQKLGVNIEELLLSQPDTGEQALEIAEALVRSGAVDIVVVDSVAALVPKAEIEGDMGDSHVGLQARLMSQALRKLSGAINKSKTIAIFINQIREK
VGVMFGNPETTPGGRALKFYSSVRLEVRRAEQLKQGNDVMGNKTKIKVVKNKVAPPFRTAEVDIMYGEGISKEGEIIDLGTELDIVQKSGSWYSYE
EERLGQGRENAKQFLKENKDIMLMIQEQIREHYGLDNNGVVQQQAEETQEELEFEE 
 
C. difficile 
MSVDQEKLKALNEALGKIEKDFGKGSVMKLGEATSMSIDVISTGAIGLDIAIGIGGLPRGRIVEVYGPESSGKTTVALSCVASAQKDGGIAAFIDAEH
ALDPVYAKALGVDVDNLIISQPDTGEQALEIAEALIRSGAIDIIVIDSVAALVPKAEIDGDMGDSHVGLQARLMSQALRKLTGSIKKSNCVAIFINQLRE
KVGIMFGNPETTTGGRALKFYSSVRLDVRKIDTIKQGDKVIGSRTRVKVVKNKVAPPFKQAEFDIMYGEGISKIGDLLDIAADVDIVKKSGSWYSYN
DTKLGQGRENVKKFLEDNLDLTTEIDEKVRAFYNLNEEHEESGTSVSKEIVEE 
 
P. aeruginosa LESB58 
MDENKKRALAAALGQIERQFGKGAVMRMGDHERQAIPAISTGSLGLDIALGIGGLPKGRIVEIYGPESSGKTTLTLSVIAEAQKQGATCAFVDAEHA
LDPDYAGKLGVNVDDLLVSQPDTGEQALEITDMLVRSNAVDVIIVDSVAALVPKAEIEGEMGDAHVGLQARLMSQALRKITGNIKNANCLVIFINQI
RMKIGVMFGNPETTTGGNALKFYASVRLDIRRTGAVKEGDEVVGSETRVKVVKNKVSPPFRQAEFQILYGKGIYRTGEIIDLGVQLGLVEKSGAWY
SYQGSKIGQGKANAAKYLEDNPEIGSVLEKTIRDQLLAKSGPVKADAEEVADAEAD 
 
S. pneumoniae 
MAKKPKKLEEISKKFGAEREKALNDALKLIEKDFGKGSIMRLGERAEQKVQVMSSGSLALDIALGSGGYPKGRIIEIYGPESSGKTTVALHAVAQAQK
EGGIAAFIDAEHALDPAYAAALGVNIDELLLSQPDSGEQGLEIAGKLIDSGAVDLVVVDSVAALVPRAEIDGDIGDSHVGLQARMMSQAMRKLGASI
NKTKTIAIFINQLREKVGVMFGNPETTPGGRALKFYASVRLDVRGNTQIKGTGDQKETNVGKETKIKVVKNKVAPPFKEAVVEIMYGEGISKTGEL
LKIASDLDIIKKAGAWYSYKDEKIGQGSENAKKYLAEHPEIFDEIDKQVRSKFGLIDGEEVSEQDTENKKDEPKKEEAVNEEVPLDLGDELEIEIEE 
 
Figure Cysteine conservation in RecA across selected bacteria species  
Three cysteine residues (green) are present in E. coli RecA, whereas no cysteine residues are 
present in S. aureus, B. subtilis and P. pneumoniae. 
 
As explained in Section 3.10, AUC analysis showed that AHU3 interferes with the 
formation of larger oligomeric RecA species in solution, possibly explaining the 
mechanism behind its inhibitory effect on stx2 expression. An interesting finding 
in the literature was a chloroamide-based compound with inhibitory activity on 
RAD51, the human homologue of RecA (Budke et al. 2012). The compound RI-1 
was found in a high-throughput screening platform that was looking for 
compounds able to modify the binding of RAD51 to ssDNA.  RI-1 was found to 
bind directly to a surface of RAD51 that serves as an interface between protein 
subunits of the RAD51 filaments (Figure 46). The striking structural similarity 
between RI-1 and AHU3 reinforces the hypothesis that AHU3 could also be 
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inhibiting the activity of RecA by reducing the formation of larger oligomeric 
species.  
 
 
Figure 45 Proposed molecular mechanism of action of RI-1, an inhibitor of RAD51.  
A cysteine residue in RAD51 is covalently modified by RI-1, thus interfering with the formation of functional 
RAD51 filaments (Adapted from Budke et al. 2012) 
 
Although approximately 30% of drugs in the market are covalent inhibitors, there 
is reluctance in the pharmaceutical industry towards the development of drugs 
that bind irreversibly to their target protein(s), given the higher risk of off-
target activity that can lead to toxicity (Mah, Thomas, and Shafer 2014). Off-
target effects are a result of the covalent binding to other proteins that result in 
cell damage or immunological response. However, in the last few years there has 
been an increasing interest in this group of drugs. Covalent binding to the 
protein target provides higher potencies and prolonged effects in comparison to 
reversible drugs. This results in less-frequent dosing regimes, which widens the 
therapeutic margins of the drug (Bauer 2015). Furthermore, some studies have 
shown that covalent drugs could have a reduced risk for the development of 
resistance, particularly in areas like cancer or infectious diseases (Singh et al. 
2011).  
 
3.15.2 RecA as a drug target  
 
The current antibiotic resistance problem and the urgent need for new 
antimicrobial strategies have prompted the search for novel drug targets. In 
recent years, RecA has been in the spotlight given the important role that it 
plays in bacterial physiology. Studies have shown that recA-deficient E. coli cells 
cannot cope with the hydroxyl radical damage caused by bactericidal antibiotics, 
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suggesting that targeting RecA can potentiate the current antibiotic arsenal 
(Kohanski et al. 2007). It has also been shown that inactivation of RecA abolishes 
the mutagenic effect induced by sublethal concentrations of antibiotics, 
reducing the generation of antibiotic-resistant mutants (Thi et al. 2011). Given 
the relationship between the SOS response and the spread of antibiotic 
resistance genes through horizontal gene transfer, it is clear that inactivation of 
RecA would diminish the efficiency of horizontal gene transfer, slowing the 
development of antimicrobial resistance (Beaber, Hochhut, and Waldor 2004). 
Based on our data, we propose that RecA could be a druggable target for the 
treatment of bacterial infectious diseases and, in particular, that RecA could be 
a good target to develop therapies for STEC infections.  
 
While humans produce the RecA homologue Rad51, a recombinase also involved 
in DNA repair (Ristic et al. 2005), the low protein sequence similarity (25%, NCBI, 
BLAST) between RecA and Rad51 considerably decreases the risk of it being 
targeted by AHU3, although further studies would be needed to discard this 
possibility.  
 
3.15.3 Challenges in the development of RecA inhibitors 
 
Efforts to develop inhibitors of RecA have been attempted but little success has 
been achieved thus far. For instance, milimolar concentrations of the metal 
dications zinc(II), copper(II) and mercury(II) were shown to induce in vitro 
precipitation of RecA, effect which results from the metal-dependent initiation 
of RecA aggregation (A. M. Lee and Singleton 2004). The downside of this 
concept was the toxicity associated to these metals, limiting their use as 
therapeutics.  
Similar to other ATPases, it has been shown that RecA can be inhibited in vitro 
by ADP and non-hydrolysable ATP derivatives (Moreau and Carlier 1989; Menetski 
and Kowalczykowski 1985). This rationale led to the development of N6-
substituted ADP analogues capable of blocking the formation of RecA-DNA 
filaments (A. M. Lee et al. 2005). Unfortunately, the compounds discovered were 
of limited therapeutic utility given the membrane impermeability caused by the 
negatively charged 5’-diphosphate moiety at physiological pH. Interestingly, 
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many of the small molecules that have been found to inhibit RecA share this 
feature; they are rich in negatively charged moieties. For example, using an ATP 
hydrolysis plate assay, Wigle and Singleton discovered three polysulfated 
naphthyl compounds that inhibited RecA’s ATPase activity in vitro (Wigle and 
Singleton 2007). These compounds were suramin, Congo Red and bis-ANS. Again, 
their lack of therapeutic utility was associated to the membrane impermeability 
caused by their negative charges.  
 
The two cellular membranes and the lipopolysaccharide-coated outer membrane 
present in Gram-negative bacteria are very difficult for small molecules to cross 
(Hiroshi Nikaido 2003; H Nikaido 1994; Carpenter, Parkin, and Khalid 2016). To 
complicate things further, efflux pumps can also interfere with the accumulation 
of compounds inside bacterial cells (Silver 2011). Usually, small molecules that 
are able to cross the outer membrane do so through porins, cylinder-shaped 
channels that are lined with charged amino acids (Cowan et al. 1992). For a 
compound to enter the cell through these channels, the hydration shell of the 
amino acids has to be removed temporarily and replaced by the small molecule. 
For this reason, lipophilic molecules cannot cross the outer membrane easily. In 
fact, most of the antibiotics that are active against Gram-negative bacteria are 
highly polar and have a molecular weight of less than 600 Da (O’Shea and Moser 
2008). In practice these principles are not always the case as there are 
antibiotics that meet these criteria but lack activity against Gram-negative 
bacteria. 
 
The current understanding of the physicochemical properties that influence the 
uptake and accumulation of small molecules in Gram-negative organisms is 
mainly based on retrospective analyses of antibiotics (Brown et al. 2014). 
Recently, Richter and collaborators studied the ability of over 180 diverse 
compounds to accumulate in E. coli, in order to gain a better understanding of 
the parameters that govern the uptake of molecules in Gram-negative bacteria 
(Richter et al. 2017). Using accumulation assays in whole cells, followed by 
structure-activity (SAR) relationship studies and computational analyses, they 
found that compounds that are most likely to accumulate in E. coli contain an 
amine, are amphiphilic and rigid, and have low globularity. Experimental 
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findings like these will hopefully aid the development of compounds able to 
permeate Gram-negative organisms.  
 
A different strategy to promote the uptake of large molecules in Gram-negative 
bacteria is the development of compounds that make the outer membrane more 
permeable. For instance, Muheim and co-workers performed a HTS looking for 
molecules able to make E. coli more susceptible to vancomycin. They discovered 
the compound MAC13243, a reported inhibitor of the essential chaperone LolA 
(Muheim et al. 2017). Inhibition of this chaperone affects the integrity of the 
outer membrane, making it more permeable. Indeed, the use of subinhibitory 
concentrations of MAC13243 made the outer membrane of E. coli permeable to 
the fluorescent dye 1-N-phenylnapthylamine (NPN) and potentiated the effect of 
large scaffold antibiotics like novobiocin and erythromycin.  
 
3.15.4 RecA-independent prophage induction 
 
As previously explained, induction of all lambdoid prophages relies on the 
removal of the cI repressor from its corresponding DNA motif. The best 
understood mechanism of induction involves the RecA-mediated autoproteolysis 
of the cI repressor, via the SOS response. Self-cleavage of the cI repressor 
activates the phage lytic cycle, including production of Stx.  
 
Nonetheless, RecA-independent mechanisms for the induction of lambdoid 
phages have also been reported. Rozanov and collaborators found that two E. 
coli genes, rcsA and dsrA, can cause partial induction of the phage λ in recA-
deficient strains (Rozanov, D’ari, and Sineoky 1998). RcsA is a positive 
transcriptional regulator of the cps operons involved in capsular polysaccharide 
synthesis, also known as colanic acid. The synthesis of colonic acid is regulated 
by the RcsABC system (Stout and Gottesman 1990). Prophage induction by this 
system only occurs in the exponential phase, and it is thought to happen either 
from a reduction of cI synthesis or from a decreased repressor activity via an 
alternative RecA coprotease. DsrA is a small RNA molecule that derepresses rcsA 
transcription. Overexpression of this RNA was shown to efficiently cause 
prophage induction in both exponential and stationary phase. The mechanism 
130 
  
behind this regulation is still to be shown. Then, Imamovic and Muniesa 
discovered that chelating agents like EDTA and sodium citrate have the ability to 
induce Stx phages by causing damage to the outer membrane and by 
alkalinisation of the medium (Imamovic and Muniesa 2012).  
 
Although RecA-independent prophage induction is possible, we consider that 
targeting RecA is still a viable approach to prevent Stx expression in vivo. 
Physiologically, when STEC colonizes the human gut, the main stressors 
encountered by bacteria are hydrogen peroxide produced by neutrophils 
(Wagner, Acheson, and Waldor 2001) and antibiotics administered by physicians. 
Though hydrogen peroxide is not as good inducing agents as MMC or UV 
radiation, it has been shown that is it able to induce the bacterial SOS response, 
which implies that small molecules able to inhibit RecA would be a viable 
therapeutic strategy for STEC infections.  
  
131 
  
 
 
 
 
 
 
 
CHAPTER 4 
 
Identification of selective inhibitors of Shiga toxin 
expression by high throughput screening 
 
 
 
 
 
4 Identification of selective inhibitors of Shiga 
toxin expression by high throughput screening 
 
4.1 Introduction 
 
As a result of the successful identification of a small molecule capable of 
inhibiting Stx2 expression in E. coli O157:H7, an additional high-throughput 
screening (HTS) of small molecules was performed. This was done at the Drug 
Discovery Unit, University of Dundee. The aim was to build on our experience 
from the previous series and hopefully find a new, more potent and less toxic 
series of Stx inhibitors. 
 
Using the stx2::GFP reporter assay described in chapter 3, a total of 29,504 
compounds were screened for activity against Stx expression. The cut-off for hit 
selection was anything above 40% inhibition of stx2::GFP expression. The 
primary screen identified 130 putative hit compounds. Analysis of the 
compounds using orthogonal assay to discard false positives showed that only 9 
compounds exhibited activity in a dose-dependent manner and with no effect on 
bacterial growth. Further biological characterisation of the hit compounds 
revealed that only two molecules block expression of Stx2 in a specific and dose-
dependent manner.  
 
The work presented in this chapter goes from the development of the biological 
assay used in the primary screen, to the validation of hits and their biological 
evaluation.  
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4.2 Assay development and validation 
4.2.1 DMSO tolerance 
Since the libraries of compounds are stored as DMSO solutions, it is important to 
discard any undesirable effects that DMSO might have on the assay. To this end, 
three different concentrations of DMSO were tested in both E. coli O157 
stx2::GFP and E. coli O157:H7 rpsM::GFP. As shown in Figure 47, DMSO 
concentrations up to 1% had no significant effect on bacterial growth in both 
reporter strains.  
 
Figure 46 Effect of DMSO on bacterial growth. 
Since all the compounds in the chemical library to be screened are dissolved in DMSO, it was 
important to discard any possible interference with bacterial growth. Concentrations of DMSO up 
to 1% v/v did not have any significant effect in both the A) stx2::GFP and B) rpsM::GFP reporter 
strains. 
 
4.2.2 Statistical evaluation of the HTS assay 
In order to identify bioactive compounds using a relevant biological model, 
certain quality metrics need to be taken into account in order to make sure that 
the data meet certain standards. In the Drug Discovery Unit, three parameters 
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are routinely assessed: signal to background ratio, coefficient of variation and 
Z’-factor.  
 
Signal to background (S:B). It provides an indication of the separation between 
positive and negative controls. A good separation between controls is essential 
to identify changes in activity produced by active compounds.  It is calculated 
using the following formula: 
S:B = Msignal / Mbackground 
 
Where M is the mean of the signal. 
 
Coefficient of variation (CV): It is normally expressed as percentage and it 
provides a good indication of variability for the signal. It can be influenced by 
the assay stability, precision of liquid handling and detection instruments. It is 
calculated using the following formula 
CV = 100 x SD/M (%)  
 
Z’ factor. In 1999, Zhang and collaborators introduced the Z-factor, a 
dimensionless statistical parameter that assesses the quality of the bioassay used 
in HTS campaigns. This parameter takes into account both the assay signal 
dynamic range and the data variation associated with the signal measurements 
(Zhang, Chung, and Oldenburg 1999). The Z factor can be calculated using 
equation 1. Note that for agonist/activation assays, control means the maximum 
activation signal data; for antagonist/inhibition assays the control is the 
minimum activation signal or negative control. 
 Equation 1 𝑍 = 1−   (3 𝑆𝐷!"#$%& + 3 𝑆𝐷!"#$%"&)|𝑀𝑒𝑎𝑛!"#$%& −𝑀𝑒𝑎𝑛!"#$%"&| 
 
Similar to the Z factor, the Z’-factor (Z-prime) can be calculated using only data 
from both positive (p) and negative (n) controls (equation 2). Equation 2 shows 
that a good Z’ value is obtained when the means of both controls are strongly 
different to each other and have very low standard deviations. 
Equation 2 𝑍′ = 1−   (3 𝑆𝐷! + 3 𝑆𝐷!)|𝑀𝑒𝑎𝑛! −𝑀𝑒𝑎𝑛!| 
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The Z’ has a range of 0 to 1. The closer the value is to 1, the more robust and 
reliable the assay is. In HTS campaigns, assays with a Z’ value above or equal to 
0.5 are considered excellent assays. Table 18 shows the interpretation for 
different Z’ values.  
Table 18 Z’ value and its interpretation (modified from Zhan, Chung, and Oldenburg, 1999). 
Z’ value Interpretation 
1 An ideal assay.  
1 > Z’ ≥ 0.5 An excellent assay. Separation band is large 
0.5 > Z’  > 0 Separation band is small. More optimisation is needed 
0 No separation band, the sample and control signal variations are 
very close 
< 0 No separation band, the sample and control signal variations overlap 
 
 
 
Figure 47 Separation band the suitability of an assay for HTS. 
A good assay for a HTS campaign should have a clear separation between the tails of the 
distributions of the controls and a large signal window or separation band (>3-fold). Modified 
from Zhang, Chung, and Oldenburg 1999. 
 
The robustness of the stx2::GFP assay was assessed by performing a pilot 
experiment with a small number of plates. This was to ensure that the assay 
would reliably detect compounds that have an effect on the biological model 
using the equipment and reagents available at the screening facilities. As shown 
in Figure 49, the assay produced low standard deviations and wide assay 
windows, therefore high Z’ values were produced (>0.5). 
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Figure 48 Assay performance of the stx2::GFP reporter strain. 
Five different 384-well plates were used in a pilot experiment to assess the robustness and 
reproducibility of the assay. All five plates showed high Z’ values (>0.4), good S:B ratio (>2) and 
acceptable %CV (<10%) suggesting that the assay was robust and reliable. The data shown are the 
average of five individual experiments with standard deviation from the mean displayed as error 
bars. 
Table 19 Assay validation stx2::GFP 
  Plate number 
  1 2 3 4 5 
Negative 
control 
Mean 60944 66678 65220 52274 69927 
Median 61221 67177 65283 52030 69342 
SD 1791 3568 2295 1203 3715 
%CV 2.94% 5.35% 3.52% 2.30% 5.31% 
Positive 
control 
Mean  205574 208749 216527 178253 210310 
Median  205139 205680 213373 181683 204997 
SD 15344 9863 15784 19540 19934 
%CV 7.46% 4.72% 7.29% 10.96% 9.48% 
Robust Z’ factor 0.64 0.71 0.64 0.77 0.49 
S:B 3.3 3.13 3.31 3.40 3.0 
 
The robustness of the rpsM::GFP assay was also assessed in a pilot experiment 
with five different plates. In this case the antibiotic ampicillin was used as 
positive control (a compound that interferes with bacterial growth). As shown in 
Figure 50, the assay also produced low standard deviations and wide assay 
windows, therefore high Z’ values were produced (>0.5). 
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Figure 49 Assay performance of the rpsM::GFP reporter strain.  
Five different 384-well plates were used in a pilot experiment to assess the robustness and 
reproducibility of the assay. All five plates showed high Z’ values (>0.7), good S:B ratio (>2.5) 
and acceptable %CV (<10%) suggesting that the assay was robust and reliable. The data shown 
are the average of five individual experiments with standard deviation from the mean displayed 
as error bars.  
 
Table 20 Assay validation rpsM::GFP 
  Plate number 
  1 2 3 4 5 
Negative 
control 
Mean 59225 53494 64070 51589 63841 
Median 58656 53646 63726 51817 63695 
SD 2790 1296 1310 1714 1154 
%CV 4.71 % 2.42% 2.04% 3.32% 1.80% 
Positive 
control 
Mean  196035 202197 165513 193151 162963 
Median  194778 200256 163569 191705 162585 
SD 5721 6311 5585 7448 7844 
%CV 2.91% 3.12% 3.37% 3.85% 4.81% 
Robust Z’ factor 0.85 0.89 0.84 0.85 0.74 
S:B 3.3 3.7 2.5 3.7 2.5 
 
4.3 High throughput screening at the Drug Discovery Unit 
(DDU) University of Dundee 
 
After optimisation and validation of the stx2::GFP assay, a single point screen of 
small molecules was carried out at the University of Dundee using the stx2::GFP 
expression assay. A total of 29,504 compounds from three different libraries 
were screened: the Gates and DDU targeting sets, the Epigenetics set and 
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Easyset. All of the compounds in the libraries are from synthetic origin, sourced 
from commercial suppliers and highly curated to cover diverse chemical space. 
The HTS was performed in a 384-well format, using the layout shown in Figure 
51. The compounds were aliquoted in columns 1 to 22 to give a final 
concentration of 30 µM. Columns 23 and 24 were used as the positive (0% 
inhibition) and negative (100% inhibition) controls, respectively. The screening 
was carried out in 7 batches of 10-20 plates over the course of 3 weeks.  
 
 
Figure 50 Single point HTS to identify inhibitors of Stx2 expression in E. coli O157:H7.  
The screening of small molecules was performed at a final concentration of 30 µM using the 
stx2::GFP reporter assay. A) 384-well plate layout used for the screening of compounds; wells in 
columns 1 to 22 contained the compounds to test, wells in columns 23 and 24 were used as the 
positive (0% inhibition) and negative (100% inhibition) controls, respectively. B) Plot of S:B ratio 
and Z’ factor for all the plates screened. Dotted lines indicate the quality control thresholds 
used in the DDU (Z’=0.5, S:B=2). 
 
The quality and robustness of the screen was constantly monitored between 
plates and batches. The quality control criteria for acceptance of the assay 
were: S:B ratio ≥ 2, CV % < 10% and Z’ ≥ 0.4. Although the screen performance 
was as expected, an important drop in S:B was observed as some plates had 
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values well below the acceptance limit (Figure 51B). However, the Z’ factor of 
most of the plates remained above the 0.4 limit, suggesting that screen 
remained robust throughout the campaign. 
 
Once the plates were screened, the hit identification process took place. The 
cut-off for hit selection was anything above 40% inhibition of stx2::GFP 
expression (Figure 52). The percentage effect for each compound tested was 
calculated using fluorescence (in relative fluorescence units or RFUs) of MMC 
treated cells to set the 0% effect and MMC untreated cells to set the 100% 
effect.  
 
 
Figure 51 Hit selection from the HTS campaign.  
Any compound that showed a decrease in stx2::GFP expression equal or superior to 40% (red 
dots) was considered a potential hit. Dotted line shows the 40% cut-off. 
 
As shown in Figure 53, screening data is typically not normally distributed. 
Instead, it is asymmetrical with long tails or ‘outliers’ comprising the active 
compounds. As a result, using the average and standard deviation for hit 
selection is not a valid approach. To overcome this issue, a different parameter 
is taken, the median absolute deviation (MAD). MAD can be defined as: 
 
MAD = 1.4826 x median (| xij – median(x) |) 
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where x indicates all the values in the sample wells of a plate and xij the sample 
well at the row i  and the column j. The number 1.4826 is used as a constant to 
make MAD comparable to SD when the data is normally distributed (Chung et al. 
2008). Thus, in the Z’ score formula, the mean and the SD are replaced with 
median and MAD. 
 
 
 
Figure 52 Response distribution of the HTS.  
The screen output is represented as % inhibition of stx2::GFP and plotted as a frequency 
distributions of all compounds tested. Compounds that inhibited stx2::GFP by 40% (red square) or 
more were designated potential inhibitors. 
 
Interestingly, the majority of the compounds screened appeared to enhance 
fluorescence rather than decrease it. This can also be seen in the distribution 
profile of the compounds shown in Figure 53 where it can be clearly seen that 
the number of enhancers of stx2::GFP surpassed the number of inhibitors. This 
can be attributed to possible autofluorescence properties of the compounds or 
potential triggers of the SOS response. Another possible factor for this behaviour 
could be a defective distribution of heat in the plates, a problem known as the 
edge effect (Lundholt, Scudder, and Pagliaro 2003).  
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4.4 Dose response evaluation of putative hit compounds 
and counter-screen 
 
In order to confirm the activity of the compounds and to establish their potency, 
the 130 hit compounds identified in the primary screen were further re-tested in 
a dose-response assay. The assay consisted in a 10-point 2-fold serial dilution of 
the test compounds from 100 µM to 0.01 µM, using the same conditions used in 
the primary screen. Since compounds that affect bacterial growth would result 
in a decrease in GFP expression, a counter-screen using E. coli rpsm::GFP was 
performed in parallel to identify false positives. The rpsM promoter activity (30S 
ribosomal subunit) was chosen as a housekeeping gene control as it is not related 
to Stx expression (Roe et al. 2004). The plate layout used for the dose-response 
assay and counter-screen is shown in Figure 54. Columns 1 to 10 and 13 to 22 
contained the compounds serially diluted. Columns 11 and 23 were used as the 
positive control (0% inhibition) and columns 12 and 24 as the negative control 
(100% inhibition). Both assays complied with the quality controls from the DDU. 
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Figure 53 Secondary screening of the hit compounds using the rpsM::GFP.  
In order to discard false positives, the hit compounds were evaluates using the rpsM::GFP 
reporter assay. A) 384-well plate layout used for the counter-screen; wells in columns 1 to 10 
and 13 to 22 contained the compounds serially diluted. Columns 11 and 23 were used as the 
positive control (0% inhibition) and columns 12 and 24 as the negative control (100% inhibition) 
B) Plot of S:B ratio and Z’ factor for all the plates screened. Dotted lines indicate the quality 
control thresholds used in the DDU (Z’=0.5, S:B=2). 
 
From the 130 hit compounds identified, only 9 compounds exhibited activity in a 
dose-dependent manner without affecting bacterial growth (Table 22). The 
potency of these compounds was determined by calculation of their XC50 values, 
where ‘X’ denotes either antagonistic (IC50) or agonistic (EC50) activity. In HTS 
campaigns, the XC50 values are routinely reported as pXC50 values (negative 
logarithm of the molar concentration). Table 21 shows a conversion table 
between these two values. The higher the pXC50, the more potent a compound is. 
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Table 21 Conversion table between pXC50 and µM . 
pXC50 µM 
4 100 
4.3 50 
4.6 25 
4.9 12.5 
5.2 6.25 
5.5 3.125 
5.8 1.563 
6.1 0.781 
6.4 0.391 
6.7 0.195 
7.0 0.098 
 
The pXC50 values were obtained through the construction of dose-response 
curves, where different concentrations of the compounds are plotted against the 
corresponding assay response (GFP expression). A dose-response curve has four 
parameters: top asymptote (maximal response), bottom asymptote (baseline 
response), slope (Hill slope) and the XC50 value (Goktug, Chai, and Chen 2013).  
The dose response curves were fit using the following equation: 
 y = A + B − A1 + 10!x ! 
 
where A is the minimum fold change, B is the maximum fold change, C is the Log 
XC50 value and D is the slope factor; x is the drug concentration and Y is the fold 
change. Data were fitted using the Levenburg Marquardt algorithm. The dose 
response analysis identified 8 compounds as specific inhibitors of stx2::GFP 
expression in the primary assay, with pIC50  values ranging from 4 to 5.64 (Figure 
55).
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Table 22 Chemical structures of the hit compounds, potency and activity. 
Compound structure and name 
Molecular 
formula 
pXC50 
 
Maximum 
effect (%) 
 
DDD00040598 
C18H15BrN2O3 5.64 77 
 
DDD00058801 
C13H10N2O3S 5.55 89 
 
DDD00074091 
C17H14N2O3 4.83 91 
 
DDD01049435 
C13H17N5O3 4.67 56 
 
DDD01292781 
C15H20Cl2N4O2 4.65 51 
 
DDD01257835 
C13H17ClN2O2 4.67 64 
 
DD01302463 
C11H21F3N2O3S 4.0 97 
 
DDD01304030 
C11H16F3N3O3S 4.1 86 
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Figure 54 Dose-response curves from the hit compounds identified in the primary screen. 
The potency of the hit compounds was assessed using the stx2::GFP assay, two-fold serial 
dilutions of the compounds. For all data analysis, the RFU of each well was normalised to as 
percentage effect (% Effect) of the positive control. Potency was determined using a 4–
parameter logistic fit (minimum, maximum, hill slope and IC50), being defined in reference to the 
negative logarithm of the molar value at the point of inflection of a sigmoidal dose-response 
curve (pIC50). All the plates assessed were subject to quality control analysis, ensuring that the 
SB ratio ≥ 2, CV %<10% and Z’ ≥ 0.4. 
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4.5 Characterisation of hit compounds  
 
To further evaluate the compounds, they were repurchased from commercial 
suppliers, and their purity was verified using LC-MS. It is important to repurchase 
or synthesise a new batch of the hit compounds as impurities could confer 
supposed activity in the primary assay. The compounds were re-tested in the 
stx2::GFP primary assay to confirm their activity. Upon re-evaluation, only the 
compounds DDD00040598, DDD00058801, DDD01049435, DDD01302463 and 
DD01304030 showed a dose-dependent reduction of fluorescence in the 
stx2::GFP reporter assay (Figure 56). 
 
 
Figure 55 Re-evaluation of the hit compounds in the stx2::GFP reporter assay.  
The freshly acquired compounds were tested in our laboratory to confirm the results obtained in 
the primary screen. Only 5 of the 8 hit compounds showed a dose-dependent reduction of 
fluorescence: (A) DDD00040598, (B) DDD00058801, (C) DDD01049435,  (D) DDD01302463 and (E) 
DD01304030. The data shown are the average of three biological replicates with standard 
deviation from the mean displayed as error bars.  
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4.5.1 The compounds DDD01302463 and DDD01304030 block the 
phage lytic development  
 
Next, we decided to test if the compounds had any effect on Stx prophage 
induction and phage lytic development. Transduction assays were performed 
using E. coli JP10819, which carries the lysogenic Stx2 prophage φP27 with a 
tetracycline resistance cassette inserted into the stx2 gene (Quiles-Puchalt et al. 
2014). The non-lysogenic E. coli MG1665 was used as the acceptor strain. Only 
two hit compounds effectively reduced the production of phage particles: 
compounds DDD01302463 and DDD01304030. As shown in Figure 57, bacterial 
cultures that were not induced with MMC produced low levels of Stx phage (105 
PFU/mL), whereas the presence of MMC increased the levels by four logs to 109.  
The presence of 200 µM of DDD01302463 significantly decreased the amount of 
Stx phage produced with a titre of 105 PFU/mL. This demonstrated that 
DDD01302463 inhibits the production of functional Stx phages. Similar results 
were observed for DDU01304030, although it appeared to be less potent in 
comparison to DDD01302463. 
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Figure 56 Effect of the compounds DDU01302463 and DDU01304030 on MMC-induced phage 
production.  
Induction of JP10819 with 2 µg/ml MMC resulted in significantly increased Stx phage production. 
(A) DDU01302463 produced a significant decrease in phage production by both non-induced and 
MMC-induced JP10819. (B) Similarly, DDU01304030 decreased the production of phage particles 
in a dose-dependent manner. The data shown are the average of three independent experiments 
with standard deviation from the mean displayed as error bars.  
 
As previously mentioned, prophage induction is intrinsically liked with bacterial 
lysis (Mauro and Koudelka 2011). Thus, inhibition of MMC-induced bacterial lysis 
is a confirmatory phenotype of the compound’s ability to prevent Stx 
production.  
To test this hypothesis, cultures of E. coli O157:H7 were incubated in the 
presence of DDU01302463 and DDU01304030, and induced with MMC. As shown in 
Figure 58, bacterial lysis was inhibited in a dose dependent manner. These 
results are in accordance with the data obtained in the transduction assay. The 
compounds seem to be effectively blocking phage lytic development. 
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Figure 57 Effect of the compounds DDU01302463 and DDU01304030 on MMC-induced cell 
lysis. 
Dose-dependent inhibition of bacteriophage mediated lysis in the presence of the compounds (A) 
DDU01302463 and (B) DDU01304030. The data shown are the average of three independent 
experiments with standard deviation from the mean displayed as error bars.  
 
The pXC50 values for both compounds were recalculated using the freshly 
purchased compounds. For DDD01302463 the pCX50 was 4.0 and for DDD01304030 
it was 4.1 (Figure 59), similar to the values previously obtained (table 22). 
 
 
Figure 58 Potency of the hit compounds DDD01302463 and DDD01304030  
The confirmed hit compounds were repurchased and tested in the stx2::GFP assay. E. coli 
O157:H7 was treated with 7-point, 2-fold serial dilution of the compounds. A) Calculated pXC50 
for DDD01302463 B) Calculated pXC50 for DDD01304030 
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4.5.2 The compounds DDD01302463 and DDD01304030 do not 
affect bacterial growth and are specific against Stx 
expression. 
It was essential to verify that the reduction in fluorescence in the stx2::GFP 
assay by the compounds DDD01302463 and DDD01304030 was not due to effects 
on bacterial growth. Bacterial cultures of E. coli O157:H7 were grown in the 
presence of different concentrations of the compounds. Ampicillin was used as a 
positive control i.e. inhibition of growth. As shown in Figure 60-A,C, 
DDD01302463 and DDD01304030 did not have a significant effect on bacterial 
growth. This was also confirmed using the rpsM::GFP reporter assay (Figure 60-
B-D). The presence of the compound did not cause any significant decrease in 
fluorescence, confirming that the compounds are specific inhibitors of stx 
expression.  
 
Figure 59 Evaluation of effect of compounds DDD01302463 and DDD01304030 in bacterial 
growth and rpsm::GFP expression.  
A) Bacterial growth curve of E. coli O157:H7 in the presence of different concentrations of 
DDD01302463. B) Evaluation of DDD01302463 in the rpsM::GFP reporter assay demonstrated that 
the activity is specific only against Stx expression. Ampicillin was used as control to show a 
negative effect on growth and fluorescence measurements. C) Bacterial growth curve of E. coli 
O157:H7 in the presence of different concentrations of DDD01304030. D) Evaluation of 
DDD01302463 in the rpsm::GFP reporter. The data shown are the average of triplicate individual 
experiments with standard deviation from the mean displayed as error bars.  
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4.5.3 Evaluation of the compounds DDD01302463 and 
DDD01304030 in the Shiga toxin cytotoxicity assay 
 
As previously discussed, when prophage induction occurs in STEC, the lysates of 
such cultures are toxic to Vero cells (Konowalchuk, Speirs, and Stavric 1977). 
Hence, testing the toxicity of the cell lysates in the presence and absence of the 
hit compounds is an indirect way of assessing their inhibitory activity on Stx 
expression.  
 
To do this, we used the C. rodentium strain carrying the λstx2dact gene (Mallick et 
al. 2012). Cultures were treated with 200 µM of DDD01302463 and DDD01304030. 
An additional culture treated with 50 µM of the RecA inhibitor AHU3 was used as 
a control. Stx production was triggered by the addition of 1 µg/mL of MMC to the 
samples containing the compounds and to the MMC-only control. Cultures were 
filter sterilised using 0.2 µm syringe filters and serially diluted. The dilutions of 
the lysates were added to Vero cells plates and incubated for further 48 h at 
37°C in a humidified 5% CO2 incubator. Cytotoxicity was assessed using the 
methylthiazolydiphenyl-tetrazolium bromide (MTT) assay (Denizot and Lang 
1986). 
 
   
Figure 60 Effect of DDD01302463 and DDD01304030 on viability of Vero cells treated with 
lysates of C. rodentium λstx2dact.  
Vero cells were treated with lysates of C. rodentium λstx2dact prepared from cultures: untreated 
(negative control), treated with 1 µg/mL MMC to induce Stx expression (positive control), 200 µM 
of DDD01302463 and DDD01304030 and 50 µM of AHU3 as control. Results represent mean values 
from three independent experiments, with error bars indicating SD. Statistical significance is 
shown as P values obtained by t test (***p < 0.001).  
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As shown in Figure 61, the compounds DDD01302463 and DDD01304030 did not 
show a significant decrease in the toxicity of C. rodentium λstx2dact lysates in 
comparison to the AHU3 compound. This result might be due higher potency that 
AHU3 has or the type of interaction involved in the biological effect. AHU3 could 
be more potent given the covalent nature of its binding its receptor, the RecA 
protein.  
 
Western Blot analysis of C. rodentium λstx2dact supernatants showed that the 
compound DDD01302463 indeed inhibits Stx expression in a dose dependent 
manner, but that it is less effective than AHU3. Similarly to the effect seen in E. 
coli O157:H7, DDD01302463 also blocked phage-mediated lysis in C. rodentium 
λstx2dact  (Figure 62). 
 
Figure 61 Effect of DDD01302463 on Stx production in C. rodentium λstx2dact. 
A) DDD01302463 blocks phage-mediated lysis in C. rodentium λstx2dact in a dose-dependent 
manner. B) Supernatants of C. rodentium non-induced and induced with MMC was blotted for 
Sxt2B. Lane 1: non-induced culture, Lane 2: MMC –induced culture, Lane 3: 50 µM DDD01302463, 
Lane 4:  100 µM, Lane 5: 200 µM, Lane 6: 50 µM AHU3.  
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4.6 Discussion  
Using a phenotypic GFP-based reporter assay, we successfully performed a HTS 
of small molecules to identify inhibitors of Shiga toxin expression in E. coli 
O157:H7.  
The use of bacterial biosensors in HTS campaigns allows the screening of 
multiple targets simultaneously, in comparison to the target-based assays (Urban 
et al. 2007; Alksne et al. 2000). Cell-based assays also facilitate the 
identification of compounds able to cross the bacterial outer membrane, a 
common issue encountered in the development of drugs active against Gram-
negative bacteria (Payne et al. 2007). 
 
The performance of the screen was very good and in accordance with the Drug 
Discovery Unit guidelines. The stx2::GFP and the rpsM::GFP assays produced 
solid data, achieving S:B ratios ≥ 2, CV % < 10% and Z’ ≥ 0.4, which are above 
pre-set industry standards (Iversen et al. 2006; Zhang, Chung, and Oldenburg 
1999). The screen identified two hit compounds, DDD01302463 and DDD01304030 
that specifically block expression of Stx2. The potency of these compounds was 
found to be in the micromolar range. 
 
The secondary assay using the rpsM::GFP reporter fusion greatly facilitated the 
hit selection process.  One of the main challenges in HTS campaigns is the 
differentiation between compounds that have genuine activity against 
compounds that interfere with elements of the biological assay (Thorne, Auld, 
and Inglese 2010). Since compounds that affect bacterial growth would result in 
a decrease in GFP expression, it was important to discard any compound with 
antimicrobial activity. There are other ways in which compounds can also 
interfere with the assay. For example, fluorescent compounds can affect light-
based detection methods that rely on fluorescence or luminescence 
measurements. Alternatively, certain compounds can reduce the excited state of 
the fluorophore (quenching), which results in decreased light emission (Shapiro, 
Walkup, and Keating 2009). Although certain measures can be taken to avoid or 
solve assay interferences, the most logical option is to run an orthogonal assay 
to verify that the compounds are active against the target or phenotype of 
interest. 
 154 
 
 
4.6.1 Potential of the compounds DDD01302463 and DDD01304030 
as lead compounds 
The evaluation of the compounds DDD01302463 and DDD01304030 in biological 
assays confirmed their inhibitory activity on Stx expression. The relatively high 
pXC50 means that more work is required in order to optimize the activity. This 
will involve thorough structure-activity relationship studies (SARs) in order to 
obtain more potent and efficient derivatives. 
Both DDD01302463 and DDD01304030 have the potential to be optimised and 
taken forward for development. For instance, they do not have functional groups 
that can cause problems later in drug development. Some functional groups are 
known to cause problems like toxicity or a higher susceptibility to 
biotransformation. A summary of the functional groups that can cause liabilities 
in drug development are listed in Table 23 (Huggins, Venkitaraman, and Spring 
2011). 
Table 23 Liable functional groups in drug discovery. 
1,2 dicarbonyls 
 
Metabolically unstable and potential mutagenic 
properties 
1,2 dimethoxys 
1,4 dimethoxys 
Susceptible to oxidation yielding reactive quinones 
αβ-unsaturated carbonyls Reactive as Michael acceptors 
Acetals  
Acylhydrazides 
Metabolically unstable due to acetal hydrolysis 
Aliphatic ketones Metabolically unstable due to nucleophilic attack 
Alkenes  Susceptible to epoxidation 
Aminothiazoles Toxicity 
Anthracene/phenantrene 
derivatives 
Possible DNA intercalation 
Nitro groups Susceptible to reduction and potential 
hepatotoxicity 
Methylenedioxys Metabolically unstable and prone to oxidation 
Thioureas Potential non-specific protein binding and 
metabolically unstable 
Unflanked pyridyls Can interfere with cytochrome P450 due to metal 
ion coordination 
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4.6.2 Stereochemistry and its implication in drug development 
 
One of the features of the hit compounds identified is the presence of a chiral 
centre in the molecules (Figure 63).  A molecule is ‘chiral’ when it cannot be 
superimposed on its mirror image, just like right and left hands. A chiral centre 
is usually a carbon atom that contains four different substituents. When one 
chiral carbon is present in the molecule it gives origin to enantiomers, the mirror 
images of one another (Gal 2013).  
About half of the drugs commercially available are chiral molecules and near 90% 
of these are racemates, an equimolar mixture of two enantiomers (Nguyen, He, 
and Pham-Huy 2006).  
 
           
 
Figure 62 Chemical structures of the compounds DDD01302463 and DDD01304030. 
The hit compounds DDD01302463 and DDD01304030 have a chiral carbon (red dotted circle) that 
gives origin to two enantiomers.  
 
The importance of chirality in drug discovery resides in the chiral nature of the 
macromolecules that form biological systems, i.e. proteins, glycolipids and 
polynucleotides (Hutf and O’grady 1996). It is therefore not surprising that the 
interaction between a drug and a chiral macromolecule occurs in a 
stereoselective manner. In the case of drugs that are enantiomers, one 
enantiomer might have the desired pharmacological activity whereas the other 
may be inactive or produce undesired effects. A good example of this is the 
tragedy caused by thalidomide. Back in the 1960s, the sedative drug thalidomide 
was prescribed for morning sickness in pregnant women (J. H. Kim and Scialli 
2011). The drug was being commercialised as a racemate, and back then little 
was know about the importance of stereochemistry in drug activity. Sadly, 
numerous babies were born with severe deformities as a consequence of the 
drug’s toxicity. It was later discovered that the toxicity was due to the 
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teratogenic activity of one of the enantiomers, S(-)-thalidomide (S. W. Smith 
2009). Although it has been proposed that the tragedy could have been 
prevented if only the R(+)-thalidomide enantiomer had been commercialised, 
more recent studies have shown that the humans interconvert both the (S) and 
(R) enantiomers in vivo (Reist et al. 1998).  It is therefore important that both 
the racemate and the individual enantiomers of the compounds DDD01302463 
and DDD01304030 are studied in an independent manner.  
 
4.6.3 Target identification: future work 
 
Since the compounds were identified using a phenotypic assay, the molecular 
target(s) remain to be elucidated. Although the identification of the target is not 
essential for approval of a drug candidate (Perola 2010), knowing the molecular 
mode of action allows the optimization of the pharmacokinetic and 
pharmacodynamic properties. 
 
Part of the future work with the hit compounds will include the identification of 
the biological target(s). Despite the number of available techniques for target 
identification, affinity chromatography is still the most widely employed method 
(Sleno and Emili 2008; Sato et al. 2010). One of the main limitations of this 
technique is the need of SAR studies on the molecule prior to its use. It also 
requires the conjugation of the molecule to an affinity tag like biotin, which 
sometimes can be problematic or interfere with bioactivity (Lomenick, Olsen, 
and Huang 2011).   
Drug Affinity Responsive Target Stability (DARTS) is a technique that is gaining 
popularity in the drug discovery setting. It relies on the principle that a small 
molecule drug stabilises the target protein that results in protease resistance 
(Figure 64). 
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Figure 63 Target identification methods. 
A) Affinity chromatography relies on the incubation of cell lysates with the immobilised small 
molecule of interest in order to ‘pull down’ the target protein. Unbound proteins are washed 
away and the target protein is eluted with an excess of free drug or denaturing conditions. B) In 
DARTS, cell lysates are incubated with the small molecule, followed by treatment with 
proteases. The drug-induced protease resistance promotes the negative enrichment of the target 
protein, while the non-target proteins are digested. Modified from Lomenick, Olsen and Huang, 
2011. 
 
In the particular case of this set of compounds, another possible approach would 
be to study the effect DDD01302463 and DDD01304030 have on the expression of 
bacteriophage genes crucial for lytic development (e.g. N, Q) or lysogenic state 
preservation (e.g. cI) (Vohradsky 2017). Bloch and collaborators applied this 
approach to investigate the mode of action of a set of compounds able to block 
the phage lytic development in E. coli (Bloch et al. 2018). 
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CHAPTER 5 
 
Exploring the inhibition of quorum sensing as a 
potential strategy to prevent Shiga toxin expression 
in Escherichia coli O157:H7 
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5 Exploring the inhibition of quorum sensing as a 
potential strategy to prevent Shiga toxin 
expression in Escherichia coli O157:H7 
 
5.1 Introduction 
 
Quorum sensing (QS) can be defined as the production and secretion of signalling 
molecules that regulate gene expression in bacteria, in response to cell 
population density (M. B. Miller and Bassler 2001). 
Studies have shown that QS plays a key role in virulence in enterohemorrhagic E. 
coli, including production of Shiga toxin and formation of attaching and effacing 
(AE) lesions on the intestinal epithelial cells (Sperandio et al. 2001). E. coli has 
several QS systems, including the LuxS/AI-2 system (Walters, Sircili, and 
Sperandio 2006; Sperandio et al. 1999), AI-3/epinephrine/norepinephrine system 
(Sperandio et al. 2003; Walters and Sperandio 2006), indole (D. Wang, Ding, and 
Rather 2001; J. Kim and Park 2015), and the LuxR homolog SdiA (Kanamaru et al. 
2000). Different lines of evidence suggest that quorum sensing regulates 
production of Stx in EHEC.  More specifically, expression of stx has been linked 
with two QS pathways, the adrenaline/noradrenaline/AI-3 and the LuxS/AI-2 
signalling systems (Pacheco and Sperandio 2012).  
 
EHEC has a membrane-embedded sensor histidine kinase, QseC, which recognises 
the host adrenergic signalling molecules adrenaline and noradrenaline, and the 
bacterial autoinducer-3 (AI-3) (Njoroge and Sperandio 2012). Sensing of these 
molecules causes autophosphorylation of QseC, which subsequently leads to 
phosphorylation of the transcription factor QseB. This leads to a series of events 
that promote activation of virulence factors, including Stx (Figure 65). Rasko and 
co-workers reported the discovery of a small molecule, LED209, able to inhibit 
QseC-dependent virulence gene activation in EHEC (Rasko et al. 2008). 
Concentrations in the picomolar range of LED209 prevented the formation of A/E 
lesions on cultural epithelial cells and decreased the expression of the stxAB 
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genes in EHEC. The compound also showed activity against QseC in other Gram-
negative bacteria, including S. tymimurium and Francisella sp. One of the main 
features of LED209 is that it does not affect bacterial growth or induces the SOS 
response at the concentrations used, which makes it a promising lead that can 
be used as an anti-virulence therapy.  
 
 
 
Figure 64 Adrenergic sensing in EHEC.  
The bacterial membrane receptor QseC senses the host adrenaline and noradrenaline (NA), and 
the AI-3. Phosphorylation of QseC and QseB initiates a phosphorelay signalling cascade that 
activates expression of the two-component system QseEF, the locus of enterocyte effacement 
(LEE) genes, motility genes (flhDC) and Stx genes (stxAB). The QseEF system is also involved in 
expression of the LEE genes, and it is possible that adrenaline and/or NA play a role in its 
signalling. Adapted from Hughes and Sperandio 2008. 
 
On the other hand, the autoinducer-2 (AI-2) is nonspecies-specific molecule 
involved in intra- and interspecies communication in Gram-negative and Gram-
positive bacteria (Chen et al. 2002; Thiel et al. 2009). The LuxS/AI-2 system was 
first described in V. harveyi (Bassler, Wright, and Silverman 1994), and later 
work showed that it is also present in E. coli and S. typhimurium (Surette, 
Miller, and Bassler 1999). In fact, the gene responsible for AI-2 biosynthesis, 
luxS, has been identified in over 70 bacterial species (Lowery, Dickerson, and 
Janda 2008).  
 
AI-2-dependent quorum sensing has been associated with regulation of genes in 
E. coli. For instance, exogenous addition of AI-2 to E. coli K12 cultures 
stimulated the formation of biofilm and motility (Gonzalez Barrios et al. 2006). 
This response was associated with the LsrK protein, suggesting that AI-2 
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signalling occurs through the Lsr system. Studies on lsrR and lsrK mutant strains 
provided evidence that support Lsr-dependent regulation of biofilm formation 
and motility in E. coli (Figure 66) (J. Li et al. 2007). In EHEC, AI-2 has also been 
associated with chemoattraction, motility and attachment to HeLa cells (Bansal 
et al. 2008). Overall, different studies show that in E. coli, the LuxS/AI-2 
signaling system is important for the regulation of biofilm formation, 
colonisation, motility and other virulence traits.   
 
 
Figure 65 The LsrR/phospho-AI-2 circuit in E. coli.  
LsrR represses the lsr operon (comprised of lsrACDBFG) and the lsrRK operon. The AI-2 is 
imported into the cells via LsrABCD; once inside the cell, AI-2 is phosphorylated by the kinase 
LsrK. Phospho-AI-2 binds to LsrR in order to relieve the repression of the lsr transporter genes. 
This stimulates additional AI-2. LsrR. DPD= 4,5-dihydroxy-2,3-pentanedione. Taken from Li et al, 
2007. 
 
 
Studies carried out by Sperandio and collaborators showed that genes involved in 
the SOS response are regulated by AI-2 (Sperandio et al. 2001). Using gene array 
technology in the EHEC strain 84-24 and an isogenic luxS mutant, they showed 
that genes involved in the SOS response were up-regulated in the wild-type 
strain in comparison to the luxS mutant. These genes were recA (20-fold), uvrA 
(20-fold) and sulA (25-fold). In addition, evaluation of the transcription of stx 
using a stx::lacZ fusion showed a threefold increase in the wild-type in 
comparison to the luxS mutant, results that were confirmed by Western blot 
analysis. A similar study carried out by Yang and co-workers also showed that 
deletion of luxS in STEC decreases production of Stx2e and expression of flagella 
in vitro (Yang et al. 2014).  
 162 
 
 
Given the important role that AI-2 system has on the virulence of human 
pathogens, it has been proposed that inhibition of this pathways could be used 
for the development of antivirulence therapies (Guo et al. 2013). To date, 
inhibition of the LuxS/AI-2 pathway to prevent Stx expression in EHEC has not 
been explored. For this reason and given the evidence that AI-2 signalling is 
related to Stx expression, we decided to explore the inhibition of this QS 
pathway using a reported small molecule inhibitor of the AI-2 synthase, LuxS.  
 
The work presented in this chapter shows that treatment of E. coli O157:H7 
cultures with the synthetic compound furanone C-30 prevents phage lytic 
development and decreases production of Stx in vitro.  Giving the suitability of 
the compound for in vivo testing, the activity of furanone C-30 was assessed in a 
murine infection model using C. rodentium λstx2dact as a surrogate organism for 
STEC infections. Although it was not possible to draw conclusions from the in 
vivo work, to our knowledge this is the first report of the use of brominated 
furanones to prevent stx expression in EHEC. 
 
5.2 Naturally occurring brominated furanones alter AI-2 
signalling in E. coli  
A series of different halogenated furanones were isolated from the marine algae 
Delisea pulchra by de Nys and collaborators (Rocky de Nys et al. 1993). These 
secondary metabolites were found to have antimicrobial and anti-fouling 
properties (Rocky de Nys et al. 1995). Later work suggested that the bioactivity 
of this class of compounds was result of their ability to interfere with quorum 
sensing systems (Givskov et al. 1996). The chemical structures of some of the 
isolated furanones from D. pulchra are shown in Figure 67.  
 
 
Figure 66 Chemical structures of the brominated furanones isolated from D. pulchra. 
 163 
 
 
Studies showed that purified samples of the compounds F1 and F2 were able to 
block processes controlled by acyl homoserine lactones (AHL), including the 
swarming motility in Serratia liquefaciens and the bioluminescence of Vibrio 
fischeri and Vibrio harveyi (Givskov et al. 1996). 
 
Later work revealed that brominated furanones could alter both AHL and 
LuxS/AI-2 signalling pathways. A DNA microarray done in E. coli K12 revealed 
that 90 genes were differentially expressed in the presence of brominated 
furanones (34 were induced and 56 were repressed) (Ren et al. 2004). 44 of the 
repressed genes were found to be induced by AI-2 and the majority of these 
genes were involved in chemotaxis, motility and flagellar synthesis. 
Interestingly, the transcription of luxS was not altered, suggesting that 
brominated furanones were affecting the AI-2 signalling pathway in a post-
transcriptional way.  
 
It was later discovered that brominated furanones covalently modify and 
inactivate LuxS, the AI-2 synthase (Zang et al. 2009). Using recombinant LuxS, in 
vitro inhibition assays of the enzyme were performed. A dose-dependent 
inhibition of LuxS enzymatic activity was observed. In addition, spectroscopic 
analysis of the reaction revealed that addition of the brominated furanone 
shifted the UV/vis absorbance of LuxS, likely as a result of covalent modification 
of one of the residues by the compound. To confirm the covalent binding, the 
LuxS-furanone complex was analysed by mass spectrometry. Protein fragments 
with changes in molecular size showed that brominated furanones were reacting 
covalently with LuxS. More specifically, the modified residue was found to be 
Cys126, a residue that has been shown to coordinate with a divalent cation, an 
essential step for enzymatic activity (Ruzheinikov et al. 2001). Treatment of 
LuxS with chloracetone caused alkylation of all four cysteine residues present in 
LuxS, whereas the brominated furanone only modified Cys126, suggesting that 
this class of compounds act in a selective manner. Figure 68 shows the proposed 
molecular mechanism of the covalent modification of LuxS by brominated 
furanones.  
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Figure 67 Proposed mechanisms for LuxS, by the brominated furanone C-30.  
Based on the studies carried out by Zang and collaborators, two possible addition-elimination 
mechanisms are proposed. (A) A nucleophile in LuxS (Cys126) adds directly to the vinyl bromide, 
which leads to elimination of the bromide, and/or (B) the vinyl bromide can also be displaced by 
addition of Cys126. Modified from Zang et al. 2009. 
 
Based on the evidence that brominated furanones can alter the AI-2 signalling in 
E. coli, we decided to explore if the synthetic furanone C-30 could prevent Stx 
expression in E. coli O157:H7. 
 
5.3 The compound furanone C-30 reduces stx2::GFP 
expression 
 
To assess if furanone C-30 had any activity against Stx expression, cultures of 
Stx-negative E. coli Sakai ZAP0273 strain transformed with the stx2::GFP 
reporter plasmid were treated with different concentrations of the compound. 
As shown in Figure 69, furanone C-30 decreased stx2::GFP expression in a dose 
dependent manner. 
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Figure 68 The compound furanone C-30 reduces stx2::GFP expression.  
E. coli ZAP0273 transformed with pstx2::GFP was cultured in the presence of 12.5 – 50 µM 
furanone C-30 (FC-30), and induced with 1 µg/ml MMC. Expression of stx2::GFP was measured by 
fluorescence. (A) Reduction of MMC-induced stx2::GFP expression by FC-30 over time. (B) FC-30 
significantly decreases stx2::GFP expression in a dose dependent manner. Experiments were 
performed in triplicate, and data plotted as the mean with standard deviation from the mean 
displayed by error bars. Asterisks indicate a significant difference (**p < 0.001, ***p < 0.0001) 
from the culture treated with MMC only, determined by Student’s unpaired t-test. 
 
5.4 Furanone C-30 block phage mediated lysis and does 
not affect bacterial growth in E. coli O157:H7 
 
As previously mentioned, bacterial lysis is intrinsically linked to Stx expression 
and release. Thus, prevention or delay of bacterial lysis is a phenotypic feature 
associated with the inhibitory effect of the furanone C-30 on stx expression. 
Bacterial cultures of E. coli ZAP0273 were incubated in the presence of various 
concentrations of the compound. Prophage induction was achieved by addition 
of 1 µg/ml MMC. As shown in Figure 70, the presence of furanone C-30 prevented 
bacterial lysis in E. coli ZAP0273 in a concentration-dependent manner in 
comparison to the MMC-only culture.  
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Figure 69 Furanone C-30 blocks phage mediated lysis in E. coli O157:H7.  
Dose-dependent inhibition of bacteriophage mediated lysis in the presence of the various 
concentrations of furanone C-30. The data shown are the average of three independent 
experiments with standard deviation from the mean displayed as error bars. 
 
The compound furanone C-30 did not affect bacterial growth at the 
concentrations used. Its specificity against stx expression was confirmed using 
the rpsM::GFP reporter strain (Figure 71). As previously mentioned, the rpsM 
promoter activity (30S ribosomal subunit) was chosen as a housekeeping gene 
control as it is not related to Stx expression (Roe et al. 2004). 
 
 
Figure 70 Evaluation of effect of furanone C-30 in bacterial growth and rpsM::GFP 
expression.  
(A) Bacterial growth curve of E. coli O157:H7 in the presence of different concentrations of 
furanone C-30. (B) Evaluation of furanone C-30 in the rpsM::GFP reporter assay demonstrated 
that the activity is specific only against Stx expression. The presence of various concentration 
did not reduce expression of rpsM::GFP (data shown correspond to t=6 h after addition of the 
compound). The data shown are the average of triplicate individual experiments with standard 
deviation from the mean displayed as error bars.  
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5.5 Furanone C-30 prevents prophage induction and 
phage lytic development 
 
Since the stx2 genes are prophage encoded, production of Stx2 is intrinsically 
linked with the prophage lytic cycle. Hence, furanone C-30 is expected to 
reduce the number of Stx-encoding phages produced under SOS-inducing 
conditions. To test this hypothesis, transduction assays were performed using E. 
coli JP10819, which carries the lysogenic Stx2 prophage φP27 with a tetracycline 
resistance cassette inserted into the stx2 gene (Quiles-Puchalt et al. 2014). The 
non-lysogenic E. coli K-12 MG1665 was used as the acceptor strain. Cultures 
were treated with various concentrations of furanone C-30 and PFU were 
analysed 4 h after SOS-induction. As shown in Figure 72, in the absence of MMC, 
basal levels of Stx were around 104 PFU/mL, whereas the addition of MMC 
increased the number by four logs to 108 PFU/mL. The presence of furanone C-
30 reduced the amount of Stx phages produced in a dose dependent manner. 
The highest concentration of furanone C-30 (50 µM) reduced the titre to basal 
levels (104), demonstrating that the compound can effectively inhibit the 
production of Stx phage particles. Since 50 µM of furanone C-30 also seemed to 
be affecting the basal levels of Stx phage in the non-induced cultures, the effect 
of the compound in the growth rate of JP10819 was studied. No significant 
reduction on growth rate was observed.  
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Figure 71 Effect of the furanone C-30 on MMC-induced phage production.  
Induction of JP10819 with 2 µg/ml MMC resulted in significantly increased Stx phage production. 
(A) furanone C-30 produced a significant decrease in phage production by both non-induced and 
MMC-induced JP10819. (B) The compound does not affect the bacterial growth rate of JP10819. 
The data shown are the average of three independent experiments with standard deviation from 
the mean displayed as error bars.  
 
5.6 Western blot analysis of the effect of furanone C-30 
on Stx production in C. rodentium λstx2dact 
 
Western Blot analysis of C. rodentium λstx2dact supernatants showed that 
furanone C-30 prevents Stx expression in a dose dependent manner (Figure 73). 
Similarly to E. coli O157:H7, the effect of furanone C-30 on the growth rate of C. 
rodentium was studied and no negative effect was observed. Phage mediated 
lysis was also prevented in the presence of the compound in a concentration-
dependent manner.  
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Figure 72 Furanone C-30 prevents phage-induced lysis in C. rodentium λstx2dact and 
decreases Stx2dact production.  
(A) Furanone C-30 does not interfere with C. rodentium growth rate. (B) Comparably to the 
results obtained with EHEC, the presence of furanone C-30 also showed an inhibitory effect on 
phage induced lysis in C. rodentium λstx2dact, particularly at the highest concentration (50 µM). 
(C) Western blot analysis of C. rodentium λstx2dact lysates showed a concentration dependent 
decrease in the production of Stx after prophage induction with MMC. The data shown are the 
average of three independent experiments with standard deviation from the mean displayed as 
error bars.  
 
5.7 Evaluation of furanone C-30 in the Shiga toxin 
cytotoxicity assay 
 
As previously discussed, analysis of the toxicity of STEC bacterial lysates to Vero 
cell cultures, is an indirect method to detect Stx production (Konowalchuk, 
Speirs, and Stavric 1977). Thus, we decided to test the ability of furanone C-30 
to decrease Stx2 production in C. rodentium λstx2dact (Mallick et al. 2012). 
 
Cultures of C. rodentium λstx2dact were treated with 12.5 µM, 25 µM and 50 µM of 
furanone C-30. Stx2 production was induced by the addition of 1 µg/mL of MMC 
to the samples containing the compound and to the MMC-only control. After 2-3 
h incubation, cultures were filter sterilised using 0.2 µm syringe filters and 
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serially diluted. The dilutions were added to Vero cells plates and incubated for 
further 48 h at 37°C in a humidified 5% CO2 incubator. Cytotoxicity was assessed 
using the methylthiazolydiphenyl-tetrazolium bromide (MTT) assay (Denizot and 
Lang 1986). As shown in Figure 74, the presence of furanone C-30 in C. 
rodentium λstx2dact cultures prevented the production of Stx and consequently 
reduced the cytotoxicity of the bacterial lysates. A significant difference was 
observed in the presence of 50 µM furanone C-30.  
 
 
Figure 73 Effect of furanone C-30 on viability of Vero cells treated with C. rodentium 
λstx2dact lysates.   
(A) Vero cells were treated with lysates of C. rodentium λstx2dact prepared from cultures: 
untreated (negative control), treated with 1 µg/mL MMC to induce Stx expression (positive 
control), 12.5, 25 and 50 µM of furanone C-30. Results represent mean values from three 
independent experiments, with error bars indicating SD. Statistical significance is shown as P 
values obtained by t test (***p < 0.001). (B) Representative micrographs from the experiment.  
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5.8 Is the activity of furanone C-30 on Stx expression a 
result of the inhibition of LuxS? 
 
Our results showed that furanone C-30 is acting as an inhibitor of Stx expression 
in E. coli O157:H7. Preliminary studies on the molecular mode of action of 
brominated furanones in E. coli suggest that they act as inhibitors of the AI-2 
signalling pathway by covalently binding to LuxS. Thus, we wanted to assess if 
the inhibitory activity of furanone C-30 on Stx production was due to the 
inhibition of LuxS. To do so, we planned to study the activity of furanone C-30 in 
E. coli with the luxS deletion and determine whether there was an effect on 
activity compared to the wild type strain. Using the lambda red recombineering 
system (Datsenko and Wanner 2000), the strains E. coli JP10819 ΔLuxS and E. 
coli ZAP0273 ΔLuxS were created. E. coli JP10819 ΔLuxS was used to study  the 
effect on prophage induction and phage lytic development of the Stx2 prophage 
φP27, whereas E. coli ZAP0273 ΔLuxS was transformed with the stx2::GFP 
reporter plasmid.  
As observed in Figure 75, both E. coli JP10819 wild type and its ΔLuxS mutant 
showed the same phage titre in the presence of different concentrations of 
furanone C-30. No significant differences in the number of plaque forming units 
per millilitre (PFU/mL) were observed. The same result was observed when the 
compound was studied using the stx2::GFP reporter assay in the E. coli ZAP0273 
ΔLuxS. Furanone C-30 was active in both the wild type and ΔLuxS mutant. These 
findings suggest that the inhibitory activity of furanone C-30 on Stx2 production 
is not a result of LuxS inhibition. 
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Figure 74 Effect of furanone C-30 on prophage induction in E. coli JP10819 and its ΔLuxS 
mutant.  
(A) Induction of JP10819 with 2 µg/ml MMC resulted in significantly increased Stx phage 
production. Furanone C-30 produced a significant decrease in phage production in both E. coli 
JP10819 and its ΔLuxS mutant. (B) FC-30 decreases stx2::GFP expression in a dose dependent 
manner in both E. coli ZAP0273 ΔLuxS and wild type. The data shown are the average of three 
independent experiments with standard deviation from the mean displayed as error bars.  
 
5.9 Does furanone C-30 inhibit RecA’s activity? 
 
In Chapter 3 we described the discovery of AHU3, a small molecule that 
interferes with the activity of RecA. The electrophilic nature of AHU3 suggests 
that the inhibitory activity on Stx production is a result of the covalent binding 
of the compound to RecA. Interestingly, furanone C-30 has a similar mode of 
action when it binds to LuxS (Zang et al. 2009). Given the shared reactivity of 
both compounds, we wanted to assess if furanone C-30 could also be interfering 
with RecA’s function. To do so, the ability of furanone C-30 to inhibit RecA 
mediated ATP hydrolysis was investigated. As previously explained, RecA binds 
to ssDNA, forming nucleofilaments. These activated RecA filaments mediate 
autocleavage of the key SOS response repressor LexA and prophage repressors, 
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triggering gene expression and production of assembled phage particles. As 
shown in Figure 76, furanone C-30 did not affect RecA’s ATP hydrolysis in 
comparison to AHU3. This suggests that the biological activity of furanone C-30 
in STEC is not a result of the inhibition of RecA.  
 
 
Figure 75 Furanone C-30 does not inhibit RecA’s ATPase activity.  
In order to assess if the inhibitory effect on stx expression was a result of the inhibition of the 
RecA protein, the ability of furanone C-30 to inhibit RecA-mediated ATP hydrolysis was 
investigated at concentrations between 1.56 and 200 µM. (A) The compound AHU3 inhibits the 
ATPase activity of RecA in a concentration-dependent manner, whereas furanone C-30 (B) does 
not. Data are plotted as a percentage of the inhibitory effect of ATP hydrolysis.  
 
 
5.10  In vivo evaluation of furanone C-30 as a potential 
strategy to prevent Shiga toxin expression. 
 
The ability of furanone C-30 to attenuate virulence in vivo has been explored in 
a mouse model of chronic lung infection with Pseudomonas aeruginosa PAO1 (H. 
Wu et al. 2004). As reported by Wu and collaborators, administration of 
furanone C-30 accelerated lung bacterial clearance of P. aeruginosa and reduced 
the severity of the lung pathology. In the case of P. aeruginosa, brominated 
furanones interfere with N-acyl homoserine lactone signalling. Given the positive 
results obtained in vitro and the precedent of an in vivo study using a murine 
model, we decided to assess if furanone C-30 was able to block Stx production in 
vivo. 
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5.10.1 Animal models for EHEC infections 
 
In order to study EHEC pathogenesis and facilitate the development of 
therapeutic strategies, different animal models for EHEC infection have been 
developed (Mohawk and O'Brien 2011). One of the most popular models for E. 
coli O157:H7 infection is the streptomycin-treated mouse model. This model, 
developed by Wadolkowski and co-workers, requires a prior treatment with 
streptomycin in order to reduce the animals’ normal intestinal microbiota and 
facilitate the colonisation by EHEC (Wadolkowski, Burris, and O’Brien 1990). One 
of the main limitations of this model is the need of a high inoculum of E. coli 
O157:H7 in order to cause morbidity or mortality, and the lack of symptoms 
associated with STEC pathogenesis. Other models have been developed, 
including the protein-calorie malnutrition model or the use of germ-free mice 
(reviewed by Mohawk and O'Brien 2011), but the conflicting conclusions 
concerning their utility to study EHEC infections has prompted the development 
of novel alternatives.  
 
Citrobacter rodentium is a mice pathogen that has an infection strategy and 
virulence profile similar to EPEC and EHEC (Mundy et al. 2005). In the same way 
as EPEC and EHEC, C. rodentium uses a type III secretion system (T3SS) to 
deliver effector proteins into infected enterocytes and promote the formation of 
attaching and effacing (A/E) lesions (Luperchio and Schauer 2001). Given their 
similarities, the use of C. rodentium as a surrogate organism of EHEC has been 
studied. However, one of the disadvantages of using C. rodentium is absence of 
the Stx genes, limiting its usefulness to study EHEC pathogenesis.  
 
Recently, Mallick and collaborators created a Stx-producing C. rodentium strain 
(Mallick et al. 2012). C. rodentium DBS100 was lysogenized with the phage 
Φ1720a-02, derived from the STEC strain EC1720a (Gobius, Higgs, and 
Desmarchelier 2003). The lysogenized strain C. rodentium λstx2dact strain 
produced the mucus-activatable Stx2dact at levels comparable to STEC. 
Infection of C57BL/6 mice with approximately 1x109 CFU of this strain via oral 
gavage caused lethal infection, with most mice dying 4-9 days after inoculation. 
The course of the disease in mice was characterised by a significant weight loss 
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(10-20% of starting weight) and increased faecal water content and severe 
kidney and intestinal damage. Even though this murine model does not display 
all the features associated with EHEC infection, the formation of A/E lesions 
together with Stx-mediated damage make this model a plausible alternative for 
the study of EHEC pathogenesis.  
 
5.10.2 Experimental design 
 
The C. rodentium λstx2dact strain was a kind gift from Prof. John Leong (Tufts 
University). In order to monitor the infection in real time, the lux operon was 
integrated into the chromosome via homologous recombination. This was done 
using the p16Slux vector, a plasmid that carries the P. luminescens lux operon 
and 16S rRNA insertion site (Riedel et al. 2007).  
 
A total of 26 female BALB/c mice, 6-8 weeks old, were used for the study. The 
mice were divided in four groups: Group 1 (8 mice) was infected and treated 
with furanone C-30; Group 2 (8 mice) was infected and given just pellet without 
the drug; Group 3 (5 mice) was not infected and treated with drug only and 
Group 4 (5 mice) was not infected and given just the pellet without the drug. 
The purpose of Group 3 was to assess any possible effect that the compound 
could have on the mice physiology, and Group 4 was to assess any possible effect 
that the vehicle could have.  
 
5.10.3 Preparation of peanut butter/hazelnut spread pellets 
for the delivery of the drug.  
 
Oral administration of drugs on animal models for human diseases is usually 
chosen given its practicality and non-invasive nature. Oral gavage is the most 
widely used technique for oral dosing in rodents but it has certain limitations. 
The animal resistance to the procedure usually causes complications, including 
esophageal and tracheal trauma and/or aspiration (Hoggatt et al. 2010). The 
stress induced by oral gavage can also influence different physiological processes 
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including immune function, metabolism, and inflammatory processes, amongst 
others (Corbett et al. 2012).  
 
Recently, strategies for voluntary oral drug administration in mice have been 
developed. For example, a study carried out by Gonzales and co-workers showed 
that the inclusion of active principles into peanut butter pellets allows a non-
stressful and precise drug administration in a short period of time and without 
the risks associated with oral gavage (Gonzales et al. 2014). Their findings 
showed that mice voluntarily took the pellets given their pleasant organoleptic 
properties. This approach is particularly useful in cases where chronic oral 
administration is required.  
 
Given the nature of our study (continuous administration of the compound in 
order to assess its potential to block Stx expression), we decided to apply the 
approach described by Gonzales et al. Thus, pellets containing furanone C-30 
were prepared mixing equal amounts of peanut butter and hazelnut cocoa 
spread. Approximately 100 mg ± 2.5 mg of the mixture were dispensed in 1.5 mL 
eppendorf tubes. The compound furanone C-30 was added from a 10 mM ethanol 
stock in order to get doses of 4 µg per gram of weight. Placebo pellets contained 
an equal amount of vehicle only. The pellets were thoroughly mixed by hand 
with a spatula, spun down in a bench centrifuge, and stored at -20°C until use.  
 
5.10.4 Infection of BALB/c mice with C. rodentium λstx2dact 
 
Prior to infection, mice were subjected to administration of the pellets with and 
without the active compound, depending on the group they belonged to. This 
was done to familiarise the animals to the daily dosing in order to ensure the 
voluntary consumption of the drug. Administration was performed twice a day at 
8:00 and 18:00 h, for five days. After this habituation step, mice were infected 
with the lux marked C. rodentium λstx2dact strain.  An overnight culture of the 
strain was subcultured in pre-warmed DMEM media and grown to an OD600 of 0.8. 
Bacteria were harvested by centrifugation and resuspended in sterile PBS to get 
a 100x concentrate of the original culture. The infection dose was 3.1 x 1010 
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CFU/mL. Mock-infected mice were given an equal volume of PBS only. Faecal 
shedding was used to measure colonisation levels (Figure 77).  
 
 
Figure 76 Colonisation of C. rodentium λstx2dact in BALB/c mice.  
Mice were infected with lux-marked C. rodentium λstx2dact. Colonisation was monitored by faecal 
shedding. Each group consisted of 8 animals at the start of the experiment, and data points 
represent the mean of each group with standard deviation from the mean displayed as error 
bars.  
 
Colonisation was also monitored used an in vivo imaging system (IVIS) Spectrum. 
On day 2 post-infection, mice were anaesthetised by inhalation of 2% isofluorane 
and analised using the IVIS spectrum. As shown in Figure 78, luminescence was 
detected after 1 minute exposure in mice infected with the lux-marked C. 
rodentium λstx2dact. Six mice from group 1 showed colonisation, whereas only 
four mice from group 2 appeared to be colonised. Faecal shedding showed that 
six mice of each group were colonised by day 3.  
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Figure 77 Colonisation of BALB/c mice with C. rodentium λstx2dact.  
Images of mice taken from the IVIS at day 2 post infection. Group 1, infected with C. rodentium 
λstx2dact, no treatment; Group 2, infected with C. rodentium λstx2dact and treated with furanone 
C-30. The scale bar represents luminescence flux in photons per second per cm2. Flux was 
normalised for all mice to allow comparison. On day two, only six mice from group 1 and four 
from group 2 were colonised.  
 
After infection, pellets containing furanone C-30 were voluntarily administered 
by oral route twice a day at 8:00 and 18:00 h using sterile micropipette tips. 
As described by Mallick et al. 2012, weight loss was used as a main indicator of 
Stx-induced disease. Thus, mice were weighed twice every day (morning and 
afternoon) looking at any fluctuation throughout the experiment. As observed in 
Figure 79, no significant weight loss was seen in the infected groups 1 and 2 by 
day 10, contrary to the observations reported by Mallick et al. On the other 
hand, the non-infected mice treated with furanone C-30 only (group 3) did not 
show any changes in weight as expected.  
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Figure 78 Weight monitoring of mice.  
Mice were weighed twice a day just before the administration of the compound. (A) Group 1 
infected with C. rodentium λstx2dact, no treatment; (B) Group 2, infected with C. rodentium 
λstx2dact and treated with furanone C-30; (C) Group 3, non-infected but treated with furanone C-
30 and (D) Group 4 non-infected but given the vehicle only. Animals were monitored for weight 
loss of >15% from the starting weight. Each line represents an individual mouse.  
 
High faecal shedding and luminescence in the infected mice suggested that the 
lack of symptoms was not a result of poor bacterial colonization. Given the lack 
of symptoms in the infected mice, animals were euthanized on day 10 and 
kidneys were removed and prepared for histology using H&E staining.  
 
Stx-mediated kidney damage in murine models is characterized by the presence 
of blood clots, spacing in the Bowman’s capsule in the glomeruli, tubular 
dilation and the presence of degenerated, necrotic or sloughed epithelial cells 
(Torres et al. 2016). Histological assessment of the kidneys from infected mice 
did not show signs of Stx-mediated damage as observed in Figure 80. These 
results suggest that the lack of symptoms was probably due to the lack of 
production and release of Stx2dact. Since no signs of disease were observed in 
the histological studies, the results of the experiment were taken as inconclusive 
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Figure 79 Micrographs of H&E-stained kidney sections from mock infected or C. rodentium 
λstx2dact infected mice at day 10 after infection.  
Group 1 infected with C. rodentium λstx2dact, no treatment; Group 2, infected with C. 
rodentium λstx2dact and treated with furanone C-30; Group 3, non-infected but treated with 
furanone C-30; Group 4 non-infected but given the vehicle only. No signals of Stx-mediated 
damage were observed in mice from groups 1 and 2.  
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5.11 Discussion 
 
The AI-2 signaling pathway plays a key role in the production of virulence factors 
in bacteria of clinical relevance. Hence, the development of small molecules 
that modulate AI-2 activity is a plausible alternative to create anti-virulence 
therapies. Different attempts have been made to develop inhibitors of different 
components that are involved in the production or response to AI-2 (reviewed by 
Guo et al. 2013). Examples include synthesis of LuxS substrate analogues that 
prevent the synthesis of AI-2 (Greenberg et al. 2001), synthesis of analogues of 
AI-2 to interfere with AI-2 signaling (Lowery et al. 2005) or inhibitors of the AI-2 
receptor (Peng et al. 2009).  
 
The use of brominated furanones to modulate virulence in human pathogens has 
been previously explored in other systems. For example, a study showed that 4 
µg/mL of furanone C-30 can inhibit biofilm formation by Streptococcus mutans 
without affecting bacterial growth (He et al. 2012). The anti-biofilm activity of 
brominated furanones has also been reported in Pseudomonas aeruginosa 
(Shetye et al. 2013), Escherichia coli (Han et al. 2008), Salmonella enterica 
serovar Agona (Vestby et al. 2014) and Staphylococcus epidermidis (Lonn-
Stensrud et al. 2008). 
 
To our knowledge, this is the first report of the activity of brominated furanones 
against Shiga toxin expression in EHEC. Our data shows that furanone C-30 
effectively prevents the production of Stx2 in vitro under MMC-inducing 
conditions. Since it has been shown that brominated furanones target the AI-2 
synthase LuxS, we investigated if the inhibitory on Stx expression was due to the 
inhibition of LuxS. Our results suggest that the activity could not be result of the 
inhibition of LuxS. There are several possible explanations for our observations. 
Furanone C-30 could be targeting another yet unknown E. coli quorum sensing 
system, the target could not be part of a quorum sensing system, or the 
observed activity against Stx expression is a result of the combination of effect 
on several targets.  
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Alternative pathways for the biosynthesis of AI-2 in E. coli luxS mutants have 
been identified. Tavender and co-workers reported the LuxS-independent 
formation of AI-2 via spontaneous conversion of ribulose-5-phosphate (Tavender 
et al. 2008). Their findings showed that this pathway does not contribute to the 
overall production of AI-2 in wild type E. coli strains but might be responsible for 
the synthesis of AI-2 in luxS mutants. Thus, it could be possible that our luxS 
mutant was still producing AI-2 through an alternative pathway, explaining the 
lack of differences between the wilt type and ΔluxS. 
 
The use of small molecules to disrupt quorum sensing is an attractive approach 
to develop new anti-virulence therapies. It is however important to mention that 
other pathways, different to quorum sensing, can regulate the bacterial 
virulence, so anti-QS compounds should be considered in an adjuvant or 
synergistic approach with other therapies. 
  
5.11.1 In vivo evaluation of furanone C-30 in the Citrobacter 
rodentium λstx2dact infection model. 
 
The use of Citrobacter rodentium to study the virulence of the closely related 
pathogens EPEC and EHEC has become the golden standard in recent years 
(Crepin et al. 2016). The lysogenisation with a Stx-producing phage by Mallick et 
al (2012) makes C. rodentium an even more accurate surrogate organism for 
STEC pathogenesis.  
The in vivo evaluation of compounds with promising biological activity is an 
important step in the drug development process. Thus, we decided to assess the 
ability of furanone C-30 to suppress stx expression in a murine infection model. 
Unfortunately, infection of BALB/c mice with C. rodentium λstx2dact did not 
produce the illness signs reported by Mallick (2012). According to his report, 
mice infected with the Stx-producing C. rodentium strain produced a lethal 
infection, with most mice dying 4-9 days after inoculation. In our study, no 
weight loss was observed and no signs of Stx-mediated kidney damage were seen 
in the histological analysis. Since faecal shedding showed that the mice were 
heavily colonised, the lack of symptoms could be attributed to the lack of Stx 
production in the infected mice.  
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There are many factors that could have interfered with the production of Stx. 
One of the most studied causes is the effect of the host microbiota on the 
induction of Stx-encoding prophages. For instance, it has been reported that 
elements produced by the human microbiota can interfere with prophage 
induction and stx expression in EHEC O157:H7. A study carried out by de Sablet 
and collaborators showed that molecules produced by the commensal microbiota 
are able to repress stx2 mRNA expression and block RecA-mediated prophage 
induction (de Sablet et al. 2009). Their findings showed that Bacteroides 
thetaiotaomicron, a frequently encountered organism in the normal human 
microbiota, produces compounds that prevent Stx production in the intestine. 
Although the compounds have not been identified, the inhibitory effect on stx2 
expression was found to be independent of the quorum sensing pathways 
described in E. coli O157:H7, including SdiA, QseA, QseC or AI-3. 
 
Other bacterial species have been reported to have an impact on stx expression. 
Studies carried out by Carey and collaborators showed that Lactobacillus, 
Pediococcus and Bifidobacterium strains down-regulate expression of stx2 in E. 
coli O157:H7, both in vivo and in vitro (Carey et al. 2008). In the case of 
Bifidobacterium, the inhibitory effect against stx expression has been associated 
with the production of high concentrations of acetic acid (56 mM), lowering the 
pH of the intestine. In vitro studies confirmed that the low pH caused by acetic 
acid supresses Stx production in E. coli O157:H7 (Asahara et al. 2004).  
 
The presence of non-STEC strains in the gut microbiota has also been shown to 
influence toxin production. Goswami and collaborators performed a study in vivo 
in which germfree mice were co-colonised with the non-pathogenic strain E. coli 
C600 and E. coli O157:H7. Mice that were colonised with both strains showed 
greater kidney damage, a higher concentration of Stx2a in faeces and visible 
signs of illness in comparison with mice that were infected with E. coli O157:H7 
only (Goswami et al. 2015). In fact, it has been shown that up to 10% of 
commensal E. coli in humans are susceptible to infection by Stx-encoding 
phages, which in turns leads to an increase of Stx production (Gamage et al. 
2004).  
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It is also important to point out that the type of Shiga toxin produced by the C. 
rodentium strain used in this study, Stx2dact, requires to be ‘activated’ with 
mouse or human intestinal mucus, or purified mouse elastase (Melton-Celsa, 
Kokai-Kun, and O’Brien 2002). Interestingly, the composition of the mice gut 
microbiota has been shown to have an impact on the mucus barrier in mice 
(Jakobsson et al. 2015). Thus, if the microbiota of infected mice had an impact 
on the mucus barrier, it is possible that Stx2dact could have not been activated 
to exert its toxic activity.  
 
The influence of the microbiota and commensal E. coli strains on toxin 
production by E. coli O157:H7 could explain how the infections with STEC can 
vary from being asymptomatic to the development of HUS (Figler and Dudley 
2016). In the case of our study, it would be interesting to perform a 16S 
ribosomal RNA sequencing of the gut microbiota in order to investigate this 
further. Furthermore, the use of peanut butter and hazelnut cocoa spread as a 
dosage form could have had an impact on the microbiota composition or 
physiological state of the gut so this could be further explored.  
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CHAPTER 6 
 
Final Discussion 
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6 Final discussion 
 
Shiga toxin (Stx) is the causal agent for haemolytic uremic syndrome (HUS) in 
patients infected with Shiga toxin producing E. coli (STEC). Unfortunately, there 
are no available therapies to prevent the development of Stx-mediated HUS and 
the development of new therapies has been hampered by the sporadic nature of 
STEC outbreaks and the lack of financial investment.  
 
The treatment of bacterial toxin-mediated diseases has always been a challenge 
given the lack of therapeutic strategies capable of neutralising the effects 
produced by the toxins and also the counterproductive effect of conventional 
antimicrobials. Most of the efforts to find new therapies against Stx-mediated 
HUS have focused on the neutralisation of the toxin using monoclonal antibodies 
against Stx1 and Stx2 or synthetic Stx binders that mimic the Gb3 receptor (E. A. 
Rahal et al. 2015). The outbreak nature of STEC infections complicates the 
statistics and finances to perform successful clinical trials.  For example, 
according to the FDA guidelines, a clinical trial of two groups (STEC and STEC + 
HUS) with a 5% HUS rate would require over 600 individuals to demonstrate the 
efficacy of the drug (Hall et al. 2017). Most outbreaks are less than 100 patients 
(Luna-Gierke et al. 2014; Rangel et al. 2005), making the development of 
neutralising therapies unattractive for pharmaceutical companies. For this 
reason, other alternatives have started to be explored. These include, targeting 
the unfolded protein response (UPR) (Amaral et al. 2017), the ribotoxic stress 
response (Pinto et al. 2017), intracellular trafficking of Stx (Tepshi et al. 2018) 
or production of the toxin (Sheng, Rasco, and Zhu 2016).  
 
6.1 Targeting the bacterial SOS response to prevent Shiga 
toxin expression 
 
In chapter 3 we described the discovery of a small-molecule inhibitor of RecA, a 
key component of the SOS response in bacteria. Since the genes encoding Stx are 
located on temperate lysogenic phages integrated into the bacterial 
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chromosome, the production of the toxin is intrinsically associated with phage 
induction through the SOS response. For this reason, the inhibition of the SOS 
response in STEC is a promising approach for the prevention of Stx expression in 
infected patients. Unfortunately, given the toxicity profile of the lead compound 
AHU3 it was not possible to continue its development. Nevertheless, our findings 
are a proof-of-concept of the potential that RecA has as a target to regulate stx2 
expression.  
 
The applications of targeting the SOS response go beyond the prevention of Stx 
expression. It has been proposed that inhibition of the SOS response could 
potentiate the current antimicrobial arsenal and stop the development of 
resistance to certain classes of antibiotics, such as fluoroquinolones (Recacha et 
al. 2017). Different elements of the SOS response pathway other than RecA have 
also been explored as potential drug targets. For instance, a recent study 
described the discovery of small molecules that specifically target the LexA 
autoproteolysis step in the SOS response (Mo et al. 2018).  Mo and collaborators 
also showed that targeting both LexA or RecA are viable strategies for targeting 
the SOS response, and propose that the combination of an SOS inhibitor with a 
DNA-damaging antibiotic offers the potential for lowering the antibiotics MICs 
and decrease the acquired drug resistance (Mo et al. 2016) 
 
Another proposed target is the endoribonuclease RNase E, an essential protein 
for the processing and degradation of all types of RNA. A study showed that 
deficiency of RNase E in E. coli severely limits the induction and maintenance of 
the SOS response (Manasherob et al. 2012). In fact, efforts to find small-
molecules inhibitors of RNase E have already been reported (Kime et al. 2015). 
 
6.2 The use of small molecules to modulate bacterial 
virulence 
 
Recently, there has been a growing interest in the study of small molecules that 
are capable of blocking the production of bacterial toxins or disrupt the toxins 
normal functioning. This anti-virulence approach would provide an effective 
solution to the severe toxin-mediated diseases and could also help to overcome 
 188 
 
the current antibiotic-resistance problem, as this type of drugs would put less 
selective pressure for the development of resistance mechanisms. 
 
The discovery of new therapies against bacterial infections has faced numerous 
setbacks including the lack of financial support and interest by the 
pharmaceutical sector. On the academic side, the lack of progress is likely a 
result of the limited practical experience that academic laboratories have on the 
drug development process. A potential solution to this problem is the formation 
of partnerships between academia and industry. This type of collaborations 
would encourage the exploration of novel and less validated targets or 
phenotypes in industry, and provide support and guidance to academics in the 
drug discovery landscape.  
 
Robust and quick high-throughput assays have greatly facilitated the 
identification of active compounds, as well as the technological advances that 
allow for the identification of the molecular targets in a more efficient manner. 
In collaboration with the Drug Discovery Unit, University of Dundee, we 
performed a high-throughput screening (HTS) of small-molecule libraries to 
identify inhibitors of Stx expression in E. coli O157:H7 using a fluorescence-
based reporter assay. The use of stx2::GFP cell-based assay in the HTS 
maximised the chances of finding hit compounds that can penetrate the 
membrane. It also allowed the screening of multiple targets simultaneously, in 
comparison to the target-based approach (Urban et al. 2007; Alksne et al. 2000). 
 
The work presented in chapter 4 describes the discovery of two hit compounds - 
DDD01302463 and DDD01304030 - that block stx2 expression in a specific and 
dose-dependent manner. Future work with the compounds DDD01302463 and 
DDD01304030 will involve structure-activity relationship studies to improve the 
activity, the identification of the target and mode of action, and in vivo 
evaluation. 
The assays and methods used in the HTS are an excellent platform to continue 
the study and development of small-molecule inhibitors of stx expression. 
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6.3 Concluding remarks 
This study provides insights into the discovery and biological evaluation of small 
molecules with inhibitory activity against Shiga toxin expression. We report the 
discovery of novel inhibitor of the bacterial protein RecA. We propose that 
targeting RecA is a viable approach to develop new treatment strategies against 
STEC infections. Our work also provides an excellent framework for future 
research focused on the development of inhibitors of Shiga toxin expression.  
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